2015 Medicines in Development for Cancer Drug List - …phrma-docs.phrma.org/sites/default/files/pdf/2015_cancer_drug_list.pdf · 2015 Medicines in Development for Cancer ... ACP-196

2015 Medicines in Development for Cancer

Bladder Cancer

Product Name Sponsor Indication Development Phase

ABI-009 AADi non-muscle invasive bladder cancer Phase I/II

(nanoparticle albumin-bound Pacific Palisades, CA

mTOR inhibitor)

ACP-196 Acerta Pharma platinum-refractory bladder cancer Phase II

(Btk inhibitor) San Carlos, CA (combination therapy) www.acerta-pharma.com

(see also head/neck, hematological, leukemia,

lung, lymphoma, myeloma, pancreatic)

ALT-801 Altor BioScience advanced bladder cancer, Phase II

(immunotherapy fusion protein) Miramar, FL non-muscle invasive bladder cancer www.altorbioscience.com

ALT-803 Altor BioScience non-muscle invasive bladder cancer Phase I/II

(IL-15 superagonist complex) Miramar, FL (see also hematological, myeloma, skin) www.altorbioscience.com

apatorsen OncoGenex Pharmaceuticals metastatic bladder cancer Phase II

(Hsp27 inhibitor) Bothell, WA (see also lung, pancreatic, prostate) www.oncogenex.com

apaziquone Spectrum Pharmaceuticals non-muscle invasive bladder cancer Phase III

(DNA synthesis inhibitor) Henderson, NV (Fast Track) www.sppirx.com

ASG-15ME Agensys relapsed bladder cancer Phase I

(antibody drug conjugate) Santa Monica, CA www.agensys.com

Seattle Genetics www.seattlegenetics.com

Bothell, WA

B-701 BioClin Therapeutics metastatic bladder cancer (2nd-line) Phase II

(anti-FGFR3 mAb) San Ramon, CA www.bioclintherapeutics.com

BC-819 BioCancell Therapeutics bladder cancer (2nd-line) Phase II

(gene therapy) Jerusalem, Israel (see also pancreatic) www.biocancell.com

http://www.acerta-pharma.com/

http://www.altorbioscience.com/


http://www.oncogenex.com/

http://www.sppirx.com/

http://www.agensys.com/

http://www.seattlegenetics.com/

http://www.bioclintherapeutics.com/

http://www.biocancell.com/

Bladder Cancer


CG0070 Cold Genesys non-muscle invasive bladder cancer Phase II/III

(oncolytic virus therapy) Newport Beach, CA www.coldgenesys.com

CV-301 Bavarian Nordic bladder cancer Phase II

(CEA/MUC-1 targeted active Mountain View, CA www.bavarian-nordic.com

immunotherapy)

Cyramza® Eli Lilly urothelial cancer Phase III

ramucirumab Indianapolis, IN (see also liver, lung, stomach) www.lilly.com

bladder cancer (2nd-line) Phase II

www.lilly.com

DN24-02 Dendreon HER2-positive urothelial cancer Phase II

(active cellular immunotherapy) Seattle, WA www.dendreon.com

Halaven® Eisai bladder cancer Phase I/II

eribulin Woodcliff Lake, NJ (see also lung, sarcoma) www.eisai.com

Orphan Drug

instiladrin FKD Therapies superficial bladder cancer Phase II

(gene therapy) Kuopia, Finland

JNJ-42756493 Janssen Research & Development urothelial cancer Phase II

(FGFR inhibitor) Raritan, NJ (see also lymphoma) www.janssenrnd.com

MCNA Telesta Therapeutics refractory non-muscle invasive application submitted

(mycobacterium phlei cell Point Claire, Canada bladder cancer (Fast Track) www.telestatherapeutics.com

wall-nucleic acid complex)

Keytruda® Merck bladder cancer Phase III

pembrolizumab Kenilworth, NJ (see also breast, head/neck, lung, lymphoma, www.merck.com

stomach)

http://www.coldgenesys.com/

http://www.bavarian-nordic.com/

http://www.lilly.com/


http://www.dendreon.com/

http://www.eisai.com/

http://www.janssenrnd.com/

http://www.telestatherapeutics.com/

http://www.merck.com/

Bladder Cancer


mocetinostat Mirati Therapeutics bladder cancer Phase II

(HDAC inhibitor) San Diego, CA (see also hematological, lymphoma) www.mirati.com

Opdivo® Bristol-Myers Squibb bladder cancer (2nd-line) Phase II

nivolumab Princeton, NJ (see also brain, colorectal, head/neck, hematological, www.bms.com

kidney, liver, lung, lymphoma, skin, solid tumors,

stomach, other)

RG7446 Genentech/Roche bladder cancer (2nd-line) (Breakthrough Therapy) Phase III

(anti-PD-L1 mAb) South San Francisco, CA muscle invasive bladder cancer (adjuvant) www.roche.com

(see also breast, kidney, lung, lymphoma, skin)

bladder cancer (1st-line) Phase II

www.roche.com

TMX-101 Telormedix bladder cancer Phase II

(TLR7 agonist) Bioggio, Switzerland www.telormedix.com

Orphan Drug

vesigenurtucel-L Heat Biologics bladder cancer Phase II

(cancer immunotherapy) Durham, NC www.heatbio.com

2B3-101 BBB Therapeutics brain metastases in advanced solid tumors, Phase II

(doxorubicin liposomal) Leiden, Netherlands brain metastases in breast cancer (combination therapy) www.bbbtherapeutics.com

ABT-414 AbbVie glioblastoma Phase I/II

(antibody drug conjugate) North Chicago, IL (see also solid tumors) www.abbvie.com

Orphan Drug

ADU-623 Aduro Biotech glioblastoma Phase I

(therapeutic bivalent vaccine) Berkeley, CA www.adurobiotech.com

http://www.mirati.com/

http://www.bms.com/

http://www.gene.com/


http://www.telormedix.com/

http://www.heatbio.com/

http://www.bbbtherapeutics.com/

http://www.abbvie.com/

http://www.adurobiotech.com/

Brain Cancer


AG-120 Agios Pharmaceuticals glioma Phase I

(IDH1 inhibitor) Cambridge, MA (see also leukemia, solid tumors) www.agios.com

Celgene www.celgene.com

Summit, NJ

aglatimagene besadenovec Advantagene glioma Phase II

(gene therapy) Auburndale, MA (see also pancreatic, prostate) www.advantagene.com

Orphan Drug

glioma (pediatric) Phase I/II

www.advantagene.com

aldoxorubicin CytRx glioblastoma Phase II

(delivery-enhanced doxorubicin) Los Angeles, CA (see also lung, sarcoma) www.cytrx.com

Orphan Drug

AMG 595 Amgen anaplastic astrocytoma, recurrent glioblastoma Phase I

(anti-EGFRvIII antibody drug Thousand Oaks, CA www.amgen.com

conjugate)

ANG 1005 Angiochem brain metastases from breast cancer and Phase II

(peptide-paclitaxel conjugate) Montreal, Canada NSCLC, recurrent glioblastoma (Fast Track) www.angiochem.com

Orphan Drug

antineoplaston A10/AS2-1 Burzynski Research Institute diffuse intrinsic brainstem glioma Phase II

Orphan Drug Houston, TX www.burzynskiresearch.com

Avastin® Genentech/Roche glioblastoma (1st-line) Phase III

bevacizumab South San Francisco, CA (see also breast, lung, ovarian, other) www.roche.com

BGJ398 Novartis Pharmaceuticals recurrent glioblastoma Phase II

(FGF-R kinase inhibitor) East Hanover, NJ (see also solid tumors) www.novartis.com

http://www.agios.com/

http://www.celgene.com/

http://www.advantagene.com/


http://www.cytrx.com/

http://www.amgen.com/

http://www.angiochem.com/

http://www.burzynskiresearch.com/


http://www.novartis.com/

Brain Cancer


buparlisib (BKM120) Novartis Pharmaceuticals glioblastoma Phase I/II

(PI3K inhibitor) East Hanover, NJ (see also breast, solid tumors) www.novartis.com

CC-122 Celgene glioblastoma Phase I

(pleiotropic pathway modifier) Summit, NJ (see also leukemia, liver, lymphoma) www.celgene.com

Cometriq® Exelixis astrocytoma, glioblastoma Phase II completed

cabozantinib South San Francisco, CA (see also kidney, liver) www.exelixis.com

Cotara® Peregrine Pharmaceuticals recurrent glioblastoma (Fast Track) Phase II completed

iodine I 131 derlotuximab biotin Tustin, CA www.peregrine.com

Orphan Drug

crenolanib AROG Pharmaceuticals glioma (pediatric) Phase II

(PDGFR inhibitor) Dallas, TX (see also leukemia, lung, stomach) www.arogpharma.com

Orphan Drug

CTO Tactical Therapeutics glioma (combination therapy) Phase I/II

(carboxyamidotriazole orotate) New York, NY (Fast Track) www.tacticaltherapeutics.com

DCVax®-L Northwest Biotherapeutics glioblastoma Phase III

dendritic cell-based vaccine Bethesda, MD www.nwbio.com

Orphan Drug

DM-CHOC-PEN Dekk-Tec brain tumors Phase II

(non-neurotoxic derivative of New Orleans, LA www.dekk-tec.com

penclomidine)

DNX-2401 DNAtrix glioblastoma (Fast Track) Phase I

(oncolytic virus) Houston, TX www.dnatrix.com

Orphan Drug



http://www.exelixis.com/

http://www.peregrine.com/

http://www.arogpharma.com/

http://www.tacticaltherapeutics.com/

http://www.nwbio.com/

http://www.dekk-tec.com/

http://www.dnatrix.com/

Brain Cancer


ERC1671 Epitopoietic Research grade IV glioblastoma Phase II

(therapeutic vaccine) Pasadena, CA www.ercbelgium.com

University of California

Irvine, CA

ETS2101 e-Therapeutics glioma Phase I

(dexanabinol) Oxfordshire, England www.etherapeutics.co.uk

Moores UCSD Cancer Center

La Jolla, CA

evofosfamide (TH-302) Threshold Pharmaceuticals high grade glioma Phase I/II

(hypoxia-activated prodrug) South San Francisco, CA (see also hematological, lung, pancreatic, sarcoma, www.thresholdpharm.com

University of Texas skin)

San Antonio, TX

galunisertib Eli Lilly glioblastoma Phase II

(TGF-beta 1 kinase inhibitor) Indianapolis, IN (see also liver, pancreatic) www.lilly.com

glioma Phase I/II

www.lilly.com

Gilotrif® Boehringer Ingelheim Pharmaceuticals recurrent glioma Phase II

afatinib Ridgefield, CT (see also head/neck, lung) www.boehringer-ingelheim.com

heat shock protein vaccine Agenus recurrent or newly-diagnosed glioblastoma Phase II

(Prophage Series) Lexington, MA (see also skin) www.agenus.com

Orphan Drug

ICT-107 ImmunoCellular Therapeutics newly-diagnosed glioblastoma Phase II

(dendritic cell-based vaccine) Calabasas, CA www.imuc.com

Orphan Drug

http://www.ercbelgium.com/

http://www.etherapeutics.co.uk/

http://www.thresholdpharm.com/



http://www.boehringer-ingelheim.com/

http://www.agenus.com/

http://www.imuc.com/

Brain Cancer


ICT-121 ImmunoCellular Therapeutics recurrent glioblastoma Phase I

(dendritic cell-based vaccine) Calabasas, CA www.imuc.com

indoximod NewLink Genetics primary malignant brain tumors Phase I/II

(IDO pathway inhibitor) Ames, IA (see also breast, prostate) www.newlinkgenetics.com

INXN-2001 ZIOPHARM Oncology anaplastic oligo astrocytoma, glioblastoma Phase I/II

(Ad-RTS-IL-12 gene therapy) Boston, MA (see also breast, skin) www.ziopharm.com

Jevtana® Sanofi US malignant central nervous system tumors Phase I/II

cabazitaxel Bridgewater, NJ (see also prostate) www.sanofi.com

KX02 Kinex Pharmaceuticals glioma Phase I

(Src kinase/pre-tubulin inhibitor) Buffalo, NY www.kinexpharma.com

Orphan Drug

MM-398 Baxalta glioma Phase I

(encapsulated irinotecan Cambridge, MA (see also pancreatic, solid tumors) www.baxalta.com

nanotherapeutic)

macitentan Actelion Pharmaceuticals glioblastoma Phase I

(endothelin A/B receptor antagonist) South San Francisco, CA www.actelion.com

marizomib Triphase Accelerator glioblastoma Phase I

(proteasome inhibitor) San Diego, CA (see also myeloma) www.triphaseco.com

mibefradil Cavion high-grade glioma Phase I

(T-type calcium channel antagonist) Charlottesville, VA www.cavionpharma.com

Orphan Drug

mipsagargin GenSpera glioblastoma Phase II

(thapsigargin analogue) San Antonio, TX (see also liver) www.genspera.com

http://www.imuc.com/

http://www.newlinkgenetics.com/

http://www.ziopharm.com/

http://www.sanofi.com/

http://www.kinexpharma.com/

http://www.baxalta.com/

http://www.actelion.com/

http://www.triphaseco.com/

http://www.cavionpharma.com/

http://www.genspera.com/

Brain Cancer


NEO-100 NEONC Technologies recurrent glioblastoma Phase I

(highly purified perillyl alcohol) Tucson, AZ www.neonctech.com

Orphan Drug

NVX-108 NuvOx Pharma glioblastoma Phase I/II

(radiation-sensitizing agent) Tucson, AZ www.nuvoxpharma.com

National Cancer Institute

Bethesda, MD

Odomzo® Novartis Pharmaceuticals medulloblastoma Phase II

sonidegib East Hanover, NJ (see also leukemia) www.novartis.com

Opdivo® Bristol-Myers Squibb glioblastoma Phase III

nivolumab Princeton, NJ (see also bladder, colorectal, head/neck, hematological, www.bms.com


stomach, other)

PEPIDH1M Annias Immunotherapeutics glioblastoma Phase I/II

(dendritic cell vaccine) Chapel Hill, NC www.anniasimmuno.com

PLX3397 Plexxikon glioblastoma (adjuvant) Phase II

(CSF-1R inhibitor) Berkeley, CA (see also breast, ovarian, skin, other) www.plexxikon.com

Poly-ICLC Oncovir glioblastoma Phase II

Orphan Drug Washington, DC www.oncovir.com

Reolysin® Oncolytics Biotech high grade glioma (pediatrics) Phase I

pelareorp Calgary, Canada (see also colorectal, head/neck, lung, www.oncolyticsbiotech.com

Orphan Drug myeloma, ovarian, other, pancreatic)

http://www.neonctech.com/

http://www.nuvoxpharma.com/


http://www.bms.com/

http://www.anniasimmuno.com/

http://www.plexxikon.com/

http://www.oncovir.com/

http://www.oncolyticsbiotech.com/

Brain Cancer


rindopepimut Celldex Therapeutics glioblastoma (1st-line) (Fast Track) Phase III

(EGFR antagonist) Hampton, NJ www.celldex.com

Orphan Drug

recurrent glioblastoma (Fast Track) Phase II

www.celldex.com

selinexor (oral) Karyopharm Therapeutics glioblastoma Phase II

(XPO1 antagonist) Newton, MA (see also head/neck, hematological, leukemia, www.karyopharm.com

lymphoma, myeloma, prostate, sarcoma, other)

Seprehvir® Virttu Biologics glioblastoma Phase I

HSV1716 Glasgow, Scotland (see also solid tumors) www.virttu.com


Bethesda, MD

SL-701 Stemline Therapeutics adult glioblastoma (first recurrence) Phase I/II

(immunotherapy) New York, NY www.stemline.com

SurVaxM MimiVax malignant glioma Phase I

BIRC5 protein inhibitor Buffalo, NY www.mimivax.com

Toca 511 + Toca FC Tocagen anaplastic astrocytoma, glioblastoma Phase II/III

(gene therapy) San Diego, CA (Fast Track) www.tocagen.com

TPI 287 Cortice Biosciences recurrent glioblastoma Phase II

(abeotaxane) New York, NY www.corticebio.com

breast cancer brain metastases, Phase I

secondary brain metastases www.corticebio.com

http://www.celldex.com/


http://www.karyopharm.com/

http://www.virttu.com/

http://www.stemline.com/

http://www.mimivax.com/

http://www.tocagen.com/

http://www.corticebio.com/

http://www.corticebio.com/

Brain Cancer


TRC105 TRACON Pharmaceuticals glioblastoma Phase II

(END protein inhibitor) San Diego, CA (see also breast, colorectal, kidney, liver, lung, www.traconpharma.com

National Cancer Institute sarcoma, other)

Bethesda, MD

TSC Diffusion Pharmaceuticals glioblastoma Phase I/II

(trans-sodium crocetinate) Charlottesville, VA www.diffusionpharma.com

Orphan Drug

TVI-Brain-1 TVAX Biomedical glioma Phase II

(personalized cancer immunotherapy) Lenexa, KS www.tvaxbiomedical.com

Orphan Drug

VAL-083 DelMar Pharmaceuticals glioblastoma Phase I/II

(N7-alkylating agent) Vancouver, Canada www.delmarpharma.com

Orphan Drug

VB-111 VBL Therapeutics recurrent glioblastoma (Fast Track) Phase II

(targeted anti-angiogenic agent) Tel Aviv, Israel (see also ovarian, other) www.vblrx.com

Orphan Drug

veliparib AbbVie brain metastases Phase II

(PARP inhibitor) North Chicago, IL (see also breast, colorectal, lung, skin) www.abbvie.com

Breast Cancer


abemaciclib Eli Lilly metastatic breast cancer Phase III

(CDK 4/6 inhibitor) Indianapolis, IN (see also lung, lymphoma) www.lilly.com

ABP 980 Allergan breast cancer Phase III

(trastuzumab biosimilar) Parsippany, NJ www.amgen.com

Amgen

Thousand Oaks, CA

http://www.traconpharma.com/

http://www.diffusionpharma.com/

http://www.tvaxbiomedical.com/

http://www.delmarpharma.com/

http://www.vblrx.com/




Breast Cancer


Abraxane® Celgene triple-negative breast cancer (1st-line) Phase III

paclitaxel protein-bound Summit, NJ (see also pancreatic) www.celgene.com

particles for injectable

suspension (albumin-bound)

ADI-PEG 20 Polaris Pharmaceuticals HER2-negative breast cancer Phase I

(PEG arginine deiminase) San Diego, CA (see also liver, lung, ovarian, pancreatic, skin, www.polarispharma.com

stomach)

AE37 Antigen Express breast cancer Phase II

(immunotherapeutics) Worcester, MA (see also prostate) www.antigenexpress.com

anti-HER2 Bristol-Myers Squibb breast cancer Phase I

Princeton, NJ www.bms.com

ARRY-380/ONT-380 Array BioPharma breast cancer Phase I

(HER2 inhibitor) Boulder, CO www.arraybiopharma.com

Oncothyreon www.oncothyreon.com

Seattle, WA

Avastin® Genentech/Roche HER2-negative breast cancer (adjuvant), Phase III

bevacizumab South San Francisco, CA HER2-positive breast cancer (adjuvant) www.roche.com

(see also brain, lung, ovarian, other)

AZD5363 AstraZeneca breast cancer Phase II

(Akt kinase inhibitor) Wilmington, DE www.astrazeneca.com

AZD9496 AstraZeneca estrogen receptor (ER)-positive breast cancer Phase I

(selective estrogen receptor Wilmington, DE www.astrazeneca.com

downregulator [SERD])

bavituximab Peregrine Pharmaceuticals HER2-negative breast cancer Phase I completed

Tustin, CA (see also colorectal, lung, skin) www.peregrineinc.com


http://www.polarispharma.com/

http://www.bms.com/

http://www.arraybiopharma.com/

http://www.oncothyreon.com/


http://www.astrazeneca.com/


http://www.peregrineinc.com/

Breast Cancer


BBI608 Boston Biomedical breast cancer Phase II

(cancer stem cell inhibitor) Cambridge, MA (see also colorectal, hematological, liver, lung, www.bostonbiomedical.com

ovarian, pancreatic, skin, stomach)

BEL-0222 Belrose Pharma triple-negative breast cancer Phase II

(angiogenesis inhibitor) Princeton, NJ (see also other) www.belrosepharma.com

buparlisib (BKM120) Novartis Pharmaceuticals metastatic breast cancer (2nd-line) Phase III

(PI3K inhibitor) East Hanover, NJ (ER-positive aromatase inhibitor (AI)- www.novartis.com

resistant mTOR naïve) (combination therapy)

(see also brain, solid tumors)

metastatic breast cancer Phase II

(ER-positive post-AI and mTOR inhibitor) www.novartis.com

CC-486 Celgene metastatic breast cancer Phase II

(DNA methylation inhibitor) Summit, NJ (see also hematological, leukemia, lung, lymphoma, www.celgene.com

other)

cobimetinib Genentech/Roche triple-negative breast cancer (combination therapy) Phase II

(MEK inhibitor) South San Francisco, CA (see also skin) www.roche.com

Cynviloq™ NantPharma breast cancer in clinical trials

paclitaxel polymeric micelle Lincolnshire, IL www.nantpharma.com

for injection

docetaxel injection concentrate, Teikoku Pharma USA breast cancer application submitted

non-alcohol formula San Jose, CA (see also head/neck, lung, prostate, stomach) www.teikokuusa.com

DPX-0907 Immunovaccine breast cancer Phase I

(T lymphocyte modulator) Halifax, Canada (see also ovarian, prostate) www.imvaccine.com

http://www.bostonbiomedical.com/

http://www.belrosepharma.com/





http://www.nantpharma.com/

http://www.teikokuusa.com/

http://www.imvaccine.com/

Breast Cancer


ENMD-2076 CASI Pharmaceuticals triple-negative breast cancer Phase II

(aurora A/angiogenic kinase Rockville, MD (see also ovarian, sarcoma) www.casipharmaceuticals.com

inhibitor)

enobosarm GTx ER-positive and androgen receptor (AR)-positive Phase II

(SARM) Memphis, TN breast cancer, AR-positive triple-negative www.gtxinc.com

breast cancer

entinostat Syndax Pharmaceuticals hormone receptor (HR)-positive metastatic Phase III

(HDAC inhibitor) Waltham, MA breast cancer www.syndax.com

(see also lung, skin)

etirinotecan pegol (NKTR-102) Nektar Therapeutics metastatic breast cancer (Fast Track) Phase III

(PEGylated irinotecan) San Francisco, CA (see also colorectal, ovarian) www.nektar.com

Faslodex® AstraZeneca HR-positive advanced breast cancer (1st-line) Phase III

fulvestrant Wilmington, DE www.astrazeneca.com

ganetespib Synta Pharmaceuticals breast cancer Phase II

(Hsp90 inhibitor) Lexington, MA (see also leukemia, lung, ovarian) www.syntapharma.com

GDC-0810 Genentech/Roche ER-positive HER2-negative breast cancer Phase I

(SERD) South San Francisco, CA www.roche.com

glembatumumab vedotin CellDex Therapeutics triple-negative breast cancer (Fast Track) Phase II

(antibody drug conjugate) Hampton, NJ (see also skin) www.celldex.com

HER2 cancer immunotherapy AlphaVax late-stage breast cancer Phase I/II

(AVX901) Research Triangle Park, NC www.alphavax.com

http://www.casipharmaceuticals.com/

http://www.gtxinc.com/

http://www.syndax.com/

http://www.nektar.com/


http://www.syntapharma.com/



http://www.alphavax.com/

Breast Cancer


Ibrance® Pfizer high-risk early breast cancer, Phase III

palbociclib New York, NY recurrent advanced breast cancer www.pfizer.com

(see also hematological)

IMMU-132 Immunomedics relapsed/refractory triple-negative breast cancer Phase II

(sacituzumab govitecan) Morris Plains, NJ (Fast Track) www.immunomedics.com

(see also other)

indoximod NewLink Genetics metastatic HER2-negative breast cancer Phase II

(IDO pathway inhibitor) Ames, IA (see also brain, prostate) www.newlinkgenetics.com

INO-1400 Inovio Pharmaceuticals breast cancer Phase I

(hTERT immunotherapy) Plymouth Meeting, PA (see also lung, pancreatic) www.inovio.com

interleukin-12 gene therapy OncoSec Medical triple-negative breast cancer Phase II

San Diego, CA (see also head/neck, skin) www.oncosec.com

INXN-2001 ZIOPHARM Oncology breast cancer Phase II

(Ad-RTS-IL-12 gene therapy) Boston, MA (see also brain, skin) www.ziopharm.com

ipatasertib Array BioPharma triple-negative breast cancer Phase II

(Akt inhibitor) Boulder, CO (see also prostate, stomach) www.roche.com

Genentech/Roche

South San Francisco, CA

Jakafi® Incyte breast cancer Phase II

ruxolitinib Wilmington, DE (see also colorectal, lung, pancreatic) www.incyte.com

Kadcyla® Genentech/Roche HER2-positive breast cancer (adjuvant monotherapy), Phase III

ado-trastuzumab emtansine South San Francisco, CA HER2-positive breast cancer (adjuvant combination www.roche.com

therapy), HER2-positive breast cancer

(neoadjuvant combination therapy)

(see also lung, stomach)

http://www.pfizer.com/

http://www.immunomedics.com/


http://www.inovio.com/

http://www.oncosec.com/



http://www.incyte.com/


Breast Cancer


Keytruda® Merck breast cancer Phase II

pembrolizumab Kenilworth, NJ (see also bladder, head/neck, lung, lymphoma, www.merck.com

stomach)

LEE011 Novartis Pharmaceuticals HR-positive HER2-negative postmenopausal Phase III

(CDK4/6 inhibitor) East Hanover, NJ advanced breast cancer (1st-line) www.novartis.com

(combination therapy)

HR-positive HER2-negative premenopausal Phase II

advanced breast cancer (1st-line) www.novartis.com


HR-positive HER2-negative premenopausal Phase I

advanced breast cancer (1st-/2nd-line) www.novartis.com


lucitanib Clovis Oncology metastatic breast cancer Phase II

(FGFR/VEGFR/PDGFR inhibitor) Boulder, CO (see also lung) www.clovisoncology.com

LY2606368 Eli Lilly metastatic breast cancer Phase II

(Chk1 inhibitor) Indianapolis, IN (see also ovarian) www.lilly.com

Lynparza® AstraZeneca germline BRCA-mutated triple-negative breast Phase III

olaparib Wilmington, DE cancer (adjuvant), germline BRCA-mutated www.astrazeneca.com

metastatic breast cancer

(see also ovarian, pancreatic, prostate, stomach)

margetuximab MacroGenics metastatic breast cancer Phase II

(anti-HER2 mAb) Rockville, MD www.macrogenics.com

MEDI-573 MedImmune metastatic breast cancer Phase II

(anti-CD19 mAb) Gaithersburg, MD www.medimmune.com





http://www.clovisoncology.com/



http://www.macrogenics.com/

http://www.medimmune.com/

Breast Cancer


mifepristone Corcept Therapeutics triple-negative breast cancer Phase I

Menlo Park, CA www.corcept.com

MM-302 Merrimack Pharmaceuticals advanced HER2-positive breast cancer Phase II

(HER2-targeted nanotheraputic) Cambridge, MA www.merrimackpharma.com

NeuVax™ Galena Biopharma node-positive breast cancer Phase III

nelipepimut-S Portland, OR (HER2 IHC 1+/2+) www.galenabiopharma.com

(see also stomach)

node-positive and triple-negative Phase II

breast cancer (HER2 IHC 1+/2+) www.galenabiopharma.com


neoadjuvant node-positive and negative Phase II

breast cancer (HER2 IHC 3+) www.galenabiopharma.com


niraparib TESARO BRCA-positive breast cancer Phase III

(PARP inhibitor) Waltham, MA (see also ovarian, sarcoma) www.tesarobio.com

NK012 Nippon Kayaku breast cancer Phase II

(DNA topoisomerase I inhibitor) Tokyo, Japan (see also colorectal, lung) www.nipponkayaku.co.jp

ONT-10 Oncothyreon breast cancer Phase I

(cancer immunotherapy) Seattle, WA (see also ovarian) www.oncothyreon.com

OPT-822/OPT-821 OBI Pharma metastatic breast cancer Phase II/III

(cancer immunotherapy) Taipei, Taiwan www.obipharma.com

patritumab Daiichi Sankyo breast cancer Phase II

(anti-HER3 antibody) Parsippany, NJ (see also lung) www.dsi.com

http://www.corcept.com/

http://www.merrimackpharma.com/

http://www.galenabiopharma.com/



http://www.tesarobio.com/

http://www.nipponkayaku.co.jp/


http://www.obipharma.com/

http://www.dsi.com/

Breast Cancer


PB272 Puma Biotechnology breast cancer (adjuvant), metastatic Phase III

(neratinib) Los Angeles, CA breast cancer (combination therapy) www.pumabiotechnology.com

(see also lung)

metastatic breast cancer (combination Phase II

therapy), breast cancer with brain www.pumabiotechnology.com

metastases (combination therapy)

(combination therapy), breast cancer

(neoadjuvant)

Perjeta® Genentech/Roche early HER2-positive breast cancer, Phase III

pertuzumab South San Francisco, CA HER2-positive metastatic breast cancer www.roche.com

(2nd-line)

(see also stomach)

PF-05280014 Pfizer metastatic breast cancer Phase III

(trastuzumab biosimilar) New York, NY www.pfizer.com

pictilisib Genentech/Roche ER-positive breast cancer, metastatic Phase II

(PI3K inhibitor) South San Francisco, CA HER2-negative/HR-positive breast cancer www.roche.com

(see also lung)

PLX3397 Plexxikon metastatic breast cancer Phase II

(CSF-1R inhibitor) Berkeley, CA (see also brain, ovarian, skin, other) www.plexxikon.com

PM01183 Pharma Mar metastatic breast cancer Phase II

(marine-derived alkylating agent) Madrid, Spain (see also leukemia, ovarian) www.pharmamar.com

POL6326 Polyphor metastatic breast cancer Phase I

(CXCR4 receptor antagonist) Allschwil, Switzerland (see also hematological) www.polyphor.com

pyrotinib Jiangsu Hengrui Medicine HER2-positive breast cancer Phase I

(tyrosine kinase inhibitor) Jiangsu Province, China (see also stomach) www.hrs.com.cn

http://www.pumabiotechnology.com/






http://www.pharmamar.com/

http://www.polyphor.com/

http://www.hrs.com.cn/

Breast Cancer


RAD1901 Radius Health metastatic breast cancer Phase I

(SERM modulator) Waltham, MA www.radiuspharm.com

reparixin Dompe early-stage breast cancer Phase II

(IL-8A/B receptor antagonist) Milan, Italy www.dompe.com

metastatic breast cancer Phase I

www.dompe.com

RG6047 Genentech/Roche ER-positive HER2-negative metastatic breast cancer Phase I

(SERD) South San Francisco, CA www.roche.com

RG7116 Genentech/Roche metastatic breast cancer Phase I

(ERBB-3 receptor antagonist) South San Francisco, CA www.roche.com

RG7446 Genentech/Roche triple-negative breast cancer Phase III

(anti-PD-L1 mAb) South San Francisco, CA (see also bladder, kidney, lung, lymphoma, skin) www.roche.com

rucaparib Clovis Oncology breast cancer Phase II

(PARP inhibitor) Boulder, CO (see also ovarian, pancreatic, other) www.clovisoncology.com

seribantumab (MM-121) Merrimack Pharmaceuticals breast cancer Phase II

(ErbB-3 receptor antagonist) Cambridge, MA (see also lung, ovarian) www.merrimackpharma.com

SGN-LIV1A Seattle Genetics relapsed breast cancer Phase I

(antibody drug conjugate) Bothell, WA www.seattlegenetics.com

TAK-228 Takeda Oncology breast cancer Phase II

(mTORC1/2 inhibitor) Cambridge, MA (see also kidney, other) www.takedaoncology.com

talazoparib BioMarin Pharmaceutical metastatic breast cancer Phase III

(PARP inhibitor) Novato, CA (genetically defined) www.bmrn.com

http://www.radiuspharm.com/

http://www.dompe.com/

http://www.dompe.com/







http://www.takedaoncology.com/

http://www.bmrn.com/

Breast Cancer


taselisib Genentech/Roche ER-positive HER2-negative metastatic Phase III

(PI3K inhibitor) South San Francisco, CA breast cancer www.roche.com

ER-positive HER2-negative breast cancer Phase II

www.roche.com

tesevatinib (KD019) Kadmon Pharmaceuticals HER2-positive metastatic breast cancer Phase I/II

(TKI inhibitor) Warrendale, PA (see also lung) www.kadmon.com

ThermoDox® Celsion recurrent breast cancer Phase II

doxorubicin liposomal Lawrenceville, NJ (see also liver) www.celsion.com

TPIV100 TapImmune breast cancer Phase I

(cancer immunotherapy) Seattle, WA www.tapimmune.com

TPIV200 TapImmune breast cancer (combination therapy) Phase I

(folate receptor alpha vaccine) Seattle, WA (see also ovarian) www.tapimmune.com

TRC105 TRACON Pharmaceuticals breast cancer Phase I

(END protein inhibitor) San Diego, CA (see also brain, colorectal, kidney, liver, lung, sarcoma, www.traconpharma.com

other)

trebananib Amgen metastatic breast cancer Phase I

(Ang 1 / Ang 2 inhibitor) Thousand Oaks, CA (see also lung, ovarian) www.amgen.com

vantictumab OncoMed Pharmaceuticals HER2-negative breast cancer (combination therapy) Phase I

(anti-Fzd7) Redwood City, CA (see also lung, pancreatic) www.oncomed.com

veliparib AbbVie BRCA-deficient breast cancer, triple-negative Phase III

(PARP inhibitor) North Chicago, IL breast cancer (neoadjuvant therapy) www.abbvie.com

(see also brain, colorectal, lung, skin)



http://www.kadmon.com/

http://www.celsion.com/

http://www.tapimmune.com/




http://www.oncomed.com/


Breast Cancer


Xgeva® Amgen delay of prevention of bone metastases in Phase III

denosumab Thousand Oaks, CA breast cancer www.amgen.com

(see also lung, myeloma)

Xtandi® Astellas Pharma US breast cancer Phase II

enzalutamide Northbrook, IL (see also liver, prostate) www.astellas.com

Medivation www.medivation.com

San Francisco, CA

Zytiga® Janssen Research & Development metastatic ER-positive HER2 negative Phase II

abiraterone acetate Raritan, NJ breast cancer in post-menopausal women www.janssenrnd.com

Colorectal Cancer


ABP 494 Allergan metastatic colorectal cancer Phase III

(bevacizumab biosimilar) Parsippany, NJ www.amgen.com

Amgen

Thousand Oaks, CA

bavituximab Peregrine Pharmaceuticals rectal cancer Phase I

Tustin, CA (see also breast, lung, skin) www.peregrineinc.com

BBI608 Boston Biomedical colorectal cancer Phase III

(cancer stem cell inhibitor) Cambridge, MA (see also breast, hematological, liver, www.bostonbiomedical.com

lung, ovarian, pancreatic, skin, stomach)

colorectal cancer (combination therapy) Phase III

www.bostonbiomedical.com


http://www.astellas.com/

http://www.medivation.com/






Colorectal Cancer


CEA cancer immunotherapy AlphaVax late-stage colorectal cancer Phase I/II

(AVX701) Research Triangle Park, NC www.alphavax.com

Duke University

Durham, NC

CPX-1 Celator Pharmaceuticals colorectal cancer Phase II

(irinotecan/floxuridine liposomal) Ewing, NJ www.celatorpharma.com

CRLX101 Cerulean Pharma non-metastatic rectal cancer Phase II

(nanoparticle drug conjugate) Cambridge, MA (see also kidney, ovarian) www.ceruleanrx.com

E7820 Eisai colorectal cancer Phase II

(integrin alpha2 inhibitor) Woodcliff Lake, NJ www.eisai.com

encapsulated cell therapy Rogosin Institute metastatic colorectal cancer Phase II

New York, NY (see also pancreatic, prostate) www.rogosin.org

Metromedia Bio-Science www.metromediabioscience.com

New York, NY

ensituximab Precision Biologics advanced colorectal cancer Phase II

(neoplasm antigen inhibitor) Dallas, TX (see also pancreatic) www.precision-biologics.com

ETBX-011 Etubics colorectal cancer Phase II

(vector cancer vaccine) Seattle, WA www.etubics.com

etirinotecan pegol (NKTR-102) Nektar Therapeutics colorectal cancer (2nd-line) Phase II completed

(PEGylated irinotecan) San Francisco, CA (see also breast, ovarian) www.nektar.com

GEN 1 Celsion colorectal cancer Phase II

(cancer immunotherapy) Lawrenceville, NJ (see also ovarian) www.celsion.com

imalumab (BAX 069) Baxalta metastatic colorectal cancer Phase II

(MIF inhibitor) Cambridge, MA www.baxalta.com

http://www.alphavax.com/

http://www.celatorpharma.com/

http://www.ceruleanrx.com/


http://www.rogosin.org/

http://www.metromediabioscience.com/

http://www.precision-biologics.com/

http://www.etubics.com/




Colorectal Cancer


Imprime PGG® Biothera metastatic colorectal cancer (3rd-line) Phase III

intravenous immunostimulant Eagan, MN (see also leukemia, lung, lymphoma, pancreatic) www.biothera.com

Jakafi® Incyte colorectal cancer Phase II

ruxolitinib Wilmington, DE (see also breast, lung, pancreatic) www.incyte.com

labetuzumab-SN-38 Immunomedics metastatic colorectal cancer Phase II

(IMMU-130) Morris Plains, NJ www.immunomedics.com

MGD007 MacroGenics late-stage colorectal cancer Phase I

(gpA33/CD3 bispecific antibody) Rockville, MD www.macrogenics.com

MORAb-004 Eisai colorectal cancer Phase II

(CD248 antigen inhibitor) Woodcliff Lake, NJ (see also sarcoma, skin) www.eisai.com

NK012 Nippon Kayaku colorectal cancer Phase II

(DNA topoisomerase I inhibitor) Tokyo, Japan (see also breast, lung) www.nipponkayaku.co.jp

OncoVAX® Vaccinogen stage II colon cancer (Fast Track) Phase III

cancer immunotherapy Frederick, MD www.vaccinogeninc.com

Opdivo® Bristol-Myers Squibb microsatellite instability (MSI)-positive colon cancer Phase II

nivolumab Princeton, NJ (see also bladder, brain, head/neck, hematological, www.bms.com


stomach, other)

polyclonal antibody stimulator Cancer Advances colorectal cancer Phase II completed

(G17DT) Durham, NC (see also pancreatic, stomach) www.canceradvancesinc.com

Reolysin® Oncolytics Biotech metastatic colorectal cancer Phase I

pelareorp Calgary, Canada (see also brain, head/neck, lung, myeloma, ovarian, www.oncolyticsbiotech.com

other, pancreatic)

http://www.biothera.com/






http://www.vaccinogeninc.com/

http://www.bms.com/

http://www.canceradvancesinc.com/


Colorectal Cancer


RG7221 Genentech/Roche metastatic colorectal cancer Phase II

(Ang2-VEGF mAb) South San Francisco, CA www.roche.com

RRx-001 EpicentRx metastatic colorectal cancer Phase II

(free radical stimulant) Mountain View, CA (see also liver, lung, lymphoma, other) www.radiorx.com

SM04755 Samumed advanced colorectal cancer Phase I

(Wnt inhibitor) San Diego, CA (see also liver, pancreatic, stomach) www.samumed.com

Stivarga® Bayer HealthCare Pharmaceuticals colorectal cancer with resected liver metastases Phase III

regorafenib Whippany, NJ (see also kidney, liver) www.healthcare.bayer.com

Tafinlar® Novartis Pharmaceuticals BRAF V600-positive colorectal cancer Phase I/II

dabrafenib East Hanover, NJ (see also lung, skin) www.novartis.com

Mekinist™

trametinib

combination

TAS-102 Taiho Oncology colorectal cancer (Fast Track) application submitted

(tipiracil/trifluridine) Princeton, NJ (see also stomach) www.taihooncology.com

TRC105 TRACON Pharmaceuticals colorectal cancer Phase I

(END protein inhibitor) San Diego, CA (see also brain, breast, kidney, liver, lung, www.traconpharma.com

sarcoma, other)

Vargatef® Boehringer Ingelheim Pharmaceuticals metastatic colorectal cancer Phase III

nintedanib Ridgefield, CT (see also lung, ovarian) www.boeringer-ingelheim.com

Vectibix® Amgen chemo refractory wild-type KRAS exon 2 Phase III

panitumumab Thousand Oaks, CA metastatic colorectal cancer www.amgen.com

veliparib AbbVie metastatic colorectal cancer Phase II

(PARP inhibitor) North Chicago, IL (see also brain, breast, lung, skin) www.abbvie.com


http://www.radiorx.com/

http://www.samumed.com/


http://www.taihooncology.com/


http://www.boeringer-ingelheim.com/



Head and Neck Cancer


Xilonix™ XBiotech metastatic colorectal cancer (Fast Track) Phase III

IgG1k Mab Austin, TX www.xbiotech.com

Zelboraf® Genentech/Roche BRAF mutation-positive metastatic Phase III

vemurafenib South San Francisco, CA colorectal cancer (adjuvant) www.roche.com

Daiichi Sankyo (see also skin, other)

Parsippany, NJ

ACP-196 Acerta Pharma advanced head and neck cancer Phase II

(Btk inhibitor) San Carlos, CA (combination therapy) www.acerta-pharma.com

(see also bladder, hematological, leukemia, lung,

lymphoma, myeloma, pancreatic)

Ad-IL-24 MultiVir head and neck cancer Phase II

(interleukin-24 gene therapy) San Diego, CA www.multivir.com

ADXS-HPV Advaxis head and neck cancer (neoadjuvant) Phase II

(immunotherapy vaccine) Princeton, NJ (see also other) www.advaxis.com

Orphan Drug

metastatic head and neck cancer Phase I/II

(combination therapy) www.advaxis.com

docetaxel injection concentrate, Teikoku Pharma USA head and neck cancer application submitted

non-alcohol formula San Jose, CA (see also breast, lung, prostate, stomach) www.teikokuusa.com

GC4419 Galera Therapeutics head and neck cancer (1st-line) Phase I

(superoxide dismutase modulator) Malvern, PA www.galeratx.com

Gilotrif® Boehringer Ingelheim Pharmaceuticals squamous cell carcinoma of the head and neck Phase III

afatinib Ridgefield, CT (see also brain, lung) www.boehringer-ingelheim.com

http://www.xbiotech.com/



http://www.multivir.com/

http://www.advaxis.com/



http://www.galeratx.com/




GL-0817 Gliknik squamous cell cancer of the oral cavity Phase II

(cancer immunotherapy) Baltimore, MD www.gliknik.com

Orphan Drug

GL-ONC1 Genelux head and neck cancer Phase I

(oncolytic virus immunomodulator) San Diego, CA (see also lung, other) www.genelux.com

HF10 Takara Bio head and neck cancer Phase I

(oncolytic virus immunomodulator) Shiga, Japan (see also skin) www.takara-bio.com

INO-3112 Inovio Pharmaceuticals head and neck cancer caused by HPV Phase I/II

(cancer immunotherapy) Plymouth Meeting, PA types 16 and 18 www.inovio.com

(see also other)

interleukin-12 gene therapy OncoSec Medical metastatic head and neck cancer Phase II

San Diego, CA (see also breast, skin) www.oncosec.com

IRX-2 IRX Therapeutics head and neck cancer Phase II

(immunostimulant) New York, NY www.irxtherapeutics.com

Keytruda® Merck head and neck cancer Phase III

pembrolizumab Kenilworth, NJ (see also bladder, breast, lung, lymphoma, www.merck.com

stomach)

MEDI4736 MedImmune squamous cell head and neck cancer (2nd-line) Phase III

(anti-PD-L1 mAb) Gaithersburg, MD (see also lung, solid tumors) www.medimmune.com

MGA271 Macrogenics squamous cell cancer of the head and neck Phase I

(CD276 protein inhibitor) Rockville, MD (combination therapy) www.macrogenics.com

(see also lung, skin)

Multikine® CEL-SCI head and neck cancer (1st-line) Phase III

leukocyte interleukin injection Vienna, VA www.cel-sci.com

http://www.gliknik.com/

http://www.genelux.com/

http://www.takara-bio.com/



http://www.irxtherapeutics.com/




http://www.cel-sci.com/



motolimod VentiRx Pharmaceuticals head and neck cancer Phase II

(TLR8 agonist immunotherapy) Seattle, WA (see also ovarian) www.ventirx.com

Opdivo® Bristol-Myers Squibb head and neck cancer (2nd-line) Phase III

nivolumab Princeton, NJ (see also bladder, brain, colorectal, hematological, www.bms.com


stomach, other)

Reolysin® Oncolytics Biotech platinum-refractory head and neck cancer Phase III

pelareorp Calgary, Canada (see also brain, colorectal, lung, myeloma, www.oncolyticsbiotech.com

ovarian, other, pancreatic)

RM-1929 Aspyrian Therapeutics recurrent head and neck cancer Phase I

(EGFR antagonist) San Diego, CA www.aspyriantherapeutics.com

selinexor (oral) Karyopharm Therapeutics head and neck squamous cell carcinoma Phase II

(XPO1 antagonist) Newton, MA (see also brain, hematological, leukemia, lymphoma, www.karyopharm.com

myeloma, prostate, sarcoma, other)

Hematological Malignancies


ACP-196 Acerta Pharma B-cell malignancies (combination therapy) Phase I/II

(Btk inhibitor) San Carlos, CA (see also bladder, head/neck, leukemia, lung, www.acerta-pharma.com

lymphoma, myeloma, pancreatic)

ALT-803 Altor BioScience hematological malignancies Phase I/II

(IL-15 superagonist complex) Miramar, FL (see also bladder, myeloma, skin) www.altorbioscience.com

AMG 319 Amgen hematological malignancies Phase I

(PI3K-delta inhibitor) Thousand Oaks, CA www.amgen.com

http://www.ventirx.com/

http://www.bms.com/


http://www.aspyriantherapeutics.com/







AMG 900 Amgen hematological malignancies Phase I

(aurora kinase inhibitor) Thousand Oaks, CA (see also solid tumors) www.amgen.com

anti-LAG3 Bristol-Myers Squibb hematological malignancies Phase I


APTO-253 Aptose Biosciences relapsed/refractory blood cancers Phase I

(MTF-1 inhibitor) San Diego, CA www.aptose.com

AR-42 Arno Therapeutics hematological malignancies Phase I/II

(pan-DAC inhibitor) Flemington, NJ (see also solid tumors) www.arnothera.com

Aranesp® Amgen low-risk myelodysplastic syndromes Phase III

darbepoetin alfa Thousand Oaks, CA www.amgen.com

ASB183 Novartis Pharmaceuticals hematological malignancies Phase I

East Hanover, NJ (see also solid tumors) www.novartis.com

ASTX727 Astex Pharmaceuticals myelodysplastic syndromes Phase I

DNA methylation inhibitor/ Pleasanton, CA www.astx.com

nucleoside deaminase inhibitor)

AZD9150 AstraZeneca hematological malignancies Phase I

(STAT3 inhibitor) Wilmington, DE www.astrazeneca.com

Isis Pharmaceuticals www.isispharm.com

Carlsbad, CA

BBI608 Boston Biomedical hematological malignancies Phase I

(cancer stem cell inhibitor) Cambridge, MA (see also breast, colorectal, liver, www.bostonbiomedical.com



http://www.bms.com/

http://www.aptose.com/

http://www.arnothera.com/



http://www.astx.com/


http://www.isispharm.com/




BB-MPI-03 Benovus Bio myelodysplastic syndromes Phase I

(multi-peptide immunotherapy) Atlanta, GA (see also leukemia, myeloma) www.benovusbio.com

BI 836858 Boehringer Ingelheim Pharmaceuticals myelodysplastic syndromes Phase I/II

Ridgefield, CT (see also leukemia) www.boehringer-ingelheim.com

birinapant TetraLogic Pharmaceuticals myelodysplastic syndromes Phase II

(apoptosis stimulator) Malvern, PA (see also lymphoma, ovarian) www.tetralogicpharma.com

BP-100-1-01 Bio-Path Holdings myelodysplastic syndromes Phase I

(liposomal Grb 2) Houston, TX (see also leukemia) www.biopathholdings.com

BPX-501 Bellicum Pharmaceuticals adjunct T-cell therapy following bone marrow Phase I/II

(T-cell replacement therapy) Houston, TX transplantation in hematological malignancies www.bellicum.com

brontictuzumab OncoMed Pharmaceuticals hematological malignancies Phase I

(NOTCH-1 inhibitor) Redwood City, CA (see also solid tumors) www.oncomed.com

BVD-523 BioMed Valley Discoveries myelodysplastic syndromes Phase I/II

(ERK 1/2 kinase inhibitor) Kansas City, MO (see also leukemia, solid tumors) www.biomed-valley.com

CB-839 Calithera Biosciences hematological malignancies Phase I

(glutaminase inhibitor) South San Francisco, CA (see also solid tumors) www.calithera.com

CC-486 Celgene myelodysplastic syndromes (lower risk) Phase III

(DNA methylation inhibitor) Summit, NJ (see also breast, leukemia, lung, lymphoma, other) www.celgene.com

post hypomethylating agent (HMA) failure in Phase II

myelodysplastic syndromes www.celgene.com

CDX-301 Celldex Therapeutics stem cell transplantation in hematological Phase II

(Fms-like tyrosine kinase 3 ligand) Hampton, NJ malignancies www.celldex.com

(see also lymphoma)

http://www.benovusbio.com/


http://www.tetralogicpharma.com/

http://www.biopathholdings.com/

http://www.bellicum.com/


http://www.biomed-valley.com/

http://www.calithera.com/






CM-CS1 Celyad hematological malignancies Phase I

(NKG2D CAR T-cell therapy) Rochester, MN www.celyad.com

CPI-0610 Constellation Pharmaceuticals myelodysplastic syndromes, Phase I

(BET inhibitor) Cambridge, MA myeloproliferative disorders www.constellationpharma.com

(see also leukemia, lymphoma, myeloma)

DCR-MYC Dicerna Pharmaceuticals hematological malignancies Phase I

(c-myc inhibitor) Watertown, MA (see also liver) www.dicerna.com

duvelisib AbbVie advanced hematological malignancies Phase I

(PI3K inhibitor) North Chicago, IL (see also leukemia, lymphoma) www.abbvie.com

Infinity Pharmaceuticals www.infi.com

Cambridge, MA

E6201 Strategia Therapeutics hematological malignancies Phase I/II

(MEK-1/Flt3 dual inhibitor) Boston, MA www.strategiarx.com

entospletinib Gilead Sciences hematological malignancies Phase II

(Syk inhibitor) Foster City, CA www.gilead.com

evofosfamide (TH-302) EMD Serono hematological malignancies Phase I

(hypoxia-activated prodrug) Rockland, MA (see also brain, lung, pancreatic, sarcoma, skin) www.emdserono.com

Threshold Pharmaceuticals www.thresholdpharm.com


FF-10501 Strategia Therapeutics hematological malignancies Phase I/II

(cell differentiation stimulant) Boston, MA www.strategiarx.com

FUJIFILM Pharmaceuticals USA

Boston, MA

glasdegib (PF-04449913) Pfizer myelodysplastic syndromes Phase II

(SMO [smoothened] antagonist) New York, NY (see also leukemia) www.pfizer.com

http://www.celyad.com/

http://www.constellationpharma.com/

http://www.dicerna.com/


http://www.infi.com/

http://www.strategiarx.com/

http://www.gilead.com/

http://www.emdserono.com/


http://www.strategiarx.com/




GS-4059 Gilead Sciences B-cell malignancies Phase I

(BTK inhibitor) Foster City, CA www.gilead.com

GS-9901 Gilead Sciences hematological malignancies Phase I

(PI3K delta inhibitor) Foster City, CA www.gilead.com

HDM201 Novartis Pharmaceuticals hematological malignancies Phase I

(tumor suppressor protein East Hanover, NJ (see also sarcoma, solid tumors) www.novartis.com

p53 modulator)

HSC835 Novartis Pharmaceuticals hematological malignancies in single Phase II

(stem cell therapy) East Hanover, NJ umbilical cord blood transplantation www.novartis.com

Ibrance® Pfizer hematological malignancies Phase I

palbociclib New York, NY (see also breast) www.pfizer.com

idasanutlin Genentech/Roche hematological malignancies Phase I

(MDM2 antagonist) South San Francisco, CA (see also solid tumors) www.roche.com

imetelstat Janssen Research & Development myelofibrosis Phase II

Raritan, NJ www.janssenrnd.com

INCB40093 Incyte B-cell malignancies Phase I/II

(PI3K-delta inhibitor) Wilmington, DE www.incyte.com

INCB52793 Incyte hematological malignancies Phase I/II

(JAK1 inhibitor) Wilmington, DE www.incyte.com

INCB54329 Incyte hematological malignancies Phase I

(BRD inhibitor) Wilmington, DE www.incyte.com













JNJ-64052781 Janssen Research & Development hematological malignancies Phase I

(CD19 antigen modulator) Raritan, NJ www.janssenrnd.com

JTCR016 Juno Therapeutics myelodysplastic syndromes Phase I/II

(T lymphocyte immunotherapy) Seattle, WA (see also leukemia) www.junotherapeutics.com

KB004 KaloBios Pharmaceuticals EphA3-positive hematological Phase II

(EphA3 kinase inhibitor) South San Francisco, CA malignancies www.kalobios.com

KiroVAX-001 Kiromic hematological malignancies Phase I

(dendritic cell vaccine) Houston, TX www.kiromic.com

luspatercept (ACE-536) Acceleron Pharma myelodysplastic syndromes Phase II

(TGF-ß protein super family Cambridge, MA www.acceleronpharma.com

inhibitor) Celgene www.celgene.com

Orphan Drug Summit, NJ

MEDI-551 + rituximab MedImmune hematological malignancies Phase I

(anti-CD19 mAb/anti-CD20 mAb) Gaithersburg, MD www.medimmune.com

MK-8628 Merck hematological malignancies Phase II

(BRD-2/3/4 inhibitor) Kenilworth, NJ www.merck.com

mocetinostat Mirati Therapeutics myelodysplastic syndromes Phase II

(HDAC inhibitor) San Diego, CA (see also bladder, lymphoma) www.mirati.com

Orphan Drug

momelotinib Gilead Sciences myelofibrosis Phase III

(JAK inhibitor) Foster City, CA (see also pancreatic) www.gilead.com

Orphan Drug


http://www.junotherapeutics.com/

http://www.kalobios.com/

http://www.kiromic.com/

http://www.acceleronpharma.com/







MRX34 Mirna Therapeutics hematological malignancies Phase I

(liposome-encapsulated Austin, TX (see also liver) www.mirnarx.com

miR-34 mimic)

NiCord® Gamida Cell hematological malignancies Phase I/II

cord blood stem cell therapy Jerusalem, Israel www.gamida-cell.com

Orphan Drug

Opdivo® Bristol-Myers Squibb hematological malignancies Phase I

nivolumab Princeton, NJ (see also bladder, brain, colorectal, head/neck, kidney, www.bms.com

liver, lung, lymphoma, skin, solid tumors, stomach, other)

oprozomib Onyx Pharmaceuticals Waldenstrom's macroglobulinemia (monotherapy) Phase II

(proteasome inhibitor) South San Francisco, CA (see also myeloma, solid tumors) www.onyx.com

Orphan Drug

hematological malignancies Phase I

(combination therapy) www.onyx.com

OTX015 Merck hematological malignancies Phase I(BET inhibitor) Kenilworth, NJ (see also solid tumors) ww.merck.com

OXi4503 OxiGENE myelodysplastic syndromes Phase I

(vascular disrupting agent) South San Francisco, CA (see also leukemia) www.oxigene.com

PAC-1 Vanquish Oncology hematological malignancies Phase I

(procaspase activating compound-1) Champaign, IL (see also solid tumors) www.vanquishoncology.com

pacritinib Baxalta myelofibrosis (Fast Track) Phase III

(JAK2/FLT3 dual inhibitor) Cambridge, MA (see also leukemia) www.Baxalta.com

http://www.mirnarx.com/

http://www.gamida-cell.com/

http://www.bms.com/

http://www.onyx.com/


http://www.oxigene.com/

http://www.vanquishoncology.com/

http://www.baxlata.com/



PIM447 Novartis Pharmaceuticals myelodysplastic syndromes Phase I

(proto oncogene protein c East Hanover, NJ (see also leukemia, myeloma) www.novartis.com

pim-1 inhibitor)

POL6326 Polyphor stem cell mobilization in hematological malignancies Phase I

(CXCR4 receptor antagonist) Allschwil, Switzerland (see also breast) www.polyphor.com

pracinostat MEI Pharma myelodysplastic syndromes (1st-line), Phase II

(HDAC inhibitor) San Diego, CA refractory myelodysplastic syndromes www.meipharma.com

(see also leukemia)

PRM-151 Promedior myelofibrosis (Fast Track) Phase II

(rhPTX-1 for injection) Lexington, MA www.promedior.com

Orphan Drug

Promacta® Novartis Pharmaceuticals myelodysplastic syndromes Phase II

eltrombopag East Hanover, NJ www.novartis.com

Revlimid® Celgene myelodysplastic syndromes (non-deletion 5q) Phase III

lenalidomide Summit, NJ (see also leukemia, lymphoma, myeloma) www.celgene.com

Orphan Drug

rexlemestrocel-L Mesoblast for bone marrow regeneration in patients with Phase III

(allogeneic autologous New York, NY hematological malignancies undergoing bone www.mesoblast.com

mesenchymal precursor cells) marrow transplantation

Orphan Drug


http://www.polyphor.com/

http://www.meipharma.com/

http://www.promedior.com/



http://www.mesoblast.com/



rigosertib Onconova Therapeutics post-HMR high-risk myelodysplastic syndromes Phase III

(PI3K/Plk1 inhibitor) Newtown, PA (see also leukemia) www.onconova.com

Orphan Drug

high-risk myelodysplastic syndromes Phase II

(1st-line) (combination therapy), www.onconova.com

low-risk myelodysplastic syndromes (1st-line)

RP-323 Rich Pharmaceuticals myelodysplastic syndromes Phase II

(tetradecanoylphorbol acetate) Beverly Hills, CA (see also leukemia) www.richpharmaceuticals.com

sapacitabine Cyclacel Pharmaceuticals myelodysplastic syndromes Phase II

(DNA-directed DNA polymerase Berkeley Heights, NJ (see also leukemia, lung) www.cyclacel.com

inhibitor)

Orphan Drug

selinexor (oral) Karyopharm Therapeutics Richter's transformation Phase III

(XPO1 antagonist) Newton, MA (see also brain, head/neck, leukemia, lymphoma, www.karyopharm.com

myeloma, prostate, sarcoma, other)

SGI-110 Astex Pharmaceuticals myelodysplastic syndromes Phase II

(DNMT inhibitor) Pleasanton, CA (see also leukemia, liver, ovarian) www.astx.com

SL-401 Stemline Therapeutics blastic plasmacytoid dendritic cell neoplasm, Phase I/II

(IL-3R inhibitor) New York, NY advanced high risk myeloproliferative neoplasm www.stemline.com

(see also leukemia)

StemEx® Gamida Cell-Teva Joint Venture hematological malignancies Phase III

carlecortemcel-L Jerusalem, Israel (Fast Track) www.gamida-cell.com

TAK-659 Takeda Oncology hematological malignancies Phase I

(SYK kinase inhibitor) Cambridge, MA (see also solid tumors) www.takedaoncology.com

http://www.onconova.com/


http://www.richpharmaceuticals.com/

http://www.cyclacel.com/




http://www.gamida-cell.com/




TEN-010 Tensha Therapeutics myelodysplastic syndromes Phase I

(BET inhibitor) Cambridge, MA (see also leukemia, solid tumors) www.tenshatherapeutics.com

TGR-1202 TG Therapeutics hematological malignancies Phase I

(PI3K inhibitor) New York, NY www.tgtherapeutics.com

tosedostat CTI BioPharma myelodysplastic syndromes Phase II

(aminopeptidase inhibitor) Seattle, WA (see also leukemia) www.ctibiopharma.com

TZ101 Targazyme cord blood stem cell transplantation Phase I/II

(human recombinant enzyme) San Antonio, TX in hematological malignancies www.targazyme.com

ulocuplumab Bristol-Myers Squibb hematological malignancies Phase I

(anti-CXCR4) Princeton, NJ www.bms.com

urelumab Bristol-Myers Squibb hematological malignancies Phase I

Princeton, NJ (see also solid tumors) www.bms.com

urelumab + Bristol-Myers Squibb hematological malignancies Phase I

Opdivo® nivolumab Princeton, NJ (see also solid tumors) www.bms.com

varlilumab Celldex Therapeutics hematological malignancies Phase I

(CD27 antigen inhibitor) Hampton, NJ (see also kidney, skin) www.celldex.com

venetoclax AbbVie hematological malignancies Phase I

(Bcl-2 inhibitor) North Chicago, IL (see also leukemia, lymphoma) www.abbvie.com

Genentech/Roche www.roche.com


WT-1 cancer vaccine SELLAS Life Sciences hematological malignancies Phase II

Zug, Switzerland www.sellaslifesciences.com

http://www.tenshatherapeutics.com/

http://www.tgtherapeutics.com/

http://www.ctibiopharma.com/

http://www.targazyme.com/

http://www.bms.com/

http://www.bms.com/

http://www.bms.com/




http://www.sellaslifesciences.com/



WT2725 Sunovion Pharmaceuticals hematological malignancies Phase I

(cancer immunotherapy) Marlborough, MA (see also solid tumors) www.sunovion.com

Kidney Cancer


AGS-003 Argos Therapeutics metastatic renal cell carcinoma Phase III

(personalized dendritic Durham, NC (combination therapy) (Fast Track) www.argostherapeutics.com

cell-based vaccine)

metastatic renal cell carcinoma Phase II

(monotherapy) www.argostherapeutics.com

AGS-16C3F Agensys kidney cancer Phase I


Astellas Pharma www.astellas.com

Tokyo, Japan

AMG 172 Amgen kidney cancer Phase I

(antibody drug conjugate) Thousand Oaks, CA www.amgen.com

Archexin® Rexahn Pharmaceuticals metastatic renal cell carcinoma Phase II

Akt1 inhibitor Rockville, MD www.rexahn.com

Orphan Drug

BNC105 Bionomics renal cell carcinoma Phase II

(vascular disrupting agent) Thebarton, Australia (see also ovarian) www.bionomics.com.au

Cometriq® Exelixis renal cell carcinoma (Fast Track) Phase III

cabozantinib South San Francisco, CA (see also brain, liver) www.exelixis.com

http://www.sunovion.com/

http://www.argostherapeutics.com/

http://www.argostherapeutics.com/




http://www.rexahn.com/

http://www.bionomics.com.au/


Kidney Cancer


CRLX101 Cerulean Pharma relapsed renal cell carcinoma Phase II

(nanoparticle drug conjugate) Cambridge, MA (see also colorectal, ovarian) www.ceruleanrx.com

dalantercept Acceleron Pharma renal cell carcinoma Phase II

(ALK1 antagonist) Cambridge, MA (see also liver) www.acceleronpharma.com

HyperAcute™ Renal NewLink Genetics metastatic renal cancer Phase I

renal cancer immunotherapy vaccine Ames, IA www.newlinkgenetics.com

IMA901 immatics Biotechnologies renal cancer Phase III

(multiple tumor-associated Tuebingen, Germany www.immatics.com

peptides)

Inlyta® Pfizer renal cell carcinoma Phase III

axitinib New York, NY (see also solid tumors) www.pfizer.com

Orphan Drug

Lenvima® Eisai renal cell carcinoma Phase I/II

lenvatinib Woodcliff Lake, NJ (see also liver, lung, skin, other, solid tumors) www.eisai.com

LY2510924 Eli Lilly clear-cell renal cell carcinoma Phase II

(CXCR4 peptide antagonist) Indianapolis, IN (see also lung) www.lilly.com

Nexavar® Bayer HealthCare Pharmaceuticals renal cell carcinoma (adjuvant) Phase III

sorafenib Whippany, NJ (see also other) www.healthcare.bayer.com

OBP-801 Oncolys BioPharma recurrent renal cancer Phase I

(HDAC inhibitor) Tokyo, Japan www.oncolys.com

Opdivo® Bristol-Myers Squibb renal cell carcinoma (2nd/3rd-line) Phase III

nivolumab Princeton, NJ (see also bladder, brain, colorectal, head/neck, www.bms.com

hematological, liver, lung, lymphoma, skin,

solid tumors, stomach, other)




http://www.immatics.com/




http://www.oncolys.com/

http://www.bms.com/

Kidney Cancer


Opdivo® nivolumab + Bristol-Myers Squibb renal cell carcinoma (1st-line) Phase III

Yervoy® ipilimumab Princeton, NJ (see also lung, skin, solid tumors) www.bms.com

pexastimogene devacirepvec SillaJen Biotherapeutics treatment refractory kidney cancer Phase II

(genetically-engineered oncolytic San Francisco, CA (see also liver) www.sillajen.com

vaccinia virus)

PT-2385 Peloton Therapeutics clear cell renal cell carcinoma Phase I

(HIF-2α inhibitor) Dallas, TX www.pelotontherapeutics.com

RG7446 Genentech/Roche renal cell carcinoma Phase III

(anti-PD-L1 mAb) South San Francisco, CA (see also bladder, breast, lung, lymphoma, skin) www.roche.com

savolitinib/volitinib AstraZeneca papillary renal cell carcinoma Phase II

(MET tyrosine kinase inhibitor) Wilmington, DE www.astrazeneca.com

SGN-CD70A Seattle Genetics renal cell carcinoma Phase I

(antibody drug conjugate) Bothell, WA (see also lymphoma) www.seattlegenetics.com

sonepcizumab Lpath renal cell carcinoma Phase II

(anti-sphingosine-1-phosphate San Diego, CA www.lpath.com

mAb)

Stivarga® Bayer HealthCare Pharmaceuticals renal cell carcinoma Phase II

regorafenib Whippany, NJ (see also colorectal, liver) www.healthcare.bayer.com

Sutent® Pfizer renal cell carcinoma (adjuvant) Phase III

sunitinib New York, NY www.pfizer.com

TAK-228 Takeda Oncology renal cancer Phase II

(mTORC1/2 inhibitor) Cambridge, MA (see also breast, other) www.takedaoncology.com

http://www.bms.com/

http://www.sillajen.com/

http://www.pelotontherapeutics.com/




http://www.lpath.com/



Kidney Cancer


TRC105 TRACON Pharmaceuticals renal cell carcinoma Phase II

(END protein inhibitor) San Diego, CA (see also brain, breast, colorectal, liver, lung, www.traconpharma.com

sarcoma, other)

TVI-Kidney-1 TVAX Biomedical kidney cancer Phase II

(personalized cancer Lenexa, KS (see also brain) www.tvaxbiomedical.com

immunotherapy)

varlilumab Celldex Therapeutics metastatic clear cell renal cell carcinoma Phase I/II

(CD27 antigen inhibitor) Hampton, NJ (combination therapy) www.celldex.com

(see also hematological, skin)

Votrient® Novartis Pharmaceuticals renal cell carcinoma (adjuvant) Phase III

pazopanib East Hanover, NJ www.novartis.com

Leukemia


Å6 peptide Angstrom Pharmaceuticals chronic lymphocytic leukemia (CLL), Phase II

(CD44 antigen stimulant) Solana Beach, CA small lymphocytic leukemia www.angstrominc.com

ABL001 Novartis Pharmaceuticals chromic myeloid leukemia (CML) Phase I

(Bcr-abl tyrosine kinase inhibitor) East Hanover, NJ www.novartis.com


http://www.tvaxbiomedical.com/



http://www.angstrominc.com/


Leukemia


ACP-196 Acerta Pharma CLL Phase III

(Btk inhibitor) San Carlos, CA (see also bladder, head/neck, hematological, www.acerta-pharma.com

lung, lymphoma, myeloma, pancreatic)

relapsed/refractory and treatment naïve Phase II

deletion 17p CLL www.acerta-pharma.com

CLL (combination therapy) Phase I

www.acerta-pharma.com

ACP-319 Acerta Pharma CLL (combination therapy) Phase I/II

(Btk inhibitor) San Carlos, CA (see also lymphoma) www.acerta-pharma.com

AG-120 Agios Pharmaceuticals acute myeloid leukemia (AML) Phase I

(IDH1 inhibitor) Cambridge, MA (see also brain, solid tumors) www.agios.com


Summit, NJ

AG-221 Agios Pharmaceuticals AML Phase I

(IDH2 inhibitor) Cambridge, MA (see also solid tumors) www.agios.com

Orphan Drug Celgene www.celgene.com

Summit, NJ

alvocidib Tolero Pharmaceuticals AML (1st-line) Phase III

(angiogenesis inhibitor) Lehi, UT www.toleropharmaceuticals.com

Orphan Drug

relapsed/refractory AML Phase II

www.toleropharmaceuticals.com

AMG 232 Amgen AML Phase I

(MDM2 inhibitor) Thousand Oaks, CA (see also myeloma, skin, solid tumors) www.amgen.com









http://www.toleropharmaceuticals.com/

http://www.toleropharmaceuticals.com/


Leukemia


Arzerra® Novartis Pharmaceuticals CLL (maintenance therapy), CLL (relapse) Phase IIIofatumumab East Hanover, NJ (see also lymphoma) www.novartis.com

Orphan Drug

ASP2215 Astellas Pharma US AML Phase III

(FLT3/AXL inhibitor) Northbrook, IL (see also lung) www.astellas.com

AST-VAC1 Asterias Biotherapeutics AML Phase II completed

(telomerase-based cancer vaccine) Menlo Park, CA www.asterias.com

ATTCK20 Unum Therapeutics CLL Phase I

(viral-ACTR+anti-CD20) Cambridge, MA (see also lymphoma) www.unumrx.com

BAY1143572 Bayer HealthCare Pharmaceuticals acute leukemia Phase I

Whippany, NJ (see also other) www.healthcare.bayer.com

BB-MPI-03 Benovus Bio AML Phase I

(multi-peptide immunotherapy) Atlanta, GA (see also hematological, myeloma) www.benovusbio.com

bendamustine ready-to-dilute Eagle Pharmaceuticals CLL application submitted

liquid formulation Woodcliff Lake, NJ (see also lymphoma, solid tumors) www.eagleus.com

Orphan Drug

BI 836826 Boehringer Ingelheim Pharmaceuticals CLL Phase I

Ridgefield, CT www.boehringer-ingelheim.com

BI 836858 Boehringer Ingelheim Pharmaceuticals relapsed/refractory AML Phase I

Ridgefield, CT (see also hematological) www.boehringer-ingelheim.com

BL-8040 BioLineRx AML (combination therapy) Phase II

(CXCR4 receptor antagonist) Jerusalem, Israel www.biolinerx.com

Orphan Drug



http://www.asterias.com/

http://www.unumrx.com/


http://www.eagleus.com/



http://www.biolinerx.com/

Leukemia


Blincyto® Amgen relapsed/refractory acute lymphoblastic Phase III

blinatumomab Thousand Oaks, CA leukemia (ALL) in adults www.amgen.com

(see also lymphoma)

relapsed/refractory Philadelphia Phase II

chromosome positive (Ph+) ALL in adults, www.amgen.com

minimal residual ALL in adults

Bosulif® Pfizer chronic myeloid leukemia (CML) (1st-line) Phase III

bosutinib New York, NY www.pfizer.com

Orphan Drug

BP-100-1-01 Bio-Path Holdings AML Phase II

(liposomal Grb 2) Houston, TX (see also hematological) www.biopathholdings.com

Orphan Drug

ALL, CML Phase I

www.biopathholdings.com

BVD-523 BioMed Valley Discoveries AML Phase I/II

(ERK 1/2 kinase inhibitor) Kansas City, MO (see also hematological, solid tumors) www.biomed-valley.com

calaspargase pegol Baxalta ALL Phase III

Orphan Drug Cambridge, MA www.baxalta.com

CC-122 Celgene CLL Phase I

(pleiotropic pathway modifier) Summit, NJ (see also brain, liver, lymphoma) www.celgene.com

CC-292 Celgene CLL (combination therapy) Phase I

(Btk inhibitor) Summit, NJ (see also lymphoma) www.celgene.com

CC-486 Celgene post-induction AML maintenance Phase III

(DNA methylation inhibitor) Summit, NJ (see also breast, hematological, lung, www.celgene.com

lymphoma, other)











Leukemia


cerdulatinib Portola Pharmaceuticals CLL Phase II

(dual Syk-JAK inhibitor) South San Francisco, CA (see also lymphoma) www.portola.com

CNDO-109 Fortress Biotech AML Phase I/II

(natural killer cell stimulant) New York, NY www.fortressbiotech.com

Orphan Drug

CPI-0610 Constellation Pharmaceuticals leukemia Phase I

(BET inhibitor) Cambridge, MA (see also hematological, lymphoma, myeloma) www.constellationpharma.com

CPX-351 Celator Pharmaceuticals acute AML (Fast Track) Phase II

(cytarabine/daunorubicin) Ewing, NJ www.celatorpharma.com

Orphan Drug

crenolanib AROG Pharmaceuticals relapsed/refractory AML Phase III

(PDGFR inhibitor) Dallas, TX (see also brain, lung, stomach) www.arogpharma.com

newly-diagnosed AML, maintenance therapy Phase II

after bone marrow transplantation in AML www.arogpharma.com

AML (combination therapy) Phase I

www.arogpharma.com

CTL019 Novartis Pharmaceuticals ALL (Breakthrough Therapy) Phase II

(CAR immunotherapy) East Hanover, NJ (see also lymphoma) www.novartis.com

CWP232291 JW Pharmaceutical AML Phase I

(Wnt signaling pathway inhibitor) Seoul, South Korea

CX-01 Cantex Pharmaceuticals AML Phase II

(O-desulfated heparin intravenous) Weston, FL (see also lung, solid tumors) www.cantex.com

http://www.portola.com/

http://www.fortressbiotech.com/


http://www.celatorpharma.com/





http://www.cantex.com/

Leukemia


DFP-10917 Delta-Fly Pharma ALL, AML Phase I/II

(cell cycle inhibitor) Tokushima, Japan

duvelisib AbbVie relapsed/refractory CLL Phase III

(PI3K inhibitor) North Chicago, IL (see also hematological, lymphoma) www.abbvie.com

Orphan Drug Infinity Pharmaceuticals www.infi.com

Cambridge, MA

relapsed/refractory CLL previously Phase I

treated with a BTK inhibitor therapy www.abbvie.com

www.infi.com

EPZ-5676 Celgene ALL and AML with altered MLL gene Phase I

(DOT1L inhibitor) Summit, NJ www.celgene.com

Orphan Drug Epizyme www.epizyme.com

Cambridge, MA

ERY-ASP ERYTECH Pharma ALL (adults) Phase I/II

(asparaginase pegol) Lyon, France www.erytech.com

Orphan Drug

ganetespib Synta Pharmaceuticals AML Phase II

(Hsp90 inhibitor) Lexington, MA (see also breast, lung, ovarian) www.syntapharma.com

glasdegib (PF-04449913) Pfizer AML Phase II

(SMO [smoothened] antagonist) New York, NY (see also hematological) www.pfizer.com

GMI-1271 GlycoMimetics AML Phase I

(E-selectin antagonist) Gaithersburg, MD www.glycomimetics.com

GO-203-2c Genus Oncology relapsed/refractory AML Phase I/II

(MUC1 inhibitor) Vernon Hills, IL www.genusoncology.com






http://www.epizyme.com/

http://www.erytech.com/



http://www.glycomimetics.com/

http://www.genusoncology.com/

Leukemia


HSV-Tk MolMed high risk acute leukemia Phase III

(thymidine kinase cell therapy) Milan, Italy www.molmed.com

Orphan Drug

Iclusig® ARAID Pharmaceuticals Philadelphia chromosome-positive ALL Phase II

ponatinib Cambridge, MA (Ph+ ALL) www.ariad.com

Orphan Drug (see also stomach)

IGN523 Igenica AML Phase I

(antibody drug conjugate) Burlingame, CA www.igenica.com

Imbruvica® Janssen Research & Development relapsed/refractory CLL (combination therapy), Phase III

ibrutinib Raritan, NJ treatment naïve CLL, CLL (1st-line) (combination therapy) www.janssenrnd.com

Orphan Drug (see also lymphoma)

IMGN529 ImmunoGen CLL Phase I

(CD37 protein inhibitor) Waltham, MA (see also lymphoma) www.immunogen.com

IMMU-114 Immunomedics CLL Phase I

(humanized anti-HLA-DR) Morris Plains, NJ (see also lymphoma) www.immunomedics.com

Imprime PGG® Biothera high-risk CLL (1st-line) Phase II

intravenous immunostimulant Eagan, MN (see also colorectal, lung, lymphoma, pancreatic) www.biothera.com

inotuzumab ozogamicin Pfizer acute lymphoblastic leukemia (ALL) Phase III

(CD22-targeted cytotoxic agent) New York, NY www.pfizer.com

Orphan Drug

Iomab™-B Actinium Pharmaceuticals hematopoietic stem cell transplantation in ALL Phase II

BC8-I-131 construct New York, NY www.actiniumpharma.com

JCAR014 Juno Therapeutics acute ALL, refractory CLL Phase I/II

(T lymphocyte immunotherapy) Seattle, WA (see also lymphoma) www.junotherapeutics.com

http://www.molmed.com/

http://www.ariad.com/

http://www.igenica.com/


http://www.immunogen.com/




http://www.actiniumpharma.com/


Leukemia


JCAR015 Juno Therapeutics B-cell ALL Phase I/II

(T lymphocyte immunotherapy) Seattle, WA www.junotherapeutics.com

Orphan Drug

JCAR017 Juno Therapeutics leukemia Phase I/II


JCAR018 Juno Therapeutics ALL Phase I

(T lymphocyte immunotherapy) Seattle, WA (see also lymphoma) www.junotherapeutics.com

JNJ-56022473 CSL AML Phase I

(anti-CD123 mAb) Victoria, Australia www.janssenrnd.com

Janssen Research & Development

Raritan, NJ

JTCR016 Juno Therapeutics ALL, CML Phase I/II

(T lymphocyte immunotherapy) Seattle, WA (see also hematological) www.junotherapeutics.com

KX01 Kinex Pharmaceuticals AML Phase I completed

(non-ATP competitive Sre Buffalo, NY www.kinexpharma.com

kinase inhibitor)

Kyprolis® Onyx Pharmaceuticals pediatric ALL (combination therapy) Phase I/II

carfilzomib South San Francisco, CA (see also lung, myeloma) www.onyx.com

lintuzumab Ac-225 Actinium Pharmaceuticals AML (1st-line) Phase I/II

New York, NY www.actiniumpharma.com

Marqibo® Spectrum Pharmaceuticals elderly Ph-negative ALL (1st-line) Phase III

vinCRIStine sulfate LIPOSOME Henderson, NV (Fast Track) www.sppirx.com

injection (see also lymphoma)

Orphan Drug








http://www.actiniumpharma.com/


Leukemia


MEDI-551 MedImmune CLL Phase II

(anti-CD19 mAb) Gaithersburg, MD (see also lymphoma) www.medimmune.com

MGD006 MacoGenics AML Phase I

(CD123/CD3 bispecific antibody) Rockville, MD www.macrogenics.com

milatuzumab-doxorubicin conjugate Immunomedics ALL Phase I/II

(antibody drug conjugate) Morris Plains, NJ (see also lymphoma) www.immunomedics.com

mogamulizumab Kyowa Hakko Kirin adult T-cell leukemia-lymphoma Phase II

(anti-CCR4 antibody) Princeton, NJ (see also lymphoma) www.kyowa-kirin.com

Orphan Drug

MOR208 MorphoSys ALL, CLL Phase II

(CD19 antigen inhibitor) Martinsried, Germany (see also lymphoma) www.morphosys.com

Orphan Drug

moxetumomab pasudotox MedImmune hairy cell leukemia Phase III

(anti-CD22 recombinant Gaithersburg, MD www.medimmune.com

immunotoxin)

ALL (pediatric) Phase II

www.medimmune.com

Odomzo® Novartis Pharmaceuticals acute leukemia Phase II

sonidegib East Hanover, NJ (see also brain) www.novartis.com

Oncaspar® Baxalta lyophilized ALL Phase III

pegaspargase Cambridge, MA www.baxalta.com

Orphan Drug

AML Phase II

www.baxalta.com




http://www.kyowa-kirin.com/

http://www.morphosys.com/






Leukemia


Oncoquest™-CLL XEME Biopharma CLL (1st-line) Phase I

personalized cancer vaccine Monmouth Junction, NJ www.xemebiopharma.com

Opdivo® nivolumab + Bristol-Myers Squibb CML Phase I

Sprycel® dasatinib Princeton, NJ www.bms.com

otlertuzumab Emergent BioSolutions CLL Phase II

(CD37 protein inhibitor) Gaithersburg, MD www.emergentbiosolutions.com

OVI-123 (cordycepin) OncoVista Innovative Therapies TdT-positive leukemia Phase I/II

(RNA synthesis inhibitor) San Antonio, TX www.oncovista.com

Orphan Drug

OXi4503 OxiGENE refractory AML Phase I

(vascular disrupting agent) South San Francisco, CA (see also hematological) www.oxigene.com

Orphan Drug

pacritinib Baxalta AML Phase I

(JAK2/FLT3 dual inhibitor) Cambridge, MA (see also hematological) www.baxalta.com

PIM447 Novartis Pharmaceuticals AML Phase I

(proto oncogene protein c East Hanover, NJ (see also hematological, myeloma) www.novartis.com

pim-1 inhibitor)

PKC412 Novartis Pharmaceuticals AML Phase III

(signal transduction inhibitor) East Hanover, NJ www.novartis.com

Orphan Drug

PM01183 Pharma Mar acute leukemia Phase II

(marine-derived alkylating agent) Madrid, Spain (see also breast, ovarian) www.pharmamar.com

http://www.xemebiopharma.com/

http://www.bms.com/

http://www.emergentbiosolutions.com/

http://www.oncovista.com/





Leukemia


pracinostat MEI Pharma AML (1st-line) Phase II

(HDAC inhibitor) San Diego, CA (see also hematological) www.meipharma.com

Orphan Drug

PRI-724 PRISM Pharma AML, CML Phase I/II

(CBP/beta catenin inhibitor) Tokyo, Japan (see also pancreatic) www.prismbiolabs.com

Qinprezzo® Sunesis Pharmaceuticals relapsed/refractory AML (Fast Track) Phase III

vosaroxin South San Francisco, CA www.sunesis.com

Orphan Drug

quizartinib Ambit Biosciences relapsed/refractory AML (Fast Track) Phase III

(FLT3 inhibitor) San Diego, CA www.ambitbio.com

Orphan Drug

REGN1979 Regeneron Pharmaceuticals CLL Phase I

(CD20/CD3 antigen inhibitor) Tarrytown, NY (see also lymphoma) www.regeneron.com

Revlimid® Celgene CLL maintenance (2nd-line) Phase III

lenalidomide Summit, NJ (see also hematological, lymphoma, myeloma) www.celgene.com

Orphan Drug

RG6016 Genentech/Roche AML Phase I

(LSD1 inhibitor South San Francisco, CA www.roche.com

RG7775 Genentech/Roche AML Phase I

(proto-oncogene protein c South San Francisco, CA www.roche.com

MDM2 inhibitor)

rigosertib Onconova Therapeutics high-risk AML (1st-line) Phase III

(PI3K/Plk1 inhibitor) Newtown, PA (see also hematological) www.onconova.com

Orphan Drug


http://www.prismbiolabs.com/

http://www.sunesis.com/

http://www.ambitbio.com/

http://www.regeneron.com/





Leukemia


RP-323 Rich Pharmaceuticals AML Phase II

(tetradecanoylphorbol acetate) Beverly Hills, CA (see also hematological) www.richpharmaceuticals.com

sapacitabine Cyclacel Pharmaceuticals AML Phase III

(DNA-directed DNA polymerase Berkeley Heights, NJ (see also hematological, lung) www.cyclacel.com

inhibitor)

Orphan Drug

selinexor (oral) Karyopharm Therapeutics AML Phase III

(XPO1 antagonist) Newton, MA (see also brain, head/neck, hematological, lymphoma, www.karyopharm.com

Orphan Drug myeloma, prostate, sarcoma, other)

SG2000 Spirogen AML, CLL Phase I/II

(DNA cross linking agent) London, England

SGI-110 Astex Pharmaceuticals AML Phase III

(DNMT inhibitor) Pleasanton, CA (see also hematological, liver, ovarian) www.astx.com

SGN-CD19A Seattle Genetics relapsed ALL Phase I

(antibody drug conjugate) Bothell, WA (see also lymphoma) www.seattlegenetics.com

SGN-CD33A Seattle Genetics AML (1st-line), relapsed AML Phase I

(antibody drug conjugate) Bothell, WA www.seattlegenetics.com

SL-401 Stemline Therapeutics relapsed/refractory AML Phase I/II

(IL-3R inhibitor) New York, NY (see also hematological) www.stemline.com

Sprycel® Bristol-Myers Squibb leukemia (pediatric) Phase II

dasatinib Princeton, NJ www.bms.com

TAK-924 Takeda Oncology AML Phase I

(NEDD 8 activating enzyme Cambridge, MA www.takedaoncology.com

inhibitor)

http://www.richpharmaceuticals.com/







http://www.bms.com/


Leukemia


Tasigna® Novartis Pharmaceuticals CML treatment free remission Phase III

nilotinib East Hanover, NJ www.novartis.com

Orphan Drug

ALL (pediatric), CML (pediatric) Phase I/II

www.novartis.com

TEN-010 Tensha Therapeutics AML Phase I

(BET inhibitor) Cambridge, MA (see also hematological, solid tumors) www.tenshatherapeutics.com

TG02 Tragara Pharmaceuticals refractory AML, relapsed CLL Phase I

(CDK inhibitor) Carlsbad, CA (see also myeloma) www.tragarapharma.com

TG-1101 TG Therapeutics CLL (combination therapy) Phase III

(anti-CD20 mAb) New York, NY (see also lymphoma) www.tgtherapeutics.com

Orphan Drug

CLL (monotherapy) Phase I/II

www.tgtherapeutics.com

tosedostat CTI BioPharma AML Phase II

(aminopeptidase inhibitor) Seattle, WA (see also hematological) www.ctibiopharma.com

Orphan Drug

venetoclax AbbVie CLL (1st-line), relapsed/refractory CLL Phase III

(Bcl-2 inhibitor) North Chicago, IL (combination therapy) (Breakthrough Therapy) www.abbvie.com

Genentech/Roche (see also hematological, lymphoma) www.roche.com


AML, relapsed/refractory 17p-deletion CLL Phase II

www.abbvie.com

www.roche.com

volasertib Boehringer Ingelheim Pharmaceuticals AML (Breakthrough Therapy) Phase III

(PLK-1 antagonist) Ridgefield, CT www.boehringer-ingelehim.com

Orphan Drug




http://www.tragarapharma.com/








http://www.boehringer-ingelehim.com/

Leukemia


WT1-CTL Atara Biotherapeutics AML Phase I

(immunostimulant) South San Francisco, CA (see also myeloma) www.atarabio.com

Zydelig® Gilead Sciences CLL (1st-line), relapsed/refractory CLL Phase III

idelalisib Foster City, CA (see also lymphoma) www.gilead.com

Liver Cancer


AD-p53 gene therapy MultiVir liver metastases from colorectal cancer Phase I

San Diego, CA www.multivir.com

ADI-PEG 20 Polaris Pharmaceuticals hepatocellular carcinoma Phase III

(PEG arginine deiminase) San Diego, CA (see also breast, lung, ovarian, pancreatic, www.polarispharma.com

Orphan Drug skin, stomach)

BA-003 Onxeo hepatocellular carcinoma (2nd-line) Phase III

(doxorubicin nanoparticles) Paris, France www.onxeo.com

Orphan Drug

BBI503 Boston Biomedical hepatocellular carcinoma Phase I

(cancer stemness kinase inhibitor) Cambridge, MA (see also ovarian) www.bostonbiomedical.com

BBI608 Boston Biomedical hepatocellular carcinoma Phase I

(cancer stem cell inhibitor) Cambridge, MA (see also breast, colorectal, hematological, www.bostonbiomedical.com


CC-122 Celgene hepatocellular carcinoma Phase I

(PPM Pleiotropic pathway modifier) Summit, NJ (see also brain, leukemia, lymphoma) www.celgene.com

CF102 Can-Fite BioPharma metastatic hepatocellular carcinoma Phase II

(A3 adenosine receptor agonist) Petach Tikva, Israel www.canfite.com

http://www.atarabio.com/


http://www.multivir.com/


http://www.onxeo.com/




http://www.canfite.com/

Liver Cancer


Cometriq® Exelixis advanced hepatocellular carcinoma Phase III

cabozantinib South San Francisco, CA (see also brain, kidney) www.exelixis.com

CX-4945 Senhwa Biosciences cholangiocarcinoma (combination therapy) Phase I/II

(CK2 inhibitor) San Diego, CA www.senhwabiosciences.com

Cyramza® Eli Lilly hepatocellular carcinoma Phase III

ramucirumab Indianapolis, IN (see also bladder, lung, stomach) www.lilly.com

Orphan Drug

dalantercept Acceleron Pharma hepatocellular carcinoma Phase I/II

(ALK1 antagonist) Cambridge, MA (see also kidney) www.acceleronpharma.com

DCR-MYC Dicerna Pharmaceuticals hepatocellular carcinoma Phase I/II

(c-myc inhibitor) Watertown, MA (see also hematological) www.dicerna.com

galunisertib Eli Lilly metastatic hepatocellular carcinoma Phase II

(TGF-beta 1 kinase inhibitor) Indianapolis, IN (see also brain, pancreatic) www.lilly.com

ipafricept Bayer HealthCare Pharmaceuticals hepatocellular carcinoma Phase I

(Wnt protein inhibitor) Whippany, NJ (combination therapy) www.healthcare.bayer.com

OncoMed Pharmaceuticals (see also ovarian, pancreatic) www.oncomed.com

Redwood City, CA

Lenvima® Eisai hepatocellular carcinoma Phase III

lenvatinib Woodcliff Lake, NJ (see also kidney, lung, skin, other, www.eisai.com

Orphan Drug solid tumors)

melphalan drug delivery system Delcath Systems secondary liver cancer arising from application submitted

(drug-device combination) New York, NY metastatic ocular melanoma www.delcath.com

Orphan Drug

hepatocellular carcinoma, Phase II

intrahepatic cholangiocarcinoma www.delcath.com


http://www.senhwabiosciences.com/



http://www.dicerna.com/




http://www.delcath.com/

http://www.delcath.com/

Liver Cancer


mipsagargin GenSpera hepatocellular carcinoma Phase II

(thapsigargin analogue) San Antonio, TX (see also brain) www.genspera.com

Orphan Drug

MRX34 Mirna Therapeutics unresectable primary liver cancer, Phase I

(liposome-encapsulated Austin, TX liver metastases from other solid tumors www.mirnarx.com

miR-34 mimic) (see also hematological)

oncolytic virus Omnis Pharmaceuticals hepatocellular carcinoma, liver metastases Phase I

(genetically engineered strain Rochester, MN www.omnispharma.com

of vesicular stomatitis virus)

Opdivo® Bristol-Myers Squibb hepatocellular carcinoma Phase I


hematological, kidney, lung, lymphoma, skin,


pexastimogene devacirepvec SillaJen Biotherapeutics advanced primary liver cancer Phase II

(genetically-engineered oncolytic San Francisco, CA (see also kidney) www.sillajen.com

vaccinia virus)

Orphan Drug

PDT with Photofrin® Concordia Laboratories unresectable advanced perihilar Phase III

porfimer sodium Toronto, Canada cholangiocarcinoma Bismuth type III/IV www.pinnaclebiologics.com

Orphan Drug Pinnacle Biologics

Chicago, IL

PV-10 Provectus Biopharmaceuticals hepatocellular carcinoma, liver metastases Phase I

(rose bengal disodium) Knoxville, TN (see also skin) www.pvct.com

Orphan Drug

RG7686 Genentech/Roche hepatocellular carcinoma Phase II

(glypican-3 mAb) South San Francisco, CA www.roche.com

http://www.genspera.com/

http://www.mirnarx.com/

http://www.omnispharma.com/

http://www.bms.com/

http://www.sillajen.com/

http://www.pinnaclebiologics.com/

http://www.pvct.com/


Liver Cancer


RRx-001 EpicentRx cholangiocarcinoma Phase II

(free radical stimulant) Mountain View, CA (see also colorectal, lung, lymphoma, other) www.radiorx.com

SGI-110 Astex Pharmaceuticals hepatocellular carcinoma Phase II

(DNMT inhibitor) Pleasanton, CA (see also hematological, leukemia, ovarian) www.astx.com

SM04755 Samumed advanced liver cancer Phase I

(Wnt inhibitor) San Diego, CA (see also colorectal, pancreatic, stomach) www.samumed.com

SPI-1620 Spectrum Pharmaceuticals biliary cancer Phase II

(endothelin B receptor agonist) Henderson, NV (see also lung) www.sppirx.com

Stivarga® Bayer HealthCare Pharmaceuticals hepatocellular carcinoma (2nd-line) Phase III

regorafenib Whippany, NJ (see also colorectal, kidney) www.healthcare.bayer.com

tepotinib EMD Serono hepatocellular cancer Phase II

(c-Met kinase inhibitor) Rockland, MA (see also lung) www.emdserono.com

ThermoDox® Celsion inoperable/unresectable hepatocellular Phase III

doxorubicin liposomal Lawrenceville, NJ carcinoma (1st-line) (Fast Track) www.celsion.com

Orphan Drug (see also breast)

liver metastases Phase II

www.celsion.com

tivantinib ArQule hepatocellular carcinoma Phase III

(c-Met inhibitor) Woburn, MA www.arqule.com

Daiichi Sankyo www.dsi.com

Parsippany, NJ

TRC105 TRACON Pharmaceuticals hepatocellular carcinoma Phase I

(END protein inhibitor) San Diego, CA (see also brain, breast, colorectal, kidney, lung, www.traconpharma.com

sarcoma, other)








http://www.arqule.com/

http://www.dsi.com/


Liver Cancer


VT-122 Vicus Therapeutics hepatocellular carcinoma Phase II

(cancer immunotherapy) Morristown, NJ (see also prostate) www.vicustherapeutics.com

Xtandi® Astellas Pharma US hepatocellular carcinoma Phase II

enzalutamide Northbrook, IL (see also breast, prostate) www.astellas.com

Medivation www.medivation.com

San Francisco, CA

Lung Cancer


abemaciclib Eli Lilly non-small-cell lung cancer (NSCLC) Phase III

(CDK 4/6 inhibitor) Indianapolis, IN (see also breast, lymphoma) www.lilly.com

ABP 215 Allergan advanced NSCLC Phase III

(bevacizumab biosimilar) Parsippany, NJ www.amgen.com

Amgen

Thousand Oaks, CA

AC0100MA ACEA Biosciences NSCLC Phase I/II

(epidermal growth factor receptor San Diego, CA www.aceabio.com

inhibitor)

ACP-196 Acerta Pharma advanced NSCLC Phase II


leukemia, lymphoma, myeloma, pancreatic)

ADI-PEG 20 Polaris Pharmaceuticals malignant pleural mesothelioma, NSCLC Phase I

(PEG arginine deiminase) San Diego, CA (see also breast, liver, ovarian, pancreatic, www.polarispharma.com

Orphan Drug skin, stomach)

Afinitor® Novartis Pharmaceuticals neuroendocrine lung tumors Phase III

everolimus East Hanover, NJ (see also lymphoma, stomach) www.novartis.com

http://www.vicustherapeutics.com/





http://www.aceabio.com/




Lung Cancer


aldoxorubicin CytRx small-cell lung cancer (SCLC) Phase II

(delivery-enhanced doxorubicin) Los Angeles, CA (see also brain, sarcoma) www.cytrx.com

Orphan Drug

alectinib Genentech/Roche ALK-positive NSCLC (1st-line) Phase III

(ALK inhibitor) South San Francisco, CA (Breakthrough Therapy) www.roche.com

ALK-positive NSCLC (2nd-line) Phase II

(Breakthrough Therapy) www.roche.com

alisertib Takeda Oncology SCLC Phase II

(aurora A kinase inhibitor) Cambridge, MA www.takedaoncology.com

anti-fucosyl-GM1 Bristol-Myers Squibb lung cancer Phase I


antroquinonol Golden Biotechnology NSCLC Phase II

New Taipei City, Taiwan www.goldenbiotech.com.tw

apatorsen OncoGenex Pharmaceuticals NSCLC Phase II

(Hsp27 inhibitor) Bothell, WA (see also bladder, pancreatic, prostate) www.oncogenex.com

ASP2215 Astellas Pharma US NSCLC Phase I

(FLT3/AXL inhibitor) Northbrook, IL (see also leukemia) www.astellas.com

ASP8273 Astellas Pharma US NSCLC Phase I

(mutant-selective irreversible Northbrook, IL www.astellas.com

EGFR inhibitor)





http://www.bms.com/

http://www.goldenbiotech.com.tw/




Lung Cancer


Avastin® Genentech/Roche NSCLC (adjuvant) Phase III

bevacizumab South San Francisco, CA (see also brain, breast, ovarian, other) www.roche.com

EGFR-positive NSCLC Phase II

(combination therapy) www.roche.com

avelumab EMD Serono NSCLC (2nd-line) Phase III

(anti-PD-L1 mAb) Rockland, MA (see also skin, solid tumors) www.emdserono.com

Pfizer www.pfizer.com

New York, NY

AZD3759 AstraZeneca advanced EGFR metastatic NSCLC Phase I

(EGFR tyrosine kinase inhibitor) Wilmington, DE www.astrazeneca.com

AZD9291 AstraZeneca advanced EGFR mutation-positive T790M NSCLC Phase II/III

(EGFR tyrosine kinase inhibitor) Wilmington, DE (2nd-line or greater) (Breakthrough Therapy) www.astrazeneca.com

(Fast Track), advanced EGFR mutation-positive NSCLC

(1st-line)

advanced EGFR mutation-positive NSCLC Phase I

(combination therapy) www.astrazeneca.com

bavituximab Peregrine Pharmaceuticals NSCLC (2nd-line) Phase III

Tustin, CA (see also breast, colorectal, skin) www.peregrineinc.com

NSCLC (1st-line) Phase I completed

www.peregrineinc.com

BBI608 Boston Biomedical NSCLC Phase II


liver, ovarian, pancreatic, skin, stomach)











Lung Cancer


Beleodaq® Spectrum Pharmaceuticals NSCLC Phase II

belinostat Henderson, NV (see also lymphoma) www.sppirx.com

BGB324 BerGenBio NSCLC Phase I

(RTK inhibitor) Bergen, Norway www.bergenbio.com

BIND-014 BIND Therapeutics KRAS-mutated NSCLC, squamous histology NSCLC Phase II

(PSMA-targeted docetaxel) Cambridge, MA www.bindtherapeutics.com

brigatinib ARIAD Pharmaceuticals ALK-positive NSCLC (Breakthrough Therapy) Phase II

(ALK inhibitor) Cambridge, MA www.ariad.com

CC-486 Celgene advanced NSCLC Phase II

(DNA methylation inhibitor) Summit, NJ (see also breast, hematological, leukemia, www.celgene.com

lymphoma, other)

CD40LGVAX Cellular Biomedicine NSCLC Phase II completed

(immunotherapy vaccine) Palo Alto, CA www.cellbiomedgroup.com

crenolanib AROG Pharmaceuticals NSCLC Phase II

(PDGFR inhibitor) Dallas, TX (see also brain, leukemia, stomach) www.arogpharma.com

CRS-207 Aduro BioTech mesothelioma (combination therapy) Phase I

(cancer immunotherapy) Berkeley, CA (see also pancreatic) www.aduro.com

Orphan Drug

custirsen (OGX-111) OncoGenex Pharmaceuticals advanced NSCLC Phase III

(antisense olignucleotide) Bothell, WA (see also prostate) www.oncogenex.com

CX-01 Cantex Pharmaceuticals SCLC Phase II

(O-desulfated heparin intravenous) Weston, FL (see also leukemia, solid tumors) www.cantex.com


http://www.bergenbio.com/

http://www.bindtherapeutics.com/



http://www.cellbiomedgroup.com/


http://www.aduro.com/



Lung Cancer


Cyramza® Eli Lilly EGFR-positive NSCLC (1st-line) Phase III

ramucirumab Indianapolis, IN (see also bladder, liver, stomach) www.lilly.com

dacomitinib Pfizer EGFR-mutant NSCLC Phase III

(pan-HER inhibitor) New York, NY www.pfizer.com

Orphan Drug

demcizumab OncoMed Pharmaceuticals non-squamous NSCLC Phase II

(DLL4 inhibitor) Redwood City, CA (see also ovarian, pancreatic) www.oncomed.com

DKN-01 HealthCare Pharmaceuticals NSCLC Phase I

(DKK1 protein inhibitor) Cambridge, MA (see also myeloma, other) www.healthcarepharmaceuticals.com

docetaxel injection concentrate, Teikoku Pharma USA NSCLC application submitted

non-alcohol formula San Jose, CA (see also breast, head/neck, prostate, stomach) www.teikokuusa.com

DPV-001 UbiVac definitely-treated stage IIIA/B NSCLC Phase II

(toll-like receptor agonist) Portland, OR (see also prostate) www.ubivac.com

EGF816 Novartis Pharmaceuticals NSCLC (combination therapy) Phase I/II

(TKI inhibitor) East Hanover, NJ www.novartis.com

emibetuzumab Eli Lilly NSCLC Phase II

(c-Met antibody) Indianapolis, IN (see also other) www.lilly.com

entinostat Syndax Pharmaceuticals NSCLC (combination therapy) Phase I/II

(HDAC inhibitor) Waltham, MA (see also breast, skin) www.syndax.com

epacadostat Incyte NSCLC Phase I/II

(IDO1 inhibitor) Wilmington, DE (see also ovarian, skin, other) www.incyte.com




http://www.healthcarepharmaceuticals.com/


http://www.ubivac.com/





Lung Cancer


evofosfamide (TH-302) EMD Serono NSCLC Phase II

(hypoxia-activated prodrug) Rockland, MA (see also brain, hematological, pancreatic, www.emdserono.com

Threshold Pharmaceuticals sarcoma, skin) www.thresholdpharm.com


ficlatuzumab AVEO Oncology advanced NSCLC Phase II

(HGF/c-Met inhibitor) Cambridge, MA www.aveooncology.com

FP-1039 Five Prime Therapeutics mesothelioma, squamous NSCLC Phase I

(FGF ligand trap) South San Francisco, CA www.fiveprime.com

ganetespib Synta Pharmaceuticals NSCLC (Fast Track) Phase III

(Hsp90 inhibitor) Lexington, MA (see also breast, leukemia, ovarian) www.syntapharma.com

GI-4000 GlobeImmune NSCLC Phase II

(mutated Ras cancer vaccine) Louisville, CO (see also pancreatic) www.globeimmune.com

Gilotrif® Boehringer Ingelheim Pharmaceuticals squamous cell carcinoma of the lung Phase III

afatinib Ridgefield, CT (see also brain, head/neck) www.boehringer-ingelheim.com

GL-ONC1 Genelux pleural cavity cancers Phase I

(oncolytic virus immunomodulator) San Diego, CA (see also head/neck, other) www.genelux.com

Halaven® Eisai NSCLC Phase III

eribulin Woodcliff Lake, NJ (see also bladder, sarcoma) www.eisai.com

Imprime PGG® Biothera metastatic NSCLC (1st-line) Phase II

intravenous immunostimulant Eagan, MN (see also colorectal, leukemia, lymphoma, pancreatic) www.biothera.com

INC280 Novartis Pharmaceuticals NSCLC Phase I/II

(c-Met inhibitor) East Hanover, NJ www.novartis.com



http://www.aveooncology.com/

http://www.fiveprime.com/


http://www.globeimmune.com/






Lung Cancer


INCB39110 Incyte NSCLC Phase II

(JAK1 inhibitor) Wilmington, DE (see also lymphoma, pancreatic) www.incyte.com

INO-1400 Inovio Pharmaceuticals lung cancer Phase I

(hTERT immunotherapy) Plymouth Meeting, PA (see also breast, pancreatic) www.inovio.com

Jakafi® Incyte NSCLC Phase II

ruxolitinib Wilmington, DE (see also breast, colorectal, pancreatic) www.incyte.com

Kadcyla® Genentech/Roche HER2-positive NSCLC Phase II

ado-trastuzumab emtansine South San Francisco, CA (see also breast, stomach) www.roche.com

Keytruda® Merck NSCLC application submitted

pembrolizumab Kenilworth, NJ (see also bladder, breast, head/neck, www.merck.com

lymphoma, stomach)

Kyprolis® Onyx Pharmaceuticals SCLC Phase I/II

carfilzomib South San Francisco, CA (see also leukemia, myeloma) www.onyx.com

L-DOS47 Helix BioPharma non-squamous NSCLC Phase I

(urease stimulant) Aurora, Canada www.helixbiopharma.com

Lenvima® Eisai NSCLC (3rd-line), NSCLC (RET translocations) Phase II

lenvatinib Woodcliff Lake, NJ (see also kidney, liver, skin, solid tumors, other) www.eisai.com

lifastuzumab vedotin Genentech/Roche NSCLC Phase I

(antibody drug conjugate) South San Francisco, CA (see also ovarian) www.roche.com

lucitanib Clovis Oncology squamous NSCLC Phase II

(FGFR/VEGFR/PDGFR inhibitor) Boulder, CO (see also breast) www.clovisoncology.com







http://www.helixbiopharma.com/




Lung Cancer


lung cancer DNA vaccine Immune Cell Therapy NSCLC Phase I

(IC 1001) Chicago, IL www.immcellther.com

LY2510924 Eli Lilly SCLC Phase II

(CXCR4 peptide antagonist) Indianapolis, IN (see also kidney) www.lilly.com

LY3023414 Eli Lilly NSCLC Phase II

(PI3K/mTOR dual inhibitor) Indianapolis, IN (see also prostate) www.lilly.com

ME-344 MEI Pharma SCLC Phase II

(mitochondrial inhibitor) San Diego, CA (see also ovarian) www.meipharma.com

MEDI4736 MedImmune stage III NSCLC, NSCLC (3rd-line) Phase III

(anti-PD-L1 mAb) Gaithersburg, MD (see also head/neck, solid tumors) www.medimmune.com

MEDI4736 + AZD9291 MedImmune advanced EGFR metastatic NSCLC Phase I

(anti-PD-L1 mAb/EGFR tyrosine Gaithersburg, MD www.medimmune.com

kinase inhibitor)

NSCLC Phase I

www.medimmune.com

MEDI4736 + Iressa® MedImmune NSCLC Phase I

(anti-PD-L1 mAb/EGFR tyrosinene Gaithersburg, MD www.medimmune.com

kinase inhibitor)

MGA271 Macrogenics metastatic NSCLC (combination therapy) Phase I

(CD276 protein inhibitor) Rockville, MD (see also head/neck, skin) www.macrogenics.com

MGCD265 Mirati Therapeutics late-stage NSCLC Phase I/II

(c-Met/Axl kinase inhibitor) San Diego, CA www.mirati.com

MORAb-003 Eisai NSCLC Phase II

(IgG1 mAb) Woodcliff Lake, NJ (see also ovarian) www.eisai.com

http://www.immcellther.com/











Lung Cancer


MORAb-009 Eisai mesothelioma Phase II

(amatuximab) Woodcliff Lake, NJ www.eisai.com

NC-6004 NanoCarrier NSCLC Phase I/II

(nanoparticle cisplatin) Tokyo, Japan www.nanocarrier.co.jp

necitumumab Eli Lilly squamous NSCLC application submitted

(EGFR inhibitor) Indianapolis, IN www.lilly.com

NGR-TNF MolMed late-stage mesothelioma Phase III

(recombinant fusion protein) Milan, Italy www.molmed.com

NK012 Nippon Kayaku SCLC Phase II

(DNA topoisomerase I inhibitor) Tokyo, Japan (see also breast, colorectal) www.nipponkayaku.co.jp

onalespib (AT13387) Astex Pharmaceuticals NSCLC Phase II

(Hsp90 inhibitor) Pleasanton, CA (see also skin) www.astx.com

Opdivo® Bristol-Myers Squibb NSCLC (1st-line), Phase III

nivolumab Princeton, NJ non-squamous NSCLC (2nd-line) www.bms.com

(see also bladder, brain, colorectal, head/neck,

hematological, kidney, liver, lymphoma, skin,


Opdivo® nivolumab + Bristol-Myers Squibb NSCLC Phase I

Yervoy® ipilimumab Princeton, NJ (see also kidney, skin, solid tumors) www.bms.com

patritumab Daiichi Sankyo NSCLC Phase II

(anti-HER3 antibody) Parsippany, NJ (see also breast) www.dsi.com

PB272 Puma Biotechnology HER2-mutated NSCLC Phase II

(neratinib) Los Angeles, CA (see also breast) www.pumabiotechnology.com


http://www.nanocarrier.co.jp/


http://www.molmed.com/



http://www.bms.com/

http://www.bms.com/

http://www.dsi.com/


Lung Cancer


PEGPH20 Halozyme Therapeutics NSCLC Phase I/II

(pegylated recombinant San Diego, CA (see also pancreatic) www.halozyme.com

human hyaluronidase)

PF-06439535 Pfizer NSCLC Phase III

(bevacizumab biosimilar) New York, NY www.pfizer.com

PF-06463922 Pfizer ALK-mutant NSCLC Phase I

(ALK/ROS1 inhibitor) New York, NY www.pfizer.com

Orphan Drug

PF-06664178 Pfizer lung cancer Phase I

New York, NY www.pfizer.com

PF-06747775 Pfizer NSCLC Phase I

(EGFR antagonist) New York, NY www.pfizer.com

pictilisib Genentech/Roche metastatic NSCLC Phase II

(PI3K inhibitor) South San Francisco, CA (see also breast) www.roche.com

plinabulin BeyondSpring Pharmaceuticals NSCLC (2nd-line) Phase II

(tumor vascular disrupting agent) New York, NY www.beyondspringpharma.com

PT-107 Pique Therapeutics NSCLC Phase II

(allogeneic B7.1/HLA-A1 Durham, NC www.piquetherapeutics.com

transfected tumor cell vaccine)

Reolysin® Oncolytics Biotech NSCLC, squamous cell carcinoma of the lung Phase II

pelareorp Calgary, Canada (see also brain, colorectal, head/neck, www.oncolyticsbiotech.com

myeloma, ovarian, other, pancreatic)

http://www.halozyme.com/






http://www.beyondspringpharma.com/

http://www.piquetherapeutics.com/


Lung Cancer


RG7446 Genentech/Roche NSCLC (1st-line combination therapy), Phase III

(anti-PD-L1 mAb) South San Francisco, CA NSCLC (2nd-line) www.roche.com

(see also bladder, breast, kidney, lymphoma,

skin)

NSCLC (3rd-line) Phase II

www.roche.com

NSCLC (combination therapy) Phase I

www.roche.com

rociletinib Clovis Oncology EGFR-mutated NSCLC application submitted

(EGFR inhibitor) Boulder, CO (Breakthrough Therapy) www.clovisoncology.com

roniciclib Bayer HealthCare Pharmaceuticals SCLC Phase II

(CDK inhibitor) Whippany, NJ www.healthcare.bayer.com

RRx-001 EpicentRx NSCLC, SCLC Phase II

(free radical stimulant) Mountain View, CA (see also colorectal, liver, lymphoma, other) www.radiorx.com

sapacitabine Cyclacel Pharmaceuticals NSCLC Phase II

(DNA-directed DNA polymerase Berkeley Heights, NJ (see also hematological, leukemia) www.cyclacel.com

inhibitor)

SAR125844 Sanofi US NSCLC Phase II

(c-Met kinase inhibitor) Bridgewater, NJ www.sanofi.com

SC-002 Stemcentrx SCLC Phase I

(immunoconjugate) South San Francisco, CA (see also other) www.stemcentrx.com

SC16LD6.5 Stemcentrx recurrent SCLC Phase I/II

(antibody drug conjugate) South San Francisco, CA www.stemcentrx.com








http://www.stemcentrx.com/


Lung Cancer


selumetinib AstraZeneca KRAS-positive NSCLC Phase III

(MEK inhibitor) Wilmington, DE (see also other) www.astrazeneca.com

KRAS-negative NSCLC Phase II

www.astrazeneca.com

seribantumab (MM-121) Merrimack Pharmaceuticals NSCLC Phase II

(ErbB-3 receptor antagonist) Cambridge, MA (see also breast, ovarian) www.merrimackpharma.com

SPI-1620 Spectrum Pharmaceuticals NSCLC Phase II

(endothelin B receptor agonist) Henderson, NV (see also liver) www.sppirx.com

Tafinlar® Novartis Pharmaceuticals BRAF V600-positive NSCLC Phase II

dabrafenib East Hanover, NJ (see also colorectal, skin) www.novartis.com

Mekinist™

trametinib

combination

tarextumab OncoMed Pharmaceuticals extensive-stage SCLC (1st-line) Phase II

(anti-NOTCH 2/3 mAb) Redwood City, CA (see also pancreatic) www.oncomed.com

Orphan Drug

Tavocept® BioNumerik pharmaceuticals lung cancer Phase III completed

San Antonio, TX www.bionumerik.com

tepotinib EMD Serono NSCLC Phase II

(c-Met kinase inhibitor) Rockland, MA (see also liver) www.emdserono.com

tergenpumatucel-L NewLink Genetics advanced or metastatic NSCLC Phase II/III

Ames, IA www.newlinkgenetics.com

tesevatinib (KD019) Kadmon Pharmaceuticals NSCLC Phase II

(TKI inhibitor) Warrendale, PA (see also breast) www.kadmon.com







http://www.bionumerik.com/



http://www.kadmon.com/

Lung Cancer


TG4010 Transgene advanced NSCLC Phase II/III

(MVA-MUC1-IL2 vaccine) Cambridge, MA www.transgene.fr

TH-4000 Threshold Pharmaceuticals T790M-negative NSCLC Phase II

(EGFR antagonist) South San Francisco, CA www.thresholdpharm.com

TRC105 TRACON Pharmaceuticals lung cancer Phase I

(END protein inhibitor) San Diego, CA (see also brain, breast, colorectal, kidney, liver, www.traconpharma.com

sarcoma, other)

trebananib Amgen NSCLC Phase II

(Ang 1 / Ang 2 inhibitor) Thousand Oaks, CA (see also breast, ovarian) www.amgen.com

tremelimumab MedImmune mesothelioma Phase III

(anti-CTLA-4 mAb) Gaithersburg, MD www.medimmune.com

Orphan Drug

TSR-011 TESARO NSCLC Phase I/II

(ALK/TRK inhibitor) Waltham, MA (see also lymphoma) www.tesarobio.com

TUSC2 Genprex NSCLC Phase I/II

(gene therapy) Austin, TX www.genprex.com

vantictumab OncoMed Pharmaceuticals advanced NSCLC (combination therapy) Phase I

(anti-Fzd7) Redwood City, CA (see also breast, pancreatic) www.oncomed.com

Vargatef® Boehringer Ingelheim Pharmaceuticals NSCLC (combination therapy) Phase III

nintedanib Ridgefield, CT (see also colorectal, ovarian) www.boeringer-ingelheim.com

mesothelioma Phase II

www.boehringer-ingelheim.com

veliparib AbbVie NSCLC Phase III

(PARP inhibitor) North Chicago, IL (see also brain, breast, colorectal, skin) www.abbvie.com

http://www.transgene.fr/






http://www.genprex.com/





Lung Cancer


viagenpumatucel-L Heat Biologics NSCLC Phase II

(cancer immunotherapy) Durham, NC www.heatbio.com

vintafolide Endocyte NSCLC Phase II

(folate-DAVLBH) West Lafayette, IN www.endocyte.com

VS-6063 Verastem KRAS-mutant NSCLC, mesothelioma Phase II

(FAK inhibitor) Cambridge, MA (see also ovarian) www.verastem.com

Orphan Drug

X396 Xcovery ALK-positive NSCLC Phase I/II

(ALK inhibitor) Palm Beach Gardens, FL (see also solid tumors) www.xcovery.com

Xgeva® Amgen metastatic NSCLC (1st-line) Phase II

denosumab Thousand Oaks, CA (see also breast, myeloma) www.amgen.com

Yervoy® Bristol-Myers Squibb squamous NSCLC (1st-line) Phase III

ipilimumab Princeton, NJ (see also skin) www.bms.com

Zykadia™ Novartis Pharmaceuticals treatment naïve ALK-positive NSCLC (1st-line) Phase II

ceritinib East Hanover, NJ www.novartis.com

Lymphoma


ABC294640 RedHill Biopharma diffuse large B-cell lymphoma (DLBCL) Phase I/II

(sphingosine kinase inhibitor) Tel Aviv, Israel www.redhillbio.com

abemaciclib Eli Lilly mantle cell lymphoma Phase II

(CDK 4/6 inhibitor) Indianapolis, IN (see also breast, lung) www.lilly.com

http://www.heatbio.com/

http://www.endocyte.com/

http://www.verastem.com/

http://www.xcovery.com/


http://www.bms.com/


http://www.redhillbio.com/


Lymphoma


abexinostat Pharmacyclics follicular lymphoma, Phase II

(HDAC inhibitor) Sunnyvale, CA mantle cell lymphoma www.pharmacyclics.com

ABP 798 Allergan non-Hodgkin lymphoma (NHL) Phase III

(rituximab biosimilar) Parsippany, NJ www.amgen.com

Amgen

Thousand Oaks, CA

ACP-196 Acerta Pharma mantle cell lymphoma Phase II


leukemia, lung, myeloma, pancreatic)

activated B-cell (ABC) DLBCL, Phase I

follicular lymphoma, Waldenstrom's www.acerta-pharma.com

macroglobulinemia

ACP-319 Acerta Pharma B-cell lymphoma (combination therapy) Phase I/II

(Btk inhibitor) San Carlos, CA (see also leukemia) www.acerta-pharma.com

Adcetris® Seattle Genetics post-transplant Hodgkin lymphoma Phase III

brentuximab vedotin Bothell, WA relapse prevention, relapsed CD30-positive www.seattlegenetics.com

Orphan Drug cutaneous T-cell lymphoma, Hodgkin

lymphoma (1st-line), CD30-positive mature

T-cell lymphoma (1st-line)

Hodgkin lymphoma in elderly (1st-line), Phase II

CD30-positive DLBCL www.seattlegenetics.com

AEB071 Novartis Pharmaceuticals CD79-mutant or ABC-subtype DLBCL Phase I/II

(PKC inhibitor) East Hanover, NJ (combination therapy) www.novartis.com

(see also other)

Afinitor® Novartis Pharmaceuticals DLBCL Phase III

everolimus East Hanover, NJ (see also lung, stomach) www.novartis.com

http://www.pharmacyclics.com/









Lymphoma


AFM 13 Affimed Therapeutics Hodgkin lymphoma Phase II

(CD30 antigen modulator) Heidelberg, Germany www.affimed.com

Orphan Drug

AR-12 Arno Therapeutics lymphoma Phase I

(PI3K/Akt inhibitor) Flemington, NJ (see also solid tumors) www.arnothera.com

Arzerra® Novartis Pharmaceuticals refractory NHL, relapsed NHL Phase III

ofatumumab East Hanover, NJ (see also leukemia) www.novartis.com

ASP4132 Astellas Pharma US advanced lymphoma Phase I

Northbrook, IL (see also solid tumors) www.astellas.com

ATTCK20 Unum Therapeutics NHL Phase I

(viral-ACTR+anti-CD20) Cambridge, MA (see also leukemia) www.unumrx.com

Beleodaq® Spectrum Pharmaceuticals peripheral T-cell lymphoma (PTCL) (1st-line) Phase I

belinostat Henderson, NV (see also lung) www.sppirx.com

Orphan Drug

bendamustine ready-to-dilute Eagle Pharmaceuticals NHL application submitted

liquid formulation Woodcliff Lake, NJ (see also leukemia, solid tumors) www.eagleus.com

Orphan Drug

BI 695500 Boehringer Ingelheim Pharmaceuticals follicular lymphoma (1st-line) Phase III

(rituximab biosimilar) Ridgefield, CT www.boehringer-ingelheim.com

birinapant TetraLogic Pharmaceuticals cutaneous T-cell lymphoma (CTCL) Phase II

(apoptosis stimulator) Malvern, PA (see also hematological, ovarian) www.tetralogicpharma.com

Blincyto® Amgen DLBCL Phase II

blinatumomab Thousand Oaks, CA (see also leukemia) www.amgen.com

http://www.affimed.com/




http://www.unumrx.com/






Lymphoma


CC-122 Celgene DLBCL, relapsed/refractory indolent lymphoma Phase I

(pleiotropic pathway modifier) Summit, NJ (see also brain, leukemia, liver) www.celgene.com

CC-292 Celgene relapsed/refractory B-cell lymphoma Phase I

(Btk inhibitor) Summit, NJ (see also leukemia) www.celgene.com

CC-486 Celgene lymphoma Phase I

(DNA methylation inhibitor) Summit, NJ (see also breast, hematological, leukemia, lung, other) www.celgene.com

CDX-301 Celldex Therapeutics B-cell lymphoma Phase I/II

(Fms-like tyrosine kinase 3 ligand) Hampton, NJ (see also hematological) www.celldex.com

cerdulatinib Portola Pharmaceuticals NHL Phase II

(dual Syk-JAK inhibitor) South San Francisco, CA (see also leukemia) www.portola.com

CMD-003 Cell Medica EBV-positive, extranodal natural killer/T-cell lymphoma Phase II

(cell therapy) London, England www.cellmedica.co.uk

coltuximab ravtansine ImmunoGen DLBCL Phase II

(antibody drug conjugate) Waltham, MA www.immunogen.com

copanlisib Bayer HealthCare Pharmaceuticals NHL Phase III(PI3K inhibitor) Whippany, NJ www.healthcare.bayer.com

Orphan Drug

DLBCL Phase II

www.healthcare.bayer.com

CPI-0610 Constellation Pharmaceuticals lymphoma Phase I

(BET inhibitor) Cambridge, MA (see also hematological, leukemia, myeloma) www.constellationpharma.com

CPI-1205 Constellation Pharmaceuticals B-cell lymphoma Phase I

(EZH2 enzyme inhibitor) Cambridge, MA www.constellationpharma.com





http://www.portola.com/

http://www.cellmedica.co.uk/


http://www.healthcare.bayer.com/



Lymphoma


CTL019 Novartis Pharmaceuticals DLBCL Phase I

(CAR immunotherapy) East Hanover, NJ (see also leukemia) www.novartis.com

CUDC-427 Curis late-stage lymphoma Phase I

(IAP inhibitor) Lexington, MA (see also solid tumors) www.curis.com

CUDC-907 Curis late-stage lymphoma Phase I

(HDAC/PI3K inhibitor) Lexington, MA (see also myeloma, solid tumors) www.curis.com

DI-Leu16-IL2 ALOPEXX Oncology NHL Phase I/II

(CD20 antigen inhibitor) Concord, MA www.alopexx.com

DS-3032 Daiichi Sankyo late-stage lymphoma Phase I

(MDM2 inhibitor) Parsippany, NJ (see also solid tumors) www.dsi.com

DS-3078 Daiichi Sankyo lymphoma Phase I

(mTOR inhibitor) Parsippany, NJ (see also solid tumors) www.dsi.com

DS-8273 Daiichi Sankyo late-stage lymphoma Phase I

(anti-DR5 antibody) Parsippany, NJ (see also solid tumors) www.dsi.com

duvelisib AbbVie previously-treated follicular lymphoma Phase III

(PI3K inhibitor) North Chicago, IL (see also hematological, leukemia) www.abbvie.com

Orphan Drug Infinity Pharmaceuticals www.infi.com

Cambridge, MA

refractory indolent NHL Phase II

www.abbvie.com

www.infi.com

treatment naïve follicular lymphoma Phase I

www.abbvie.com

www.infi.com


http://www.curis.com/


http://www.alopexx.com/

http://www.dsi.com/

http://www.dsi.com/

http://www.dsi.com/







Lymphoma


EPZ-6438 Epizyme NHL Phase I/II

(EZH2 inhibitor) Cambridge, MA (see also solid tumors) www.epizyme.com

Folotyn® Spectrum Pharmaceuticals PTCL Phase I

pralatrexate injection Henderson, NV www.sppirx.com

Orphan Drug

Gazyva® Genentech/Roche DLBCL, indolent NHL (1st-line), Phase III

obinutuzumab South San Francisco, CA refractory indolent NHL www.roche.com

GDC-0575 (RG7741) Genentech/Roche lymphoma Phase I

(ChK1 inhibitor) South San Francisco, CA (see also solid tumors) www.roche.com

GS-5829 Gilead Sciences DLBCL Phase I

(BET inhibitor) Foster City, CA (see also solid tumors) www.gilead.com

Imbruvica® Janssen Research & Development relapsed/refractory mantle cell lymphoma, Phase III

ibrutinib Raritan, NJ treatment naïve mantle cell lymphoma www.janssenrnd.com

(combination therapy), relapsed/refractory

indolent NHL (combination therapy),

newly-diagnosed non-germinal center

B-cell subtype of DLBCL, previously treated

Waldenstrom's macroglobulinemia


(see also leukemia)

IMGN529 ImmunoGen NHL Phase I

(CD37 protein inhibitor) Waltham, MA (see also leukemia) www.immunogen.com

IMMU-114 Immunomedics NHL Phase I

(humanized anti-HLA-DR) Morris Plains, NJ (see also leukemia) www.immunomedics.com









Lymphoma


IMO-8400 Idera Pharmaceuticals DLBCL, Waldenstrom's macroglobulinemia Phase I/II

(TLR antagonist) Cambridge, MA www.iderapharma.com

Orphan Drug

Imprime PGG® Biothera advanced indolent NHL Phase II

intravenous immunostimulant Eagan, MN (see also colorectal, leukemia, lung, pancreatic) www.biothera.com

INCB39110+INCB40093 Incyte B-lymphoid malignancies Phase I/II

(JAK1 inhibitor) Wilmington, DE (see also lung, pancreatic) www.incyte.com

INCB50465 Incyte B-lymphoid malignancies Phase I

(PI3K-delta inhibitor) Wilmington, DE www.incyte.com

Istodax® Celgene PTCL (1st-line) Phase III

romidepsin Summit, NJ www.celgene.com

JCAR014 Juno Therapeutics NHL Phase I/II


JCAR018 Juno Therapeutics NHL Phase I


JNJ-42756493 Janssen Research & Development late-stage lymphoma Phase I

(FGFR inhibitor) Raritan, NJ (see also bladder) www.janssenrnd.com

Keytruda® Merck Hodgkin lymphoma Phase II

pembrolizumab Kenilworth, NJ (see also bladder, breast, head/neck, lung, stomach) www.merck.com

http://www.iderapharma.com/









Lymphoma


KTE-C19 CAR Kite Pharma B-cell lymphoma Phase II/III

(chimeric antigen receptor) Santa Monica, CA www.kitepharma.com

Orphan Drug

DLBCL Phase I/II

www.kitepharma.com

Marqibo® Spectrum Pharmaceuticals aggressive NHL (1st-line) Phase III

vinCRIStine sulfate LIPOSOME Henderson, NV (see also leukemia) www.sppirx.com

injection

MEDI-551 MedImmune DLBCL Phase II

(anti-CD19 mAb) Gaithersburg, MD (see also leukemia) www.medimmune.com

MEDI-551 + MEDI0680 MedImmune DLBCL Phase I

(anti-CD19 mAb/anti-PD-1 mAb) Gaithersburg, MD www.medimmune.com

milatuzumab-doxorubicin conjugate Immunomedics NHL Phase I/II

(antibody drug conjugate) Morris Plains, NJ (see also leukemia) www.immunomedics.com

mocetinostat Mirati Therapeutics DLBCL Phase II

(HDAC inhibitor) San Diego, CA (see also bladder, hematological) www.mirati.com

Orphan Drug

mogamulizumab Kyowa Hakko Kirin CTCL Phase III

(anti-CCR4 antibody) Princeton, NJ (see also leukemia) www.kyowa-kirin.com

Orphan Drug

adult T-cell leukemia-lymphoma Phase II

www.kyowa-kirin.com

MOR208 MorphoSys NHL Phase II

(CD19 antigen inhibitor) Martinsried, Germany (see also leukemia) www.morphosys.com

http://www.kitepharma.com/










Lymphoma


MT-3724 Molecular Templates NHL Phase I

(CD20 antigen inhibitor) Georgetown, TX www.moleculartemplates.com

Oncoquest™-L XEME Biopharma follicular lymphoma Phase II

personalized cancer vaccine Monmouth Junction, NJ www.xemebiopharma.com

Opdivo® Bristol-Myers Squibb Hodgkin lymphoma (Breakthrough Phase II

nivolumab Princeton, NJ Therapy), DLBCL, follicular lymphoma www.bms.com

(see also bladder, brain, colorectal,

head/neck, hematological, kidney, liver,

lung, skin, solid tumors, stomach, other)

PF-05280586 Pfizer follicular lymphoma (1st-line therapy) Phase III

(rituximab biosimilar) New York, NY www.pfizer.com

pidilizumab Medivation DLBCL Phase II completed

San Francisco, CA www.medivation.com

Pixuvri® CTI BioPharma DLBCL, follicular grade 3 lymphoma Phase III

pixantrone Seattle, WA www.ctibiopharma.com

PNT2258 ProNAi Therapeutics relapsed/refractory DLBCL, Phase II

(Bcl-2 oncogene inhibitor) Plymouth, MI relapsed/refractory NHL www.pronai.com

polatuzumab vedotin Genentech/Roche DLBCL, NHL Phase II

(antibody drug conjugate) South San Francisco, CA www.roche.com

REGN1979 Regeneron Pharmaceuticals NHL Phase I

(CD20/CD3 antigen inhibitor) Tarrytown, NY (see also leukemia) www.regeneron.com

Resimmune™ Angimmune CTCL Phase I/II

A-dmDT390-bisFv immunotoxin Rockville, MD (see also skin) www.angimmune.com

http://www.moleculartemplates.com/

http://www.xemebiopharma.com/

http://www.bms.com/




http://www.pronai.com/



http://www.angimmune.com/

Lymphoma


Revlimid® Celgene DLBCL (maintenance therapy), Phase III

lenalidomide Summit, NJ DLBCL-ABC subtype (1st-line), www.celgene.com

follicular lymphoma (1st-line),

relapsed/refractory indolent lymphoma

(see also hematological, leukemia, myeloma)

RG7446 Genentech/Roche lymphoma Phase I

(anti-PD-L1 mAb) South San Francisco, CA (see also bladder, breast, kidney, lung, www.roche.com

skin)

ricolinostat Acetylon Pharmaceuticals lymphoma Phase I/II

(HDAC inhibitor) Boston, MA (see also myeloma) www.acetylon.com

RRx-001 EpicentRx lymphoma Phase I

(free radical stimulant) Mountain View, CA (see also colorectal, liver, lung, other) www.radiorx.com

SD101 Dynavax Technologies B-cell lymphoma Phase I/II

(TLR9 agonist) Berkeley, CA (combination therapy) www.dynavax.com

selinexor (oral) Karyopharm Therapeutics DLBCL Phase III

(XPO1 antagonist) Newton, MA (see also brain, head/neck, hematological, www.karyopharm.com

Orphan Drug leukemia, myeloma, prostate, sarcoma, other)

SGN-CD19A Seattle Genetics NHL Phase I

(antibody drug conjugate) Bothell, WA (see also leukemia) www.seattlegenetics.com

SGN-CD70A Seattle Genetics relapsed NHL Phase I

(antibody drug conjugate) Bothell, WA (see also kidney) www.seattlegenetics.com

SGX301 Soligenix cutaneous T-cell lymphoma (Fast Track) Phase II

(hypericin) Princeton, NJ www.soligenix.com



http://www.acetylon.com/


http://www.dynavax.com/




http://www.soligenix.com/

Lymphoma


SHAPE TetraLogic Pharmaceuticals CTCL Phase II

(HDAC inhibitor) Malvern, PA www.tetralogicpharma.com

Orphan Drug

SP-02 (darinaparsin) Solasia Pharma PTCL Phase II

(apoptosis stimulant) Tokyo, Japan www.solasia.co.jp

Orphan Drug

TG-1101 TG Therapeutics mantle cell lymphoma Phase III

(anti-CD20 mAb) New York, NY (combination therapy) www.tgtherapeutics.com

Orphan Drug (see also leukemia)

NHL (monotherapy) Phase I/II

www.tgtherapeutics.com

Treanda® Teva Oncology indolent B-cell NHL (1st-line) application submitted

bendamustine Frazer, PA www.tevapharm.com

Orphan Drug

mantle cell lymphoma Phase II

www.tevapharm.com

TSR-011 TESARO lymphoma Phase I/II

(ALK/TRK inhibitor) Waltham, MA (see also lung) www.tesarobio.com

veltuzumab Immunomedics NHL Phase II

(humanized anti-CD20 mAb) Morris Plains, NJ www.immunomedics.com

veltuzumab Immunomedics aggressive NHL Phase II

(humanized anti-CD20 mAb)/ Morris Plains, NJ www.immunomedics.com

Y-90 epratuzumab tetraxetan


http://www.solasia.co.jp/



http://www.tevapharm.com/





Lymphoma


venetoclax AbbVie DLBCL, NHL Phase II

(Bcl-2 inhibitor) North Chicago, IL (see also hematological, leukemia) www.abbvie.com

Genentech/Roche www.roche.com


VS-5584 Verastem lymphoma Phase I

(PI3K/mTOR inhibitor) Cambridge, MA (see also solid tumors) www.verastem.com

VX-803 Vertex Pharmaceuticals lymphoma Phase I

Boston, MA (see also solid tumors) www.vrtx.com

Zydelig® Gilead Sciences relapsed/refractory indolent NHL Phase III

idelalisib Foster City, CA (see also leukemia) www.gilead.com

indolent NHL (1st-line) Phase II

www.gilead.com

Multiple Myeloma


ABBV-838 AbbVie multiple myeloma Phase I

(antibody drug conjugate) North Chicago, IL www.abbvie.com

ACP-196 Acerta Pharma multiple myeloma Phase I


leukemia, lung, lymphoma, pancreatic)

ACY-241 Acetylon Pharmaceuticals multiple myeloma Phase I

(HDAC6 protein inhibitor) Boston, MA www.acetylon.com

ALT-803 Altor BioScience multiple myeloma Phase I/II

(IL-15 superagonist complex) Miramar, FL (see also bladder, hematological, skin) www.altorbioscience.com




http://www.vrtx.com/







Multiple Myeloma


AMG 232 Amgen multiple myeloma Phase I

(MDM2 inhibitor) Thousand Oaks, CA (see also leukemia, skin, solid tumors) www.amgen.com

AT7519 Astex Pharmaceuticals multiple myeloma Phase II

(CDK inhibitor) Pleasanton, CA www.astx.com

BB-MPI-03 Benovus Bio multiple myeloma Phase I

(multi-peptide immunotherapy) Atlanta, GA (see also hematological, leukemia) www.benovusbio.com

CB-5083 Cleave Biosciences multiple myeloma Phase I

(P97 ATPase inhibitor) Burlingame, CA www.cleavebio.com

CPI-0610 Constellation Pharmaceuticals multiple myeloma Phase I

(BET inhibitor) Cambridge, MA (see also hematological, leukemia, lymphoma) www.constellationpharma.com

CUDC-907 Curis multiple myeloma Phase I

(HDAC/PI3K inhibitor) Lexington, MA (see also lymphoma, solid tumors) www.curis.com

daratumumab Janssen Research & Development double refractory multiple myeloma application submitted

(IgG1k mAb) Raritan, NJ (Breakthrough Therapy) (Fast Track) www.janssenrnd.com

multiple myeloma (1st-line), Phase III

multiple myeloma (1st-line, combination www.janssenrnd.com

therapy), recurrent/relapsed multiple

myeloma (combination therapy)

DKN-01 HealthCare Pharmaceuticals multiple myeloma Phase I/II

(DKK1 protein inhibitor) Cambridge, MA (see also lung, other) www.healthcarepharmaceuticals.com




http://www.cleavebio.com/






Multiple Myeloma


elotuzumab AbbVie multiple myeloma (1st-line) Phase III

(CD319 antigen modulator) North Chicago, IL (combination therapy), www.abbvie.com

Bristol-Myers Squibb relapsed/refractory multiple myeloma www.bms.com

Princeton, NJ (combination therapy) (Breakthrough Therapy)

multiple myeloma (2nd-line) Phase II

(combination therapy) www.abbvie.com

www.bms.com

filanesib Array BioPharma multiple myeloma Phase II

(KSP inhibitor) Boulder, CO www.arraybiopharma.com

I-131-CLR1404 Cellector Biosciences relapsed/refractory multiple myeloma Phase I

(molecular radiotherapeutic) Madison, WI www.cellector.com

indatuximab ravtansine (BT062) Biotest Pharmaceuticals multiple myeloma Phase I/II

(tubulin polymerisation inhibitor) Dreiech, Germany www.biotest.de

Orphan Drug

isatuximab Sanofi US multiple myeloma Phase II

(anti-CD38 naked mAb) Bridgewater, NJ www.sanofi.com

ixazomib Takeda Oncology relapsed/refractory multiple myeloma application submitted

(proteasome inhibitor) Cambridge, MA (see also solid tumors) www.takedaoncology.com

Orphan Drug

previously untreated multiple myeloma, Phase III

maintenance therapy in newly-diagnosed www.takedaoncology.com

multiple myeloma following stem cell

transplantation, maintenance therapy in

newly-diagnosed multiple myeloma not

treated with stem cell transplantation


http://www.bms.com/


http://www.bms.com/


http://www.cellector.com/

http://www.biotest.de/




Multiple Myeloma


Kyprolis® Onyx Pharmaceuticals relapsed multiple myeloma (combination therapy) application submitted

carfilzomib South San Francisco, CA (see also leukemia, myeloma) www.onyx.com

Orphan Drug

relapsed multiple myeloma, Phase III

multiple myeloma (1st-line) www.onyx.com

lirilumab + elotuzumab Bristol-Myers Squibb multiple myeloma Phase I


marizomib Triphase Accelerator relapsed/refractory multiple myeloma Phase II

(proteasome inhibitor) San Diego, CA (see also brain) www.triphaseco.com

melphalan intravenous Spectrum Pharmaceuticals multiple myeloma autologous stem cell application submitted

(Captisol-enabled® melphalan) Henderson, NV transplantation www.sppirx.com

Orphan Drug

NY-ESO-1/LAGE-1-specific T-cells Adaptimmune advanced multiple myeloma Phase I/II

Oxon, England (see also ovarian, sarcoma, skin) www.adaptimmune.com

oprozomib Onyx Pharmaceuticals multiple myeloma (monotherapy) Phase II

(proteasome inhibitor) South San Francisco, CA (see also hematological, solid tumors) www.onyx.com

Orphan Drug

multiple myeloma (combination therapy) Phase I

www.onyx.com

PIM447 Novartis Pharmaceuticals multiple myeloma Phase I/II

(proto oncogene protein c East Hanover, NJ (see also hematological, leukemia) www.novartis.com

pim-1 inhibitor)

plitidepsin PharmaMar relapsed/refractory multiple myeloma Phase III

(marine-derived medicine) Madrid, Spain www.pharmamar.com

Orphan Drug



http://www.bms.com/

http://www.triphaseco.com/


http://www.adaptimmune.com/





Multiple Myeloma


PVX-410 OncoPep smoldering multiple myeloma Phase I/II

(therapeutic cancer vaccine) North Andover, MA www.oncopep.com

Orphan Drug

Reolysin® Oncolytics Biotech relapsed/refractory multiple myeloma Phase I

pelareorp Calgary, Canada (see also brain, colorectal, head/neck, lung, www.oncolyticsbiotech.com

ovarian, other, pancreatic)

Revlimid® Celgene multiple myeloma (maintenance therapy) Phase III

lenalidomide Summit, NJ (see also hematological, leukemia, lymphoma) www.celgene.com

Orphan Drug

ricolinostat Acetylon Pharmaceuticals relapsed/refractory multiple myeloma Phase II

(HDAC inhibitor) Boston, MA (see also lymphoma) www.acetylon.com

selinexor (oral) Karyopharm Therapeutics multiple myeloma Phase III


Orphan Drug leukemia, lymphoma, prostate, sarcoma,

other)

multiple myeloma (combination therapy) Phase II

www.karyopharm.com

Sylvant® Janssen Research & Development smoldering multiple myeloma Phase II

siltuximab Raritan, NJ www.janssenrnd.com

TAS-120 Taiho Oncology advanced multiple myeloma Phase I/II

(FGF/FGFR inhibitor) Princeton, NJ (see also solid tumors) www.taihooncology.com

TG02 Tragara Pharmaceuticals multiple myeloma Phase I

(CDK inhibitor) Carlsbad, CA (see also leukemia) www.tragarapharma.com

http://www.oncopep.com/








http://www.tragarapharma.com/

Multiple Myeloma


urelumab + elotuzumab Bristol-Myers Squibb multiple myeloma Phase I


VLX1570 Vivolux multiple myeloma Phase I/II

(proteasome inhibitor) Ashburn, VA www.vivolux.com

WT1-CTL Atara Biotherapeutics multiple myeloma Phase I

(immunostimulant) South San Francisco, CA (see also leukemia) www.atarabio.com

Xgeva® Amgen prevention of skeletal-related events in Phase III

denosumab Thousand Oaks, CA multiple myeloma www.amgen.com

(see also breast, lung)

Ovarian Cancer


ADI-PEG 20 Polaris Pharmaceuticals ovarian cancer Phase I

(PEG arginine deiminase) San Diego, CA (see also breast, liver, lung, pancreatic, skin, stomach) www.polarispharma.com

Avastin® Genentech/Roche metastatic ovarian cancer (1st-line) Phase III

bevacizumab South San Francisco, CA (see also brain, breast, lung, other) www.roche.com

Orphan Drug

AZD1775 AstraZeneca ovarian cancer Phase II

(WEE-1 inhibitor) Wilmington, DE www.astrazeneca.com

BBI503 Boston Biomedical ovarian cancer Phase II

(cancer stemness kinase inhibitor) Cambridge, MA (see also liver) www.bostonbiomedical.com

BBI608 Boston Biomedical ovarian cancer Phase II


liver, lung, pancreatic, skin, stomach)

http://www.bms.com/

http://www.vivolux.com/








Ovarian Cancer


binimetinib Array BioPharma low-grade serous ovarian cancer Phase III

(MEK inhibitor) Boulder, CO (see also skin) www.arraybiopharma.com

birinapant TetraLogic Pharmaceuticals ovarian cancer Phase II

(apoptosis stimulator) Malvern, PA (see also hematological, lymphoma) www.tetralogicpharma.com

BNC105 Bionomics ovarian cancer Phase I/II

(vascular disrupting agent) Thebarton, Australia (see also kidney) www.bionomics.com.au

CRLX101 Cerulean Pharma relapsed platinum-resistant ovarian cancer Phase I

(nanoparticle drug conjugate) Cambridge, MA (see also colorectal, kidney) www.ceruleanrx.com

Orphan Drug

demcizumab OncoMed Pharmaceuticals platinum-resistant ovarian cancer Phase I/II

(DLL4 inhibitor) Redwood City, CA (see also lung, pancreatic) www.oncomed.com

DPX-0907 Immunovaccine ovarian cancer Phase I

(T lymphocyte modulator) Halifax, Canada (see also breast, prostate) www.imvaccine.com

DPX-Survivac Immunovaccine ovarian cancer Phase I/II

(peptide cancer vaccine) Halifax, Canada www.imvaccine.com

ENMD-2076 CASI Pharmaceuticals ovarian clear cell carcinoma Phase II

(aurora A/angiogenic kinase Rockville, MD (see also breast, sarcoma) www.casipharmaceuticals.com

inhibitor)

Orphan Drug

EP-100 Esperance Pharmaceuticals ovarian cancer Phase II completed

(membrane disrupting peptide) San Francisco, CA www.esperancepharma.com

epacadostat Incyte ovarian cancer Phase II

(IDO1 inhibitor) Wilmington, DE (see also lung, skin, other) www.incyte.com



http://www.bionomics.com.au/






http://www.esperancepharma.com/


Ovarian Cancer


etirinotecan pegol (NKTR-102) Nektar Therapeutics platinum-resistant ovarian cancer Phase II completed

(PEGylated irinotecan) San Francisco, CA (see also breast, colorectal) www.nektar.com

Orphan Drug

fosbretabulin OXiGENE ovarian cancer (combination therapy) (Fast Track) Phase II

(vascular targeting agent) South San Francisco, CA (see also stomach) www.oxigene.com

Orphan Drug

GALE-301 Galena Biopharma ovarian cancer Phase II

(folate binding protein Portland, OR (see also other) www.galenabiopharma.com

immunotherapy)

ganetespib Synta Pharmaceuticals ovarian cancer Phase II

(Hsp90 inhibitor) Lexington, MA (see also breast, leukemia, lung) www.syntapharma.com

GEN 1 Celsion ovarian cancer Phase II

(cancer immunotherapy) Lawrenceville, NJ (see also colorectal) www.celsion.com

ipafricept Bayer HealthCare Pharmaceuticals ovarian cancer (combination therapy) Phase I

(Wnt protein inhibitor) Whippany, NJ (see also liver, pancreatic) www.healthcare.bayer.com

OncoMed Pharmaceuticals www.oncomed.com

Redwood City, CA

Karentitecin® BioNumerik Pharmaceuticals advanced ovarian cancer Phase III

cositecan San Antonio, TX www.bionumerik.com

lifastuzumab vedotin Genentech/Roche platinum-resistant ovarian cancer Phase II

(antibody drug conjugate) South San Francisco, CA (see also lung) www.roche.com

ovarian cancer Phase I

www.roche.com







http://www.bionumerik.com/



Ovarian Cancer


LY2606368 Eli Lilly metastatic ovarian cancer Phase II

(Chk1 inhibitor) Indianapolis, IN (see also breast) www.lilly.com

Lynparza® AstraZeneca BRCA-mutated ovarian cancer (1st-line), Phase III

olaparib Wilmington, DE germline BRCA-mutated, platinum-sensitive www.astrazeneca.com

Orphan Drug recurrent ovarian cancer

(see also breast, pancreatic, prostate, stomach)

ME-344 MEI Pharma ovarian cancer Phase II

(mitochondrial inhibitor) San Diego, CA (see also lung) www.meipharma.com

mirvetuximab soravtansine ImmunoGen platinum-resistant ovarian cancer Phase I

(folate receptor 1 inhibitor) Waltham, MA (see also other) www.immunogen.com

Orphan Drug

MORAb-003 Eisai platinum-sensitive ovarian cancer Phase II

(IgG1 mAb) Woodcliff Lake, NJ (see also lung) www.eisai.com

Orphan Drug

motolimod VentiRx Pharmaceuticals ovarian cancer (Fast Track) Phase II

(TLR8 agonist immunotherapy) Seattle, WA (see also head/neck) www.ventirx.com

Orphan Drug

niraparib TESARO ovarian cancer maintenance Phase III

(PARP inhibitor) Waltham, MA (see also breast, sarcoma) www.tesarobio.com

ovarian cancer treatment Phase III

www.tesarobio.com

ovarian cancer (combination therapy) Phase I

www.tesarobio.com






http://www.ventirx.com/




Ovarian Cancer


NY-ESO-1/LAGE-1-specific T-cells Adaptimmune ovarian cancer Phase I/II

Oxon, England (see also myeloma, sarcoma, skin) www.adaptimmune.com

ONT-10 Oncothyreon ovarian cancer Phase I

(cancer immunotherapy) Seattle, WA (see also breast) www.oncothyreon.com

oregovomab Quest PharmaTech ovarian cancer Phase II

Orphan Drug Edmonton, Canada (see also pancreatic) www.questpharmatech.com

ovarian cancer vaccine MabVax Therapeutics ovarian cancer Phase II

(pentavalent) San Diego, CA www.mabvax.com

paclitaxel poliglumex CTI BioPharma ovarian cancer (1st-line) Phase III

Seattle, WA www.ctibiopharma.com

PLX3397 Plexxikon advanced ovarian cancer Phase I

(CSF-1R inhibitor) Berkeley, CA (see also brain, breast, skin, other) www.plexxikon.com

PM01183 Pharma Mar ovarian cancer Phase III

(marine-derived alkylating agent) Madrid, Spain (see also breast, lung) www.pharmamar.com

Orphan Drug

ralimetinib Eli Lilly ovarian cancer Phase II

(p38 MAP kinase inhibitor) Indianapolis, IN www.lilly.com

Reolysin® Oncolytics Biotech ovarian cancer Phase II


Orphan Drug myeloma, other, pancreatic)

RG7882 Genentech/Roche ovarian cancer Phase I

(antibody drug conjugate) South San Francisco, CA (see also pancreatic) www.roche.com



http://www.questpharmatech.com/

http://www.mabvax.com/







Ovarian Cancer


rucaparib Clovis Oncology ovarian cancer (maintenance) Phase III

(PARP inhibitor) Boulder, CO (see also breast, pancreatic, other) www.clovisoncology.com

Orphan Drug

gBRCA-mutation ovarian cancer Phase II

(Breakthrough Therapy) www.clovisoncology.com

seribantumab (MM-121) Merrimack Pharmaceuticals ovarian cancer Phase II

(ErbB-3 receptor antagonist) Cambridge, MA (see also breast, lung) www.merrimackpharma.com

SGI-110 Astex Pharmaceuticals ovarian cancer Phase II

(DNMT inhibitor) Pleasanton, CA (see also hematological, leukemia, liver) www.astx.com

STM 434 Atara Biotherapeutics ovarian cancer Phase I

(activin inhibitor) South San Francisco, CA www.atarabio.com

TPIV200 TapImmune ovarian cancer (combination therapy) Phase I

(folate receptor alpha vaccine) Seattle, WA (see also breast) www.tapimmune.com

trebananib Amgen ovarian cancer Phase III

(Ang 1 / Ang 2 inhibitor) Thousand Oaks, CA (see also breast, lung) www.amgen.com

Vargatef® Boehringer Ingelheim Pharmaceuticals ovarian cancer (1st-line) Phase III

nintedanib Ridgefield, CT (see also colorectal, lung) www.boeringer-ingelheim.com

VB-111 VBL Therapeutics ovarian cancer Phase II

(targeted anti-angiogenic agent) Tel Aviv, Israel (see also brain, other) www.vblrx.com

Vigil™ Gradalis stage III/IV ovarian cancer Phase III

autologous immunotherapy Dallas, TX (see also sarcoma) www.gradalisinc.com










http://www.gradalisinc.com/

Ovarian Cancer


VS-6063 Verastem late-stage ovarian cancer Phase II

(FAK inhibitor) Cambridge, MA (see also lung) www.verastem.com

Orphan Drug

Yondelis® Janssen Research & Development relapsed ovarian cancer Phase III

trabectedin Raritan, NJ (see also sarcoma) www.janssenrnd.com

Orphan Drug

Pancreatic Cancer


Abraxane® Celgene pancreatic cancer (adjuvant) Phase III

paclitaxel protein-bound Summit, NJ (see also breast) www.celgene.com

particles for injectable

suspension (albumin-bound)

Orphan Drug

ACP-196 Acerta Pharma advanced pancreatic cancer (combination therapy) Phase II


leukemia, lung, lymphoma, myeloma)

ADI-PEG 20 Polaris Pharmaceuticals pancreatic cancer Phase I

(PEG arginine deiminase) San Diego, CA (see also breast, liver, lung, ovarian, skin, stomach) www.polarispharma.com

aglatimagene besadenovec Advantagene pancreatic cancer Phase I/II

(gene therapy) Auburndale, MA (see also brain, prostate) www.advantagene.com

algenpantucel-L NewLink Genetics pancreatic cancer (resected) (Fast Track), Phase III

(immunotherapy vaccine) Ames, IA pancreatic cancer (borderline resectable of www.newlinkgenetics.com

Orphan Drug locally advanced unresectable)

anti-MUC1 AR20.5 mAb Quest PharmaTech pancreatic cancer Phase I/II

(chemotherapy-enhanced Edmonton, Canada www.questpharmatech.com

immunotherapy)









Pancreatic Cancer


apatorsen OncoGenex Pharmaceuticals metastatic pancreatic cancer Phase II

(Hsp27 inhibitor) Bothell, WA (see also bladder, lung, prostate) www.oncogenex.com

BBI608 Boston Biomedical pancreatic cancer Phase I


liver, lung, ovarian, skin, stomach)

BC-819 BioCancell Therapeutics pancreatic cancer (1st-line) (Fast Track) Phase II

(gene therapy) Jerusalem, Israel (see also bladder) www.biocancell.com

Orphan Drug

CPI-613 Cornerstone Pharmaceuticals pancreatic cancer Phase II

(KGDH/PHD complex inhibitor) Cranbury, NJ (see also other) www.cornerstonepharma.com

Orphan Drug

CRS-207 Aduro BioTech pancreatic cancer (combination therapy) Phase II

(cancer immunotherapy) Berkeley, CA (see also lung) www.aduro.com

Orphan Drug

demcizumab OncoMed Pharmaceuticals metastatic pancreatic ductal cancer Phase II

(DLL4 inhibitor) Redwood City, CA (see also lung, ovarian) www.oncomed.com

Orphan Drug

encapsulated cell therapy Rogosin Institute metastatic pancreatic cancer Phase II

New York, NY (see also colorectal, prostate) www.rogosin.org


New York, NY

ensituximab Precision Biologics advanced pancreatic cancer Phase II

(neoplasm antigen inhibitor) Dallas, TX (see also colorectal) www.precision-biologics.com

Orphan Drug



http://www.biocancell.com/

http://www.cornerstonepharma.com/

http://www.aduro.com/




http://www.precision-biologics.com/

Pancreatic Cancer


evofosfamide (TH-302) EMD Serono pancreatic cancer (Fast Track) Phase III

(hypoxia-activated prodrug) Rockland, MA (see also brain, hematological, lung, sarcoma, skin) www.emdserono.com

Orphan Drug Threshold Pharmaceuticals www.thresholdpharm.com


FG-3019 Fibrogen advanced pancreatic cancer Phase II

(connective tissue growth San Francisco, CA www.fibrogen.com

factor inhibitor)

galunisertib Eli Lilly pancreatic cancer Phase I/II

(TGF-beta 1 kinase inhibitor) Indianapolis, IN (see also brain, liver) www.lilly.com

GI-4000 GlobeImmune pancreatic cancer Phase II

(mutated Ras cancer vaccine) Louisville, CO (see also lung) www.globeimmune.com

glufosfamide Eleison Pharmaceuticals metastatic pancreatic cancer (Fast Track) Phase III

Orphan Drug St. Petersburg, FL www.eleison-pharma.com

Imprime PGG® Biothera advanced pancreatic ductal cancer Phase I

intravenous immunostimulant Eagan, MN (see also colorectal, leukemia, lung, lymphoma) www.biothera.com

INCB39110 Incyte pancreatic cancer Phase I

(JAK1 inhibitor) Wilmington, DE (see also lung, lymphoma) www.incyte.com

INO-1400 Inovio Pharmaceuticals pancreatic cancer Phase I

(hTERT immunotherapy) Plymouth Meeting, PA (see also breast, lung) www.inovio.com

ipafricept Bayer HealthCare Pharmaceuticals pancreatic cancer (combination therapy) Phase I

(Wnt protein inhibitor) Whippany, NJ (see also liver, ovarian) www.healthcare.bayer.com

OncoMed Pharmaceuticals www.oncomed.com

Redwood City, CA



http://www.fibrogen.com/



http://www.eleison-pharma.com/





Pancreatic Cancer


Jakafi® Incyte pancreatic cancer (Fast Track) Phase III

ruxolitinib Wilmington, DE (see also breast, colorectal, lung) www.incyte.com

KLT injection KangLaiTe USA advanced pancreatic cancer Phase II

(kanglaite) Redwood City, CA www.kanglaite-usa.com

LipoPlatin™ In Ovations Holdings pancreatic cancer Phase III

cisplatin liposomal Doral, FL www.regulon.org

Regulon

Alimos, Greece

Lynparza® AstraZeneca pancreatic cancer Phase III

olaparib Wilmington, DE (see also breast, ovarian, prostate, stomach) www.astrazeneca.com

masitinib AB Science USA metastatic pancreatic cancer Phase III

Short Hills, NJ (see also stomach) www.ab-science.com

MM-141 Merrimack Pharmaceuticals metastatic pancreatic cancer (1st-line) Phase II

(IGF-1R/ErbB3 bispecific Cambridge, MA www.merrimackpharma.com

tetravalent antibody)

Orphan Drug

MM-398 Baxalta metastatic pancreatic cancer (1st-line) (Fast Track) application submitted

(encapsulated irinotecan Cambridge, MA (see also brain, solid tumors) www.baxalta.com

nanotherapeutic)

Orphan Drug

momelotinib Gilead Sciences pancreatic cancer Phase III

(JAK inhibitor) Foster City, CA (see also hematological) www.gilead.com

necuparanib Momenta Pharmaceuticals pancreatic cancer (1st-line) Phase II

(angiogenesis inhibitor) Cambridge, MA (Fast Track) www.momentapharma.com

Orphan Drug


http://www.kanglaite-usa.com/

http://www.regulon.org/


http://www.ab-science.com/




http://www.momentapharma.com/

Pancreatic Cancer


OGF/MENK Immune Therapeutics pancreatic cancer Phase II

(methionine enkephalin) Orlando, FL www.immunetherapeutics.com

oregovomab Quest PharmaTech pancreatic cancer Phase II

Orphan Drug Edmonton, Canada (see also ovarian) www.questpharmatech.com

PBI-05204 Phoenix Biotechnology pancreatic cancer Phase II

(triple kinase inhibitor) San Antonio, TX www.phoenixbiotechnology.com

PEGPH20 Halozyme Therapeutics metastatic pancreatic cancer Phase II

(pegylated recombinant San Diego, CA (see also lung) www.halozyme.com

human hyaluronidase)

Orphan Drug

PLX7486 Plexxikon pancreatic cancer Phase I

(TRK inhibitor) Berkeley, CA www.plexxikon.com

polyclonal antibody stimulator Cancer Advances pancreatic cancer Phase III completed

(G17DT) Durham, NC (see also colorectal, stomach) www.canceradvancesinc.com

Orphan Drug

PRI-724 PRISM Pharma metastatic pancreatic adenocarcinoma Phase I/II

(CBP/beta catenin inhibitor) Tokyo, Japan (see also leukemia) www.prismbiolabs.com

Reolysin® Oncolytics Biotech metastatic pancreatic cancer Phase II


Orphan Drug myeloma, ovarian, other)

RG7882 Genentech/Roche pancreatic cancer Phase I

(antibody drug conjugate) South San Francisco, CA (see also ovarian) www.roche.com

http://www.immunetherapeutics.com/


http://www.phoenixbiotechnology.com/

http://www.halozyme.com/



http://www.prismbiolabs.com/



Pancreatic Cancer


rucaparib Clovis Oncology pancreatic cancer Phase II

(PARP inhibitor) Boulder, CO (see also breast, ovarian, other) www.clovisoncology.com

SM04755 Samumed advanced pancreatic cancer Phase I

(Wnt inhibitor) San Diego, CA (see also colorectal, liver, stomach) www.samumed.com

TAK-264 Takeda Oncology pancreatic cancer Phase II

(antibody drug conjugate Cambridge, MA (see also stomach) www.takedaoncology.com

targeting GCC)

tarextumab OncoMed Pharmaceuticals advanced pancreatic cancer Phase II

(anti-NOTCH 2/3 mAb) Redwood City, CA (see also lung) www.oncomed.com

Orphan Drug

TL-118 Tiltan Pharma pancreatic cancer (1st-line) Phase II

(angiogenesis inhibitor) Jerusalem, Israel www.tiltanpharma.com

vantictumab OncoMed Pharmaceuticals advanced pancreatic cancer Phase I

(anti-Fzd7) Redwood City, CA (combination therapy) www.oncomed.com

(see also breast, lung)

X-82 Tyrogenex pancreatic neuroendocrine tumors Phase I/II

(VEGFR/PDGFR antagonist) Palm Beach Gardens, FL www.tyrogenex.com

Y-90 clivatuzumab tetraxetan Immunomedics relapsed pancreatic cancer Phase III

Orphan Drug Morris Plains, NJ (Fast Track) www.immunomedics.com

pancreatic cancer (1st-line) Phase I/II

(Fast Track) www.immomedics.com





http://www.tiltanpharma.com/


http://www.tyrogenex.com/


http://www.immomedics.com/

Prostate Cancer


177Lu-J591 BZL Biologics metastatic prostate cancer Phase II

(PSMA mAb) New York, NY

Cornell University

Ithaca, NY

ADXS-PSA Advaxis hormone refractory prostate cancer Phase I/II

(immunotherapy vaccine) Princeton, NJ www.advaxis.com

AE37 Antigen Express prostate cancer Phase II

(immunotherapeutics) Worcester, MA (see also breast) www.antigenexpress.com

aglatimagene besadenovec Advantagene newly-diagnosed prostate cancer Phase III

(gene therapy) Auburndale, MA (see also brain, prostate) www.advantagene.com

apatorsen OncoGenex Pharmaceuticals prostate cancer Phase II

(Hsp27 inhibitor) Bothell, WA (see also bladder, lung, pancreatic) www.oncogenex.com

APC100 Adamis Pharmaceuticals prostate cancer Phase I/II

(androgen antagonist) San Diego, CA www.adamispharmaceuticals.com

ASN001 Asana BioSciences prostate cancer Phase I/II

(CYP17 lyase inhibitor) Bridgewater, NJ www.asanabiosciences.com

BPX-201 Bellicum Pharmaceuticals metastatic castration-resistant prostate cancer Phase I

(dendritic cell vaccine) Houston, TX www.bellicum.com

CFG920 Novartis Pharmaceuticals metastatic castration-resistant prostate cancer Phase I/II

(CYP17 inhibitor) East Hanover, NJ www.novartis.com

custirsen (OGX-111) OncoGenex Pharmaceuticals metastatic castration-resistant prostate cancer Phase III

(antisense olignucleotide) Bothell, WA (2nd-line) www.oncogenex.com


http://www.antigenexpress.com/



http://www.adamispharmaceuticals.com/

http://www.asanabiosciences.com/

http://www.bellicum.com/



Prostate Cancer


docetaxel injection concentrate, Teikoku Pharma USA prostate cancer application submitted

non-alcohol formula San Jose, CA (see also breast, head/neck, lung, stomach) www.teikokuusa.com

DPV-001 UbiVac advanced prostate cancer Phase I

(toll-like receptor agonist) Portland, OR (see also lung) www.ubivac.com

DPX-0907 Immunovaccine prostate cancer Phase I

(T lymphocyte modulator) Halifax, Canada (see also breast, ovarian) www.imvaccine.com

EC1169 Endocyte prostate cancer Phase I

(PSMA tubulysin) West Lafayette, IN www.endocyte.com

encapsulated cell therapy Rogosin Institute metastatic prostate cancer Phase II

New York, NY (see also colorectal, pancreatic) www.rogosin.org


New York, NY

FP-001 Foresee Pharmaceuticals late-stage prostate cancer Phase III

(leuprolide mesylate) Newark, DE www.foreseepharma.com

galeterone Tokai Pharmaceuticals metastatic prostate cancer (1st-line) Phase III

(androgen receptor antagonist) Cambridge, MA (Fast Track www.tokaipharma.com

treatment-resistant prostate cancer Phase I

(Fast Track) www.tokaipharma.com

GTx-758 GTx secondary hormone therapy for Phase II

(ER alpha agonist) Memphis, TN castration-resistant prostate cancer www.gtxinc.com

indoximod NewLink Genetics metastatic castration-resistant Phase II

(IDO pathway inhibitor) Ames, IA prostate cancer www.newlinkgenetics.com

(see also brain, breast)


http://www.ubivac.com/





http://www.foreseepharma.com/

http://www.tokaipharma.com/

http://www.tokaipharma.com/

http://www.gtxinc.com/


Prostate Cancer


ipatasertib Array BioPharma prostate cancer Phase II

(Akt inhibitor) Boulder, CO (see also breast, stomach) www.roche.com

Genentech/Roche


IRX4204 Io Therapeutics prostate cancer Phase II

(retinoid X receptor factor) Santa Ana, CA www.io-therapeutics.com

Jevtana® Sanofi US metastatic prostate cancer (1st-line) Phase III

cabazitaxel Bridgewater, NJ (see also brain) www.sanofi.com

JNJ927/ARN-509 Janssen Research & Development castration-resistant prostate cancer, Phase III

(androgen receptor antagonist) Raritan, NJ treatment naïve metastatic www.janssenrnd.com

castration-resistant prostate cancer


KLT gel cap KangLaiTe USA prostate cancer Phase II

(kanglaite) Redwood City, CA www.kanglaite-usa.com

LY3023414 Eli Lilly prostate cancer Phase II

(PI3K/mTOR dual inhibitor) Indianapolis, IN (see also lung) www.lilly.com

Lynparza® AstraZeneca prostate cancer Phase III

olaparib Wilmington, DE (see also breast, ovarian, pancreatic, stomach) www.astrazeneca.com

MER-104 Merrion Pharmaceuticals prostate cancer Phase I

(oral acyline) Dublin, Ireland www.merrionpharma.com

MOR209/ES414 Emergent BioSolutions metastatic castration-resistant prostate cancer Phase I

(bispecific immunotherapeutic) Gaithersburg, MD www.emergentbiosolutions.com

MorphoSys www.morphosys.com

Martinsried, Germany


http://www.io-therapeutics.com/



http://www.kanglaite-usa.com/



http://www.merrionpharma.com/

http://www.emergentbiosolutions.com/


Prostate Cancer


MVI-816 Madison Vaccines prostate cancer (1st-line) Phase II

(PAP plasmid DNA vaccine) Madison, WI www.madisonvaccinesinc.com

NX-1207 Nymox Pharmaceutical prostate cancer Phase III

(apoptosis stimulant) Hasbrouck Heights, NJ www.nymox.com

ODM-201 Bayer HealthCare Pharmaceuticals prostate cancer Phase III

(androgen receptor antagonist) Whippany, NJ www.healthcare.bayer.com

ONC1-13B AllaChem metastatic prostate cancer Phase I/II

(androgen receptor antagonist) Hallandale Beach, FL www.allachem.com

ozarelix Spectrum Pharmaceuticals hormone dependent prostate cancer Phase II

(GnRH inhibitor) Henderson, NV www.sppirx.com

pasireotide long acting release Novartis Pharmaceuticals castration-resistant prostate cancer Phase I/II

(SOM230) East Hanover, NJ (see also other, skin) www.novartis.com

prostate cancer vaccine OncBioMune prostate cancer Phase I

(PSA/IL-2/GM-CSF vaccine) Baton Rouge, LA www.oncbiomune.com

Prostvac® Bavarian Nordic metastatic castration-resistant Phase III

rilimogene galvacirepvec- Mountain View, VA prostate cancer (Fast Track) www.bavarian-nordic.com

rilimogene glafolivec Bristol-Myers Squibb www.bms.com

Princeton, NJ

Provenge® Dendreon recurrent early-stage prostate cancer Phase III

sipuleucel-T Seattle, WA www.dendreon.com

recurrent hormone refractory Phase II

metastatic prostate cancer www.dendreon.com

http://www.madisonvaccinesinc.com/

http://www.nymox.com/

http://www.allachem.com/



http://www.oncbiomune.com/


http://www.bms.com/



Prostate Cancer


PRX302 Sophiris Bio localized low to intermediate risk Phase II

(recombinant protein) La Jolla, CA prostate cancer www.sophirisbio.com

PSMA ADC therapeutic Progenics Pharmaceuticals prostate cancer Phase II

(antibody drug conjugate) Tarrytown, NY www.progenics.com

REIC gene therapy Momotaro-Gene prostate cancer Phase I/II

Okayama, Japan www.mt-gene.com

relugolix (TAK-385) Takeda Oncology prostate cancer Phase II

(LH-RH antagonist) Cambridge, MA www.takedaoncology.com

RG7450 Genentech/Roche prostate cancer Phase I

(anti-STEAP1 antibody drug South San Francisco, CA www.roche.com

conjugate)

selinexor (oral) Karyopharm Therapeutics prostate cancer Phase II


leukemia, lymphoma, myeloma, sarcoma, other)

stapuldencel-T Sotio metastatic castration-resistant prostate cancer Phase III

(active cellular immunotherapy) Prague, Czech Republic www.sotio.com

TT-100 TriAct Therapeutics prostate cancer Phase II completed

(IGF-1/EGF dual inhibitor) San Francisco, CA

VT-122 Vicus Therapeutics prostate cancer Phase II

(cancer immunotherapy) Morristown, NJ (see also liver) www.vicustherapeutics.com

VT-464 Innocrin Pharmaceuticals castration-resistant prostate cancer Phase II

(CYP17 lyase inhibitor) Durham, NC www.innocrinpharma.com

http://www.sophirisbio.com/

http://www.progenics.com/

http://www.mt-gene.com/




http://www.sotio.com/

http://www.vicustherapeutics.com/

http://www.innocrinpharma.com/

Prostate CancerProduct Name Sponsor Indication Development Phase

Xofigo® Bayer HealthCare Pharmaceuticals bone metastases in castration-resistant Phase III

radium-223 dichloride Whippany, NJ prostate cancer (1st-line) (combination therapy) www.healthcare.bayer.com

bone metastases in castration-resistant Phase II

prostate cancer (combination therapy) www.healthcare.bayer.com


Xtandi® Astellas Pharma US non-metastatic castration-resistant prostate Phase III

enzalutamide Northbrook, IL cancer, prostate cancer in patients with www.astellas.com

Medivation non-metastatic biochemical recurrence www.medivation.com

San Francisco, CA (see also breast, liver)

zoptarelin doxorubicin Aeterna Zentaris castration-/taxane-resistant prostate cancer Phase II

(type II DNA topoisomerase Quebec, Canada (see also other) www.aezsinc.com

inhibitor)

Sarcoma


aldoxorubicin CytRx soft tissue sarcoma (2nd-line) Phase III

(delivery-enhanced doxorubicin) Los Angeles, CA (see also brain, lung) www.cytrx.com

Orphan Drug

Kaposi's sarcoma, Phase II

soft tissue sarcoma (1st-line) www.cytrx.com

ENMD-2076 CASI Pharmaceuticals soft tissue sarcoma Phase II

(aurora A/angiogenic kinase Rockville, MD (see also breast, ovarian) www.casipharmaceuticals.com

inhibitor)



http://www.aezsinc.com/




Sarcoma


evofosfamide (TH-302) EMD Serono soft tissue sarcoma (Fast Track) Phase III

(hypoxia-activated prodrug) Rockland, MA (see also brain, hematological, lung, pancreatic, skin) www.emdserono.com

Orphan Drug Threshold Pharmaceuticals www.thresholdpharm.com


G100 Immune Design metastatic soft tissue sarcoma Phase I

(TLR4 agonist) Seattle, WA (see also skin) www.immunedesign.com

GPX-150 Gem Pharmaceuticals soft tissue sarcoma Phase II

(type II DNA topoisomerase Birmingham, AL www.gempharmaceuticals.com

inhibitor)

Halaven® Eisai soft tissue sarcoma application submitted

eribulin Woodcliff Lake, NJ (see also bladder, lung) www.eisai.com

Orphan Drug

HDM201 Novartis Pharmaceuticals liposarcoma Phase I/II

(tumor suppressor protein East Hanover, NJ (see also hematological, solid tumors) www.novartis.com

p53 modulator)

inhaled lipid-complexed cisplatin Eleison Pharmaceuticals prevention of pulmonary metastases Phase II

St. Petersburg, MD from osteosarcoma (pediatric) www.eleison-pharma.com

MORAb-004 Eisai soft tissue sarcoma Phase II

(CD248 antigen inhibitor) Woodcliff Lake, NJ (see also colorectal, skin) www.eisai.com

Orphan Drug

niraparib TESARO Ewing's sarcoma Phase I

(PARP inhibitor) Waltham, MA (see also breast, ovarian) www.tesarobio.com

NY-ESO-1/LAGE-1-specific T-cells Adaptimmune synovial sarcoma Phase I

Oxon, England (see also myeloma, ovarian, skin) www.adaptimmune.com



http://www.immunedesign.com/

http://www.gempharmaceuticals.com/






Sarcoma


olaratumab Eli Lilly soft tissue sarcoma Phase II

(PDGF-alpha receptor antagonist) Indianapolis, IN www.lilly.com

sarcoma vaccine MabVax Therapeutics metastatic sarcoma Phase II

San Diego, CA www.mabvax.com

selinexor (oral) Karyopharm Therapeutics liposarcoma Phase II

(XPO1 antagonist) Newton, MA (see also brain, head/neck, hematological, leukemia, www.karyopharm.com

lymphoma, myeloma, prostate, other)

TRC105 TRACON Pharmaceuticals soft tissue sarcoma Phase II


lung, other)

Vigil™ Gradalis Ewing's sarcoma Phase II

autologous immunotherapy Dallas, TX (see also ovarian) www.gradalisinc.com

Yondelis® Janssen Research & Development soft tissue sarcoma application submitted

trabectedin Raritan, NJ (see also ovarian) www.janssenrnd.com

Orphan Drug

Skin Cancer


ADI-PEG 20 Polaris Pharmaceuticals melanoma Phase I

(PEG arginine deiminase) San Diego, CA (see also breast, liver, lung, ovarian, pancreatic, www.polarispharma.com

Orphan Drug stomach)

AE-M Antigen Express melanoma Phase I

(immunotherapeutic) Worcester, MA www.antigenexpress.com








http://www.antigenexpress.com/

Skin Cancer


alpha-gal glycosphingolipid Agalimmune melanoma Phase I

(immunotherapy) Irvine, CA www.agalimmune.com

ALT-803 Altor BioScience metastatic melanoma Phase I/II

(IL-15 superagonist complex) Miramar, FL (see also bladder, hematological, myeloma) www.altorbioscience.com

AMG 232 Amgen metastatic melanoma Phase I/II

(MDM2 inhibitor) Thousand Oaks, CA (see also leukemia, myeloma, solid tumors) www.amgen.com

avelumab EMD Serono metastatic Merkel cell carcinoma Phase II

(anti-PD-L1 mAb) Rockland, MA (see also lung, solid tumors) www.emdserono.com


New York, NY

bavituximab Peregrine Pharmaceuticals advanced melanoma Phase I

Tustin, CA (see also breast, colorectal, lung) www.peregrineinc.com

BBI608 Boston Biomedical melanoma Phase I

(cancer stem cell inhibitor) Cambridge, MA (see also breast, colorectal, hematological, liver, www.bostonbiomedical.com

lung, ovarian, pancreatic, stomach)

binimetinib Array BioPharma BRAF-mutant melanoma, NRAS-mutant melanoma Phase III

(MEK inhibitor) Boulder, CO (see also ovarian) www.arraybiopharma.com

Cavatak™ Vitalytics metastatic melanoma Phase II

coxsackievirus A21 Sydney, Australia www.viralytics.com

Orphan Drug

CDX-1401 Celldex Therapeutics metastatic melanoma Phase II

(NY-ESO-1 cancer vaccine) Hampton, NJ www.celldex.com

http://www.agalimmune.com/








http://www.viralytics.com/


Skin Cancer


cobimetinib Genentech/Roche metastatic melanoma application submitted

(MEK inhibitor) South San Francisco, CA (combination therapy) www.roche.com

diphencyprone Rxi Pharmaceuticals cutaneous cancer metastases Phase II

(immunomodulator) Marlborough, MA www.rxipharma.com

dorgenmeltucel-L NewLink Genetics metastatic melanoma Phase II

(cancer immunotherapy) Ames, IA www.newlinkgenetics.com

eltrapuldencel-T (CLBS20) Caladrius Biosciences metastatic melanoma (Fast Track) Phase III

(dendritic cell immunotherapy) New York, NY www.caladrius.com

Orphan Drug

encorafenib (LGX818) Array BioPharma BRAF mutant melanoma Phase III

(BRAF inhibitor) Boulder, CO www.arraybiopharma.com

entinostat Syndax Pharmaceuticals melanoma (combination therapy) Phase I/II

(HDAC inhibitor) Waltham, MA (see also breast, lung) www.syndax.com

epacadostat Incyte metastatic melanoma Phase II

(IDO1 inhibitor) Wilmington, DE (see also lung, ovarian, other) www.incyte.com

Erivedge® Genentech/Roche operable basal cell carcinoma Phase II

vismodegib South San Francisco, CA www.roche.com

evofosfamide (TH-302) EMD Serono melanoma Phase II

(hypoxia-activated prodrug) Rockland, MA (see also brain, hematological, lung, www.emdserono.com

Threshold Pharmaceuticals pancreatic, sarcoma) www.thresholdpharm.com


G100 Immune Design Merkel cell carcinoma Phase I

(TLR4 agonist) Seattle, WA (see also sarcoma) www.immunedesign.com


http://www.rxipharma.com/


http://www.caladrius.com/








Skin Cancer


glembatumumab vedotin CellDex Therapeutics stage III or IV metastatic melanoma Phase II

(antibody drug conjugate) Hampton, NJ (see also breast) www.celldex.com

GR-MD-02 Galectin Therapeutics melanoma Phase II

(galectin-3 inhibitor) Norcross, GA www.galectintherapeutics.com

heat shock protein vaccine Agenus metastatic melanoma Phase II

(Prophage Series) Lexington, MA (see also brain) www.agenus.com

Orphan Drug

HF10 Takara Bio metastatic melanoma Phase II

(oncolytic virus immunomodulator) Shiga, Japan (see also head/neck) www.tkara-bio.com

IMCgp100 Immunocore metastatic melanoma Phase II

(CD3 antigen inhibitor) Oxon, England www.immunocore.com

interleukin-12 gene therapy OncoSec Medical metastatic melanoma Phase II

San Diego, CA (see also breast, head/neck) www.oncosec.com

INXN-2001 ZIOPHARM Oncology metastatic melanoma Phase II

(Ad-RTS-IL-12 gene therapy) Boston, MA (see also brain, breast) www.ziopharm.com

Lenvima® Eisai melanoma Phase II

lenvatinib Woodcliff Lake, NJ (see also kidney, liver, lung, other, solid tumors) www.eisai.com

Orphan Drug

LN-144 Lion Biotechnologies metastatic melanoma (2nd-line) Phase II completed

(autologous cell therapy) Woodland Hills, CA www.lbio.com

Orphan Drug National Cancer Institute

Bethesda, MD

metastatic melanoma (1st-line) Phase I

(combination therapy) www.lbio.com


http://www.galectintherapeutics.com/

http://www.agenus.com/

http://www.tkara-bio.com/

http://www.immunocore.com/




http://www.lbio.com/

http://www.lbio.com/

Skin Cancer


MEDI4736 + dabrafenib + MedImmune melanoma Phase I

trametinib Gaithersburg, MD www.medimmune.com

(anti-PD-L1 mAb/murine OX40

agonist/MEK inhibitor)

MGA271 Macrogenics metastatic melanoma (combination therapy) Phase I

(CD276 protein inhibitor) Rockville, MD (see also head/neck, lung) www.macrogenics.com

MORAb-004 Eisai melanoma Phase II

(CD248 antigen inhibitor) Woodcliff Lake, NJ (see also colorectal, sarcoma) www.eisai.com

NY-ESO-1/LAGE-1-specific T-cells Adaptimmune melanoma Phase I/II

Oxon, England (see also myeloma, ovarian, sarcoma) www.adaptimmune.com

onalespib (AT13387) Astex Pharmaceuticals B-raf melanoma Phase II

(Hsp90 inhibitor) Pleasanton, CA (see also lung) www.astx.com

Ontak® Eisai metastatic melanoma Phase II

denileukin diftitox Woodcliff Lake, NJ www.eisai.com

Opdivo® Bristol-Myers Squibb melanoma (adjuvant), Phase III


hematological, kidney, liver, lung, lymphoma,


Opdivo® nivolumab + Bristol-Myers Squibb melanoma (1st-line) Phase III

Yervoy® ipilimumab Princeton, NJ (see also kidney, lung, solid tumors) www.bms.com

pasireotide long acting release Novartis Pharmaceuticals merkel cell carcinoma, metastatic melanoma Phase I

(SOM230) East Hanover, NJ (combination therapy) www.novartis.com

(see also prostate, other)

pimasertib EMD Serono melanoma Phase II

(MEK inhibitor) Rockland, MA www.emdserono.com







http://www.bms.com/

http://www.bms.com/



Skin Cancer


PLX3397 Plexxikon melanoma Phase I

(CSF-1R inhibitor) Berkeley, CA (see also brain, breast, ovarian, other) www.plexxikon.com

Resimmune™ Angimmune metastatic melanoma Phase I/II

A-dmDT390-bisFv immunotoxin Rockville, MD (see also lymphoma) www.angimmune.com

RG7446 Genentech/Roche metastatic melanoma Phase I

(anti-PD-L1 mAb) South San Francisco, CA (see also bladder, breast, kidney, lung, lymphoma) www.roche.com

RTA 408 AbbVie melanoma Phase II

(NF/E2-related factor 2 stimulant) North Chicago, IL www.abbvie.com

Reata Pharmaceuticals www.reatapharma.com

Irving, TX

seviprotimut-L Polynoma metastatic melanoma Phase III

(immunotherapy vaccine) San Diego, CA www.polynoma.com

Orphan Drug

Tafinlar® Novartis Pharmaceuticals BRAF V600-positive melanoma (adjuvant) Phase III

dabrafenib East Hanover, NJ (see also colorectal, lung) www.novartis.com

Mekinist™

trametinib

combination

talimogene laherparepvec Amgen regionally and distantly metastatic melanoma application submitted

(cancer immunotherapy) Thousand Oaks, CA www.amgen.com

mid- to late-stage metastatic melanoma Phase II

www.amgen.com

TLPLDC Cancer Insight melanoma Phase II

(tumor lysate particle-loaded San Antonio, TX www.cancerinsight.com

dendritic cell vaccine) Elios Therapeutics www.eliostherapeutics.com

Austin, TX


http://www.angimmune.com/



http://www.reatapharma.com/

http://www.polynoma.com/




http://www.cancerinsight.com/

http://www.eliostherapeutics.com/

Skin Cancer


TRX518 GITR advanced melanoma Phase I

(GITR receptor antagonist) Cambridge, MA (see also solid tumors) www.gitrrx.com

varlilumab Celldex Therapeutics unresectable stage III or IV melanoma Phase I/II

(CD27 antigen inhibitor) Hampton, NJ (combination therapy) www.celldex.com

(see also hematological, kidney)

veliparib AbbVie melanoma Phase II

(PARP inhibitor) North Chicago, IL (see also brain, breast, colorectal, lung) www.abbvie.com

Yervoy® Bristol-Myers Squibb melanoma (adjuvant) Phase III

ipilimumab Princeton, NJ (see also lung) www.bms.com

Orphan Drug

melanoma (adolescent) Phase II

www.bms.com

Zelboraf® Genentech/Roche BRAF mutation-positive metastatic Phase III

vemurafenib South San Francisco, CA melanoma (adjuvant) www.roche.com

Daiichi Sankyo (see also colorectal, other)

Parsippany, NJ

BRAF mutation-positive metastatic melanoma Phase I

www.roche.com

Solid Tumors


ABBV-221 AbbVie solid tumors Phase I

(epidermal growth factor modulator) North Chicago, IL www.abbvie.com

ABBV-399 AbbVie solid tumors Phase I

(antibody drug conjugate) North Chicago, IL www.abbvie.com

http://www.gitrrx.com/



http://www.bms.com/

http://www.bms.com/





Solid Tumors


ABT-165 AbbVie solid tumors Phase I

(dual variable immunoglobulin) North Chicago, IL www.abbvie.com

ABT-414 AbbVie squamous cell solid tumors Phase II

(antibody drug conjugate) North Chicago, IL (see also brain) www.abbvie.com


(c-Met inhibitor) North Chicago, IL www.abbvie.com


(PARP inhibitor) North Chicago, IL www.abbvie.com


(epidermal growth factor receptor North Chicago, IL www.abbvie.com

antagonist)

AG-120 Agios Pharmaceuticals solid tumors Phase I

(IDH1 inhibitor) Cambridge, MA (see also brain, leukemia) www.agios.com


Summit, NJ

AG-221 Agios Pharmaceuticals advanced solid tumors Phase I/II

(IDH2 inhibitor) Cambridge, MA (see also leukemia) www.agios.com


Summit, NJ

AG-881 Agios Pharmaceuticals advanced solid tumors Phase I

(pan-IDH inhibitor) Cambridge, MA www.agios.com


Summit, NJ












Solid Tumors


AGS-22ME Agenesys relapsed solid tumors Phase I

(antibody drug conjugate) Santa Monica, CA www.agenesys.com

Seattle Genetics www.seattlegenetics.com

Bothell, WA

ALRN-6924 Aileron Therapeutics advanced solid tumors Phase I/II

(next-generation dual-specific Cambridge, MA www.aileronrx.com

MDM2/MDMX antagonist)

ALT-836 Altor BioScience solid tumors Phase I/II

(recombinant chimeric Miramar, FL www.altorbioscience.com

anti-tissue factor antibody)

altiratinib Deciphera Pharmaceuticals solid tumors Phase I

(MET/TIE2/VEGFR2 kinase Cambridge, MA www.deciphera.com

inhibitor)

AM0010 ARMO BioSciences solid tumors Phase I

(PEGylated recombinant Redwood City, CA www.armobio.com

human IL-10)

AMG 208 Amgen solid tumors Phase I

(c-Met inhibitor) Thousand Oaks, CA www.amgen.com

AMG 211/MEDI-565 Amgen solid tumors Phase I

(anti-CEA BiTE mAb) Thousand Oaks, CA www.amgen.com

MedImmune www.medimmune.com

Gaithersburg, MD


(mAb) Thousand Oaks, CA www.amgen.com


(MDM2 inhibitor) Thousand Oaks, CA (see also leukemia, myeloma, skin) www.amgen.com

http://www.agenesys.com/


http://www.aileronrx.com/


http://www.deciphera.com/

http://www.armobio.com/






Solid Tumors


AMG 780 Amgen advanced solid tumors Phase I

(angiopoietin inhibitor) Thousand Oaks, CA www.amgen.com


(c-fms inhibitor) Thousand Oaks, CA www.amgen.com


(aurora kinase inhibitor) Thousand Oaks, CA (see also hematological) www.amgen.com

anetumab ravtansine Bayer HealthCare Pharmaceuticals solid tumors Phase II

(antibody drug conjugate) Whippany, NJ www.healthcare.bayer.com

anti-LAG3 antibody + Bristol-Myers Squibb solid tumors Phase I

Opdivo® nivolumab Princeton, NJ www.bms.com

apatinib mesylate LSK BioPartners Inc. solid tumors Phase I/II

(YN968D1) Salt Lake City, UT www.lskbiopharma.com

Bukwang Pharmaceutical

Seoul, South Korea

APN401 Apeiron Biologics solid tumors Phase I

(siRNA-transfected peripheral blood Vienna, Austria www.apeiron-biologics.com

mononuclear cells)

APS001F Anaeropharma Science solid tumors Phase I

(recombinant anaerobic bacteria) Tokyo, Japan www.anaeropharma.co.jp

APX005M Apexigen solid tumors Phase I

(CD40 antigen inhibitor) San Carlos, CA www.apexigen.com

AR-12 Arno Therapeutics solid tumors Phase I

(PI3K/Akt inhibitor) Flemington, NJ (see also lymphoma) www.arnothera.com




http://www.bms.com/

http://www.lskbiopharma.com/

http://www.apeiron-biologics.com/

http://www.anaeropharma.co.jp/

http://www.apexigen.com/


Solid Tumors


AR-42 Arno Therapeutics solid tumors Phase I

(pan-DAC inhibitor) Flemington, NJ (see also hematological) www.arnothera.com

ARQ 087 ArQule metastatic solid tumors Phase I

(FGFR antagonist) Woburn, MA www.arqule.com

ARQ 092 ArQule advanced solid tumors Phase I

(Akt inhibitor) Woburn, MA www.arqule.com

ARQ 761 ArQule advanced solid tumors Phase I

(E2F1 transcription factor Woburn, MA www.arqule.com

stimulant)

ASB183 Novartis Pharmaceuticals solid tumors Phase I

East Hanover, NJ (see also hematological) www.novartis.com

ASP4132 Astellas Pharma US advanced solid tumors Phase I

Northbrook, IL (see also lymphoma) www.astellas.com

AT13148 Astex Pharmaceuticals solid tumors Phase I

(ROCK inhibitor) Pleasanton, CA www.astx.com

ATI-1123 Azaya Therapeutics solid tumors Phase I

(docetaxel liposomal) San Antonio, TX www.azayatherapeutics.com

AV-203 AVEO Oncology advanced solid tumors Phase I completed

(ERBB-3 receptor antagonist) Cambridge, MA www.aveooncology.com

avelumab EMD Serono solid tumors Phase I

(anti-PD-L1 mAb) Rockland, MA (see also lung, skin) www.emdserono.com


New York, NY








http://www.azayatherapeutics.com/

http://www.aveooncology.com/



Solid Tumors


AZD2014 AstraZeneca solid tumors Phase II

(mTOR serine/threonine Wilmington, DE www.astrazeneca.com

kinase inhibitor)

AZD4547 AstraZeneca solid tumors Phase II

(FGFR tyrosine kinase inhibitor) Wilmington, DE www.astrazeneca.com

AZD5312 AstraZeneca solid tumors Phase I

(androgen receptor inhibitor) Wilmington, DE www.astrazeneca.com

Isis Pharmaceuticals www.isispharm.com

Carlsbad, CA


(ATR serine/threonine Wilmington, DE www.astrazeneca.com

kinase inhibitor)


(PI3K beta inhibitor) Wilmington, DE www.astrazeneca.com


(PI3K alpha inhibitor) Wilmington, DE www.astrazeneca.com

BAY1125976 Bayer HealthCare Pharmaceuticals advanced solid tumors Phase I

(allosteric Akt-1/2 inhibitor) Whippany, NJ www.healthcare.bayer.com


(antibody drug conjugate) Whippany, NJ www.healthcare.bayer.com


(MPS1 inhibitor) Whippany, NJ www.healthcare.bayer.com


(type 2 FGFR antagonist) Whippany, NJ www.healthcare.bayer.com




http://www.isispharm.com/




Solid Tumors



(MPS1 inhibitor) Whippany, NJ www.healthcare.bayer.com

Beigene-283 EMD Serono solid tumors Phase I

(BRAF inhibitor) Rockland, MA www.emdserono.com

Beigene-290 EMD Serono solid tumors Phase I

(PARP inhibitor) Rockland, MA www.emdserono.com

bendamustine ready-to-dilute Eagle Pharmaceuticals solid tumors Phase I

liquid formulation Woodcliff Lake, NJ (see also leukemia, lymphoma) www.eagleus.com

BET inhibitor Bristol-Myers Squibb solid tumors Phase I


BGJ398 Novartis Pharmaceuticals solid tumors Phase II

(FGF-R kinase inhibitor) East Hanover, NJ (see also brain) www.novartis.com

BI 836845 Boehringer Ingelheim Pharmaceuticals solid tumors Phase I

(somatomedin inhibitor) Ridgefield, CT www.boehringer-ingelheim.com


(PTK2 protein inhibitor) Ridgefield, CT www.boehringer-ingelheim.com


Ridgefield, CT www.boehringer-ingelheim.com

BPM31510 Berg Pharma solid tumors Phase I

(ubidecarenone) Framingham, MA www.berghealth.com

briciclib Onconova Therapeutics metastatic solid tumors Phase I

(cyclin D1 modulator) Newtown, PA www.onconova.com




http://www.bms.com/





http://www.berghealth.com/


Solid Tumors


brontictuzumab OncoMed Pharmaceuticals solid tumors Phase I

(NOTCH-1 inhibitor) Redwood City, CA (see also hematological) www.oncomed.com

buparlisib (BKM120) Novartis Pharmaceuticals solid tumors Phase I

(PI3K inhibitor) East Hanover, NJ (see also brain, breast) www.novartis.com

BVD-523 BioMed Valley Discoveries advanced solid tumors Phase I/II

(ERK 1/2 kinase inhibitor) Kansas City, MO (see also hematological, leukemia) www.biomed-valley.com

BVD-CNV BioMed Valley Discoveries advanced solid tumors Phase I

(C. novyi-NT) Kansas City, MO www.biomed-valley.com

BYL719 Novartis Pharmaceuticals solid tumors Phase I

(PI3K-alpha inhibitor) East Hanover, NJ www.novartis.com

CB-839 Calithera Biosciences solid tumors Phase I

(glutaminase inhibitor) South San Francisco, CA (see also hematological) www.calithera.com

CBL0102 Cleveland BioLabs advanced solid tumors Phase I

(apoptosis stimulant) Buffalo, NY www.cbiolabs.com

CBL0137 Incuron advanced solid tumors Phase I

(curaxin) Buffalo, NY www.incuron.ru/en

CC-115 Celgene solid tumors Phase I

(dual TORK/DNA PK inhibitor) Summit, NJ www.celgene.com


(dual TORK inhibitor) Summit, NJ www.celgene.com


(anti-CD47 antibody) Summit, NJ www.celgene.com






http://www.calithera.com/

http://www.cbiolabs.com/

http://www.incuron.ru/en




Solid Tumors



(ERK inhibitor) Summit, NJ www.celgene.com

CEP-37440 Teva Oncology advanced solid tumors Phase I

(dual anaplastic lymphoma Frazer, PA www.tevapharm.com

kinase and PTK2 protein inhibitor)

CGM097 Novartis Pharmaceuticals solid tumors with p53 wild type status Phase I

(p53/MDM2-interaction inhibitor) East Hanover, NJ www.novartis.com

CLR457 Novartis Pharmaceuticals advanced solid tumors Phase I/II

(PI3K inhibitor) East Hanover, NJ www.novartis.com

CMB305 Immune design advanced solid tumors Phase I

(cancer immunotherapy) Seattle, WA www.immunedesign.com

crolibulin Immune Pharmaceuticals solid tumors Phase II

Cambridge, MA www.immunepharmaceuticals.com

CUDC-427 Curis late-stage solid tumors Phase I

(IAP inhibitor) Lexington, MA (see also lymphoma) www.curis.com

CUDC-907 Curis late-stage solid tumors Phase I

(HDAC/PI3K inhibitor) Lexington, MA (see also lymphoma, myeloma) www.curis.com

CX-01 Cantex Pharmaceuticals solid tumors (pediatric) Phase I

(O-desulfated heparin intravenous) Weston, FL (see also leukemia, lung) www.cantex.com

CYT-6091 CytImmune solid tumors Phase I

(nanomedicine) Rockville, MD www.cytimmune.com






http://www.immunepharmaceuticals.com/




http://www.cytimmune.com/

Solid Tumors


DCVax®-Direct Northwest Biotherapeutics inoperable solid tumors Phase I/II

dendritic cell vaccine Bethesda, MD www.nwbio.com

Debio 1347 Debiopharm late-stage solid tumors Phase I

(FGFR inhibitor) Lausanne, Switzerland www.debiopharm.com

DFP-11207 Delta-Fly Pharma advanced solid tumors Phase I

(thymidylate synthase Tokushima, Japan

expression inhibitor)

DLYE-5953A Genentech/Roche refractory solid tumors Phase I

South San Francisco, CA www.roche.com

DS-3032 Daiichi Sankyo late-stage solid tumors Phase I

(MDM2 inhibitor) Parsippany, NJ (see also lymphoma) www.dsi.com

DS-3078 Daiichi Sankyo solid tumors Phase I

(mTOR inhibitor) Parsippany, NJ (see also lymphoma) www.dsi.com


(ROS1/NTRK inhibitor) Parsippany, NJ www.dsi.com

DS-7423 Daiichi Sankyo solid tumors Phase I

(PI3K/mTOR inhibitor) Parsippany, NJ www.dsi.com


(anti-DR5 antibody) Parsippany, NJ (see also lymphoma) www.dsi.com

duligotuzumab Genentech/Roche solid tumors with mutant KRAS Phase I

(anti-HER3/EGFR DAF mAb) South San Francisco, CA www.roche.com

http://www.nwbio.com/

http://www.debiopharm.com/


http://www.dsi.com/

http://www.dsi.com/

http://www.dsi.com/

http://www.dsi.com/

http://www.dsi.com/


Solid Tumors


E7046 Eisai solid tumors Phase I

Woodcliff Lake, NJ www.eisai.com

EC1456 Endocyte solid tumors Phase I

(folate tubulysin) West Lafayette, IN www.endocyte.com

entolimod Cleveland BioLabs advanced solid tumors Phase I

(cancer immunotherapy) Buffalo, NY www.cbiolabs.com

EPZ-6438 Epizyme solid tumors Phase I/II

(EZH2 inhibitor) Cambridge, MA (see also lymphoma) www.epizyme.com

GDC-0575 (RG7741) Genentech/Roche solid tumors Phase I

(ChK1 inhibitor) South San Francisco, CA (see also lymphoma) www.roche.com


(IDO inhibitor) South San Francisco, CA www.roche.com


(ERK inhibitor) South San Francisco, CA www.roche.com

gedatolisib Pfizer solid tumors Phase I

(PI3K/mTOR inhibitor) New York, NY www.pfizer.com

GS-5745 Gilead Sciences solid tumors Phase I

(MMP9 mAb inhibitor) Foster City, CA (see also stomach) www.gilead.com

GS-5829 Gilead Sciences solid tumors Phase I

(BET inhibitor) Foster City, CA (see also lymphoma) www.gilead.com

HDM201 Novartis Pharmaceuticals advanced solid tumors Phase I

(tumor suppressor protein East Hanover, NJ (see also hematological, sarcoma) www.novartis.com

p53 modulator)



http://www.cbiolabs.com/









Solid Tumors


hetIL-15 Admune Therapeutics metastatic solid tumors Phase I

(heterodimeric interleukin-16) Danvers, MA www.admune.com


Bethesda, MD

idasanutlin Genentech/Roche solid tumors Phase I

(MDM2 antagonist) South San Francisco, CA (see also hematological) www.roche.com

IDH305 Novartis Pharmaceuticals advanced solid tumors with IDHR132 Phase I

(IDH inhibitor) East Hanover, NJ mutations www.novartis.com

INCB54828 Incyte solid tumors Phase I

(FGFR inhibitor) Wilmington, DE www.incyte.com

Inlyta® Pfizer solid tumors (combination therapy) Phase I

axitinib New York, NY (see also kidney) www.pfizer.com

IT-139 Intezyne solid tumors Phase I

(GRP78 protein inhibitor) Tampa, FL www.intezyne.com

ixazomib Takeda Oncology solid tumors Phase I

(proteasome inhibitor) Cambridge, MA (see also myeloma) www.takedaoncology.com

KBP-5209 Sihuan Pharmaceutical solid tumors Phase I

(pan-HER inhibitor) Beijing, China www.sihuanpharm.com

KiroVAX-002 Kiromic metastatic solid tumors Phase I/II


KiroVAX-003 Kiromic metastatic solid tumors Phase I/II


http://www.admune.com/





http://www.intezyne.com/


http://www.sihuanpharm.com/



Solid Tumors


KNK2801/CEP-37250 Kyowa Hakko Kirin Pharma advanced solid tumors Phase I

(anti-tumor specific glycoprotein Princeton, NJ www.kyowa-hakko-kirin.com

humanized antibody) Teva Oncology www.tevapharm.com

Frazer, PA

KTN3379 Kolltan Pharmaceuticals advanced solid tumors Phase I

(ErbB3 kinase inhibitor) New Haven, CT (see also other) www.kolltan.com

LB-100 Lixte Biotechnology solid tumors Phase I

(PP2A inhibitor) East Setauket, NY www.lixte.com

Lenvima® Eisai solid tumors (combination therapy) Phase I/II

lenvatinib Woodcliff Lake, NJ (see also kidney, liver, lung, skin, other) www.eisai.com

LEQ506 Novartis Pharmaceuticals advanced solid tumors Phase I

(SMO antagonist) East Hanover, NJ www.novartis.com

lirilumab + Opdivo® nivolumab Bristol-Myers Squibb solid tumors Phase I


LJM716 Novartis Pharmaceuticals solid tumors Phase I

(ERBB-3 receptor antagonist) East Hanover, NJ www.novartis.com

LOXO-101 Array BioPharma solid tumors Phase I

(PanTrk inhibitor) Boulder, CO www.arraybiopharma.com

Loxo Oncology www.loxooncology.com

Stamford, CT

LY2780301 Eli Lilly solid tumors Phase I

(p70S6/Akt dual inhibitor) Indianapolis, In www.lilly.com

M2698 (MSC 2363318A) EMD Serono solid tumors Phase I

(P70S6K/Akt dual inhibitor) Rockland, MA www.emdserono.com

http://www.kyowa-hakko-kirin.com/


http://www.kolltan.com/

http://www.lixte.com/



http://www.bms.com/



http://www.loxooncology.com/



Solid Tumors


M3814 (MSC 2490484A) EMD Serono solid tumors Phase I

(DNA-PK inhibitor) Rockland, MA www.emdserono.com

M9241 (NHS-IL12) EMD Serono solid tumors Phase I

(cancer immunotherapy) Rockland, MA www.emdserono.com

MEDI0562 MedImmune solid tumors Phase I

(humanized OX40 agonist) Gaithersburg, MD www.medimmune.com


(anti-DLL-4 mAb) Gaithersburg, MD www.medimmune.com


(anti-PD-1 mAb) Gaithersburg, MD www.medimmune.com


(anti-ANG-2 mAb) Gaithersburg, MD www.medimmune.com

MEDI4736 MedImmune solid tumors Phase II

(anti-PD-L1 mAb) Gaithersburg, MD (see also head/neck, lung) www.medimmune.com

solid tumors Phase I

www.medimmune.com

MEDI4736 + MEDI0680 MedImmune solid tumors Phase I

(anti-PD-L1 mAb/anti-PD-1 mAb) Gaithersburg, MD www.medimmune.com

MEDI4736 + MEDI6469 MedImmune solid tumors Phase I

(anti-PD-L1 mAb/murine Gaithersburg, MD www.medimmune.com

OX40 agonist)










Solid Tumors


MEDI4736 + tremelimumab MedImmune solid tumors Phase I

(anti-PD-L1 mAb/anti-CTLA-4 mAb) Gaithersburg, MD www.medimmune.com


(OX40 agonist) Gaithersburg, MD www.medimmune.com


(murine OX40 agonist) Gaithersburg, MD www.medimmune.com

MEDI6469 + rituximab MedImmune solid tumors Phase I

(murine OX40 agonist/anti-CD20 mAb) Gaithersburg, MD www.medimmune.com

MEDI6469 + tremelimumab MedImmune solid tumors Phase I

(murine OX40 agonist/anti-CTLA-4 mAb) Gaithersburg, MD www.medimmune.com

mesothelin antibody drug conjugate Bristol-Myers Squibb solid tumors Phase I


MGCD516 Mirati Therapeutics late-stage solid tumors Phase I

(Trk/RET/DDR kinase inhibitor) San Diego, CA www.mirati.com

MK-2206 Merck solid tumors Phase II

(Akt inhibitor) Kenilworth, NJ www.merck.com

MK-4166 Merck solid tumors Phase I

(TNF-RSF18 protein stimulant) Kenilworth, NJ www.merck.com

MK-8242 Merck solid tumors Phase I completed

(MDM-2 inhibitor) Kenilworth, NJ www.merck.com






http://www.bms.com/





Solid Tumors


MM-151 Merrimack Pharmaceuticals refractory advanced solid tumors Phase I

(EGFR antagonist) Cambridge, MA www.merrimackpharma.com

MM-398 Baxalta solid tumors (pediatric) Phase I

(encapsulated irinotecan Cambridge, MA (see also brain, pancreatic) www.baxalta.com

nanotherapeutic)

MNK-010 Mallinckrodt Pharmaceuticals solid tumors Phase I

St. Louis, MO www.mallinckrodt.com

MORAb-066 Eisai solid tumors Phase I

(tissue factor antigen inhibitor) Woodcliff Lake, NJ www.eisai.com

MUC-1 dendritic cancer vaccine MicroVAX solid tumors Phase I

Manassas, VA

MVA-BN Brachyury Bavarian Nordic solid tumors Phase I

(immunotherapy vaccine) Mountain View, CA www.bavarian-nordic.com


Bethesda, MD

NC-4016 NanoCarrier solid tumors Phase I

(DACH platin micelle) Chiba, Japan www.nanocarrier.co.jp

OMP-305B83 OncoMed Pharmaceuticals solid tumors Phase I

(DLL3 protein inhibitor) Redwood City, CA www.oncomed.com

ONC201 Oncoceutics advanced solid tumors Phase I

(TRAIL-inducing compound) Hummelstown, PA www.oncoceutics.com

OPB-111077 Otsuka Pharmaceutical solid tumors Phase I

Rockville, MD www.otsuka.com



http://www.mallinckrodt.com/



http://www.nanocarrier.co.jp/


http://www.oncoceutics.com/

http://www.otsuka.com/

Solid Tumors


Opdivo® Bristol-Myers Squibb solid tumors (signal detection) Phase I


hematological, kidney, liver, lung, lymphoma,

skin, stomach, other)

Opdivo® nivolumab + Bristol-Myers Squibb solid tumors Phase I

Yervoy® ipilimumab Princeton, NJ (see also kidney, lung, skin) www.bms.com

oprozomib Onyx Pharmaceuticals advanced solid tumors Phase I

(proteasome inhibitor) South San Francisco, CA (see also hematological, myeloma) www.onyx.com

oratecan Kinex Pharmaceuticals solid tumors Phase I

(oral irinotecan) Buffalo, NY www.kinexpharma.com

oraxol Kinex Pharmaceuticals solid tumors Phase I

(oral paclitaxel) Buffalo, NY www.kinexpharma.com

OTS167 OncoTherapy Science solid tumors Phase I

(MELK protein inhibitor) Kanagawa Prefecture, Japan www.oncotherapy.co.jp

OTX015 Merck solid tumors Phase I(BET inhibitor) Kenilworth, NJ (see also hematological) ww.merck.com

OVI-117 OncoVista Innovative Therapies solid tumors Phase I/II

(L-nucleoside conjugate) San Antonio, TX www.oncovista.com

p28 peptide CDG Therapeutics solid tumors Phase I completed

Chicago, IL www.cdgti.com

PAC-1 Vanquish Oncology solid tumors Phase I

(procaspase activating compound-1) Champaign, IL (see also hematological) www.vanquishoncology.com

http://www.bms.com/

http://www.bms.com/




http://www.oncotherapy.co.jp/

http://www.oncovista.com/

http://www.cdgti.com/

http://www.vanquishoncology.com/

Solid Tumors


paclitaxel liposomal Sun Pharma Advanced Research solid tumors Phase I

Mumbai, India www.sunpharma.in

pbi-shRNA STMN1 LP Gradalis advanced solid tumors Phase I

gene therapy Dallas, TX www.gradalisinc.com

PDR001 Novartis Pharmaceuticals solid tumors Phase I

(PDCD 1 protein inhibitor) East Hanover, NJ www.novartis.com

PEG-BCT-100 Bio-Cancer Treatment International solid tumors Phase I

(recombinant human arginase) Hong Kong www.bio-cancer.org

PF-04518600 Pfizer solid tumors Phase I



(4-1BB [CD-137] protein receptor) New York, NY www.pfizer.com

solid tumors (combination therapy) Phase I

www.pfizer.com




(immunoconjugate) New York, NY www.pfizer.com



PFK-158 Advanced Cancer Therapeutics solid tumors Phase I

(PFKFB3 inhibitor) Louisville, KY www.advancedcancertherapeutics.com

http://www.sunpharma.in/



http://www.bio-cancer.org/







http://www.advancedcancertherapeutics.com/

Solid Tumors


PLX8394 Plexxikon BRAF-mutant solid tumors Phase I/II

(BRAF inhibitor) Berkeley, CA www.plexxikon.com

PLX 9486 Plexxikon KIT-mutant solid tumors Phase I

(proto oncogene protein Berkeley, CA (see also stomach) www.plexxikon.com

c-kit inhibitor)

PM060184 PharmaMar solid tumors Phase I

(tubulin polymerisation inhibitor) Madrid, Spain www.pharmamar.com

Poly-ICLC Oncovir advanced accessible solid tumors Phase II

Washington, DC www.oncovir.com

PQR309 PIQUR Therapeutics advanced solid tumors Phase I

(pan-PI3K/mTOR inhibitor) Basel, Switzerland www.piqur.com

PT-112 Phosplatin Therapeutics late-stage solid tumors Phase I

(apoptosis stimulant) New York, NY www.phosplatin.com

PTC596 PTC Therapeutics solid tumors Phase I

(BMI1 protein inhibitor) South Plainfield, NJ www.ptcbio.com

purine nucleoside phosphorylase PNP Therapeutics late-stage solid tumors Phase I

gene therapy Birmingham, AL www.pnptherapeutics.com

QBI-139 Quintessence Biosciences solid tumors Phase I

(RNA inhibitor) Madison, WI www.quintbio.com

rebastinib Deciphera Pharmaceuticals solid tumors Phase I/II

(TRK/BCR-ABL/TIE-2 inhibitor) Cambridge, MA www.deciphera.com

RG6061 Genentech/Roche solid tumors Phase I

(HIF1 alpha inhibitor) South San Francisco, CA www.roche.com




http://www.oncovir.com/

http://www.piqur.com/

http://www.phosplatin.com/

http://www.ptcbio.com/

http://www.pnptherapeutics.com/

http://www.quintbio.com/

http://www.deciphera.com/


Solid Tumors



(CSF-1R antagonist) South San Francisco, CA www.roche.com


(Raf/MEK dual inhibitor) South San Francisco, CA www.roche.com


(CD3 antigen inhibitor) South San Francisco, CA www.roche.com


(CEA inhibitor) South San Francisco, CA www.roche.com


(antibody drug conjugate) South San Francisco, CA www.roche.com


(CD40 antigen stimulant) South San Francisco, CA www.roche.com


(anti-OX40 mAb) South San Francisco, CA www.roche.com

RX-3117 Rexahn Pharmaceuticals late-stage solid tumors Phase I

(DNA synthesis inhibitor) Rockville, MD www.rexahn.com

RX-5902 Rexahn Pharmaceuticals late-stage solid tumors Phase I

(RNA helicase inhibitor) Rockville, MD www.rexahn.com

RXDX 101 Ignyta advanced solid tumors Phase I/II

(selective tyrosine kinase inhibitor) San Diego, CA www.ignyta.com

RXDX 105 Ignyta advanced solid tumors Phase I

(BRAF kinase inhibitor) San Diego, CA www.ignyta.com










http://www.ignyta.com/

http://www.ignyta.com/

Solid Tumors


sapacitabine/seliciclib Cyclacel Pharmaceuticals solid tumors Phase I

combination Berkeley Heights, N www.cyclacel.com

SAR125844 Sanofi US solid tumors Phase I

c-Met kinase inhibitor) Bridgewater, NJ www.sanofi.com


(PI3K inhibitor) Bridgewater, NJ www.sanofi.com


(antibody drug conjugate) Bridgewater, NJ www.sanofi.com


(maytansin-loaded anti-CA6 mAb) Bridgewater, NJ www.sanofi.com

SEA-CD40 Seattle Genetics relapsed solid tumors Phase I

(CD40 antigen stimulant) Bothell, WA www.seattlegenetics.com

sEphB4-HSA VasGene Therapeutics solid tumors Phase I

(recombinant albumin fusion Los Angeles, CA www.vasgene.com

protein)

Seprehvir® Virttu Biologics non-CNS solid tumors Phase I

HSV1716 Glasgow, Scotland (see also brain) www.virttu.com

Nationwide Children's Hospital

Columbus, OH

SF1126 SignalRx Pharmaceuticals solid tumors Phase I completed

(PI3K/mTOR dual inhibitor) San Diego, CA www.signalrx.com

SOR-C13 Soricimed Biopharma cancers that overexpress the TRPV6 Phase I

(TRPV6 protein inhibitor) Sackville, Canada calcium channel www.soricimed.com







http://www.vasgene.com/

http://www.virttu.com/

http://www.signalrx.com/

http://www.soricimed.com/

Solid Tumors


TAK-117 Takeda Oncology solid tumors Phase I

(PI3K alpha inhibitor) Cambridge, MA www.takedaoncology.com


(UAE inhibitor) Cambridge, MA www.takedaoncology.com


(pan-Raf kinase inhibitor) Cambridge, MA www.takedaoncology.com


(SYK kinase inhibitor) Cambridge, MA (see also hematological) www.takedaoncology.com

TAS-114 Taiho Oncology advanced solid tumors Phase I

(dUTPase/DPD inhibitor) Princeton, NJ www.taihooncology.com

TAS-119 Taiho Oncology advanced solid tumors Phase I

(aurora kinase A inhibitor) Princeton, NJ www.taihooncology.com

TAS-120 Taiho Oncology advanced solid tumors Phase I/II

(FGF/FGFR inhibitor) Princeton, NJ (see also myeloma) www.taihooncology.com

TEN-010 Tensha Therapeutics solid tumors Phase I

(BET inhibitor) Cambridge, MA (see also hematological, leukemia) www.tenshatherapeutics.com

TEW-7197 MedPacto solid tumors Phase I

(TGF-beta type 1 receptor antagonist) Suwan, South Korea www.medpacto.com

thioureidobutyronitrile Cellceutix solid tumors Phase I

(tumor suppressor protein Beverly, MA www.cellceutix.com

p53 stimulant)









http://www.medpacto.com/

http://www.cellceutix.com/

Solid Tumors


TRX518 GITR solid tumors Phase I(GITR receptor antagonist) Cambridge, MA (see also skin) www.gitrrx.com

TVB-2640 3-V Biosciences solid tumors Phase I

(FASN inhibitor) Menlo Park, CA www.3vbio.com

U3-1565 Daiichi Sankyo solid tumors Phase I

(anti-HB=EGF antibody) Parsippany, NJ www.dsi.com

urelumab Bristol-Myers Squibb solid tumors Phase I

Princeton, NJ (see also hematological) www.bms.com

urelumab + Opdivo® nivolumab Bristol-Myers Squibb solid tumors Phase I

Princeton, NJ (see also hematological) www.bms.com

VGX 100 Ceres Oncology solid tumors Phase I

(VEGF-C antibody) Victoria, Australia www.ceresoncology.com

VLX600 Vivolux advanced solid tumors Phase I

(UCHL5/USP14 protein inhibitor) Ashburn, VA www.vivolux.com

VS-4718 Verastem late-stage solid tumors Phase I

(FAK inhibitor) Cambridge, MA www.verastem.com

VS-5584 Verastem late-stage solid tumors Phase I

(PI3K/mTOR inhibitor) Cambridge, MA (see also lymphoma) www.verastem.com

VX15 Vaccinex solid tumors Phase I

(CD1000 antigen inhibitor) Rochester, NY www.vaccinex.com

VX-803 Vertex Pharmaceuticals solid tumors Phase I

Boston, MA (see also lymphoma) www.vrtx.com

http://www.gitrrx.com/

http://www.3vbio.com/

http://www.dsi.com/

http://www.bms.com/

http://www.bms.com/

http://www.ceresoncology.com/

http://www.vivolux.com/



http://www.vaccinex.com/


Solid Tumors


VX-970 Vertex Pharmaceuticals solid tumors Phase I

(ATR protein inhibitor) Boston, MA www.vrtx.com

WT2725 Sunovion Pharmaceuticals solid tumors Phase I

(cancer immunotherapy) Marlborough, MA (see also hematological) www.sunovion.com

Xalkori® Pfizer solid tumors Phase I

crizotinib New York, NY www.pfizer.com

Stomach Cancer


ADI-PEG 20 Polaris Pharmaceuticals advanced gastrointestinal malignancies Phase I

(PEG arginine deiminase) San Diego, CA (see also breast, liver, lung, ovarian, pancreatic, skin) www.polarispharma.com

Afinitor® Novartis Pharmaceuticals non-functioning gastrointestinal neuroendocrine Phase III

everolimus East Hanover, NJ tumors www.novartis.com

(see also lung)

AMG 337 Amgen gastric/esophageal cancer Phase II

(c-Met inhibitor) Thousand Oaks, CA www.amgen.com

BBI608 Boston Biomedical gastric cancer, gastro-esophageal adenocarcinoma Phase III

(cancer stem cell inhibitor) Cambridge, MA (see also breast, colorectal, hematological, liver, www.bostonbiomedical.com

lung, ovarian, pancreatic, skin)

gastrointestinal cancer (combination therapy) Phase I

www.bostonbiomedical.com

crenolanib AROG Pharmaceuticals gastrointestinal stromal tumors (GIST) Phase III

(PDGFR inhibitor) Dallas, TX (see also brain, leukemia, lung) www.arogpharma.com


http://www.sunovion.com/








Stomach Cancer


Cyramza® Eli Lilly gastric cancer (1st-line) Phase III

ramucirumab Indianapolis, IN (see also bladder, liver, lung) www.lilly.com

Orphan Drug

docetaxel injection concentrate, Teikoku Pharma USA gastric adenocarcinoma application submitted

non-alcohol formula San Jose, CA (see also breast, head/neck, lung, prostate) www.teikokuusa.com

fosbretabulin OXiGENE gastrointestinal neuroendocrine tumors Phase II

(vascular targeting agent) South San Francisco, CA (see also ovarian) www.oxigene.com

FPA144 Five Prime Therapeutics treatment-resistant gastric cancer Phase I

(FGFR2b antibody) South San Francisco, CA www.fiveprime.com

GS-5745 Gilead Sciences gastric cancer Phase II

(MMP9 mAb inhibitor) Foster City, CA (see also solid tumors) www.gilead.com

Iclusig® ARAID Pharmaceuticals GIST Phase II

ponatinib Cambridge, MA (see also leukemia) www.ariad.com

ipatasertib Array BioPharma gastric cancer Phase II

(Akt inhibitor) Boulder, CO (see also breast, prostate) www.roche.com

Genentech/Roche www.arraybiopharma.com


Kadcyla® Genentech/Roche HER2-positive gastric cancer (2nd-line) Phase III

ado-trastuzumab emtansine South San Francisco, CA (see also breast, lung) www.roche.com

Keytruda® Merck gastric cancer Phase II

pembrolizumab Kenilworth, NJ (see also bladder, breast, head/neck, lung, lymphoma) www.merck.com

Lynparza® AstraZeneca gastric cancer (2nd-line) Phase III

olaparib Wilmington, DE (see also breast, ovarian, pancreatic, prostate) www.astrazeneca.com




http://www.fiveprime.com/








Stomach Cancer


masitinib AB Science USA late-stage GIST (1st-line) Phase III

Orphan Drug Short Hills, NJ (see also pancreatic) www.ab-science.com

MBP-426 Mebiopharm gastric cancer, gastroesophageal junction carcinoma Phase I/II

(transferrin-conjugated nano-particle Tokyo, Japan www.mebiopharm.com

formulation of oxaliplatin)

Minnelide™ 001 Minneamrita Therapeutics advanced gastrointestinal cancer Phase I

HSP70 inhibitor Moline, IL

NeuVax™ Galena Biopharma gastric carcinoma (HER2 IHC 1+/2+ or 3+) Phase I completed

nelipepimut-S Portland, OR (see also breast) www.galenabiopharma.com

Opdivo® Bristol-Myers Squibb gastric cancer Phase III


hematological, kidney, liver, lung, lymphoma, skin,

solid tumors, other)

Perjeta® Genentech/Roche HER2-positive gastric cancer Phase III

pertuzumab South San Francisco, CA (see also breast) www.roche.com

PLX9486 Plexxikon GIST Phase I

(proto oncogene protein c-kit inhibitor) Berkeley, CA (see also solid tumors) www.plexxikon.com

polyclonal antibody stimulator Cancer Advances gastric cancer Phase III completed

(G17DT) Durham, NC (see also colorectal, pancreatic) www.canceradvancesinc.com

Orphan Drug

pyrotinib Jiangsu Hengrui Medicine HER2-positive gastric cancer Phase I

(tyrosine kinase inhibitor) Jiangsu Province, China (see also breast) www.hrs.com.cn

SM04755 Samumed advanced gastric cancer Phase I

(Wnt inhibitor) San Diego, CA (see also colorectal, liver, pancreatic) www.samumed.com

http://www.ab-science.com/

http://www.mebiopharm.com/


http://www.bms.com/




http://www.hrs.com.cn/


Stomach Cancer


TAK-264 Takeda Oncology gastric cancer Phase II

(antibody drug conjugate Cambridge, MA (see also pancreatic) www.takedaoncology.com

targeting GCC)

TAS-102 Taiho Oncology advanced gastrointestinal tumors Phase I

(tipiracil/trifluridine) Princeton, NJ (see also colorectal) www.taihooncology.com

telatinib Eddingpharm gastric cancer Phase II completed

(VEGFR inhibitor) Westlake Village, CA www.eddingpharm.com

Orphan Drug

TKM-PLK1 Arbutus Biopharma gastrointestinal neuroendocrine tumors Phase I/II

(PLK1 inhibitor) Burnaby, Canada (see also other) www.arbutusbio.com

Other Cancers


177Lu-DOTATAE Advanced Accelerator Applications somastatin receptor-positive neuroendocrine Phase III

(somastatin receptor antagonist) New York, NY tumors of the small bowel (midgut carcinoid tumors) www.adacap.com

Orphan Drug

212-Pb-TCMC trastuzumab AREVA Med intra-abdominal HER-2 expressing cancers Phase I

Bethesda, MD www.averamed.avera.com

ADXS-HPV Advaxis anal cancer, cervical cancer Phase II

(immunotherapy vaccine) Princeton, NJ (see also head/neck) www.advaxis.com

Orphan Drug

cervical cancer (combination therapy) Phase I/II

www.advaxis.com

AEB071 Novartis Pharmaceuticals metastatic uveal melanoma Phase I/II

(PKC inhibitor) East Hanover, NJ (combination therapy) www.novartis.com

(see also lymphoma)



http://www.eddingpharm.com/

http://www.arbutusbio.com/

http://www.adacap.com/

http://www.averamed.avera.com/




Other Cancers


ATR-101 Atterocor adrenocortical carcinoma Phase I

(ACAT1 inhibitor) Ann Arbor, MI www.atterocor.com

Orphan Drug

Avastin® Genentech/Roche high-risk carcinoid tumors Phase III

bevacizumab South San Francisco, CA (see also brain, breast, lung, ovarian) www.roche.com

Azedra® Progenics Pharmaceuticals neuroblastoma (pediatric), neuroendocrine Phase II

iobenguane I-131 Tarrytown, NY tumors (pediatric), pheochromocytoma (Fast Track) www.progenics.com

Orphan Drug

BAY1143572 Bayer HealthCare Pharmaceuticals advanced cancer Phase I

Whippany, NJ (see also leukemia) www.healthcare.bayer.com

BEL-0222 Belrose Pharma pediatric neuroblastoma Phase I/II

(angiogenesis inhibitor) Princeton, NJ (see also breast) www.belrosepharma.com

Orphan Drug

CC-486 Celgene advanced nasopharyngeal carcinoma Phase II

(DNA methylation inhibitor) Summit, NJ (see also breast, hematological, leukemia, www.celgene.com

lung, lymphoma)

CPI-613 Cornerstone Pharmaceuticals advanced malignancies Phase I/II

(KGDH/PHD complex inhibitor) Cranbury, NJ (see also pancreatic) www.cornerstonepharma.com

CPP-1X Cancer Prevention Pharmaceuticals neuroblastoma Phase II

(eflornithine) Tucson, AZ (see also colorectal) www.canprevent.com

CPP-1X/sulindac Cancer Prevention Pharmaceuticals colorectal cancer (risk reduction) Phase III

(eflornithine/sulindac) Tucson, AZ (see also other) www.canprevent.com

http://www.atterocor.com/


http://www.progenics.com/

http://www.belrosepharma.com/


http://www.cornerstonepharma.com/

http://www.canprevent.com/

http://www.canprevent.com/

Other Cancers


cridanimod Kevelt endometrial cancer Phase II

(progesterone receptor modulator) Tallinn, Estonia www.kevelt.ee.en

Pharmsynthez www.pharmsynthez.com

St. Petersburg, Russia

DKN-01 HealthCare Pharmaceuticals esophageal cancer Phase I

(DKK1 protein inhibitor) Cambridge, MA (see also lung, myeloma) www.healthcarepharmaceuticals.com

emibetuzumab Eli Lilly advanced cancers Phase I/II

(c-Met antibody) Indianapolis, IN (see also lung) www.lilly.com

epacadostat Incyte fallopian tube cancer, peritoneal cancer Phase II

(IDO1 inhibitor) Wilmington, DE (see also lung, ovarian, skin) www.incyte.com

fenretinide lipid matrix BioMolecular Products recurrent/resistant neuroblastoma Phase I

Newburyport, MA www.biomolecularproducts.com

The EVAN Foundation

Germantown, MD

Texas Tech University

Lubbock, TX

GALE-301 Galena Biopharma endometrial cancer Phase II

(folate binding protein Portland, OR (see also ovarian) www.galenabiopharma.com

immunotherapy)

GI-6207 GlobeImmune medullary thyroid cancer Phase II

(T-cell stimulator) Louisville, CO www.globeimmune.com

GI-6301 GlobeImmune chordoma Phase II

(brachyury peptide vaccine) Louisville, CO www.globeimmune.com

advanced cancers Phase I

www.globeimmune.com

http://www.kevelt.ee.en/

http://www.pharmsynthez.com/




http://www.biomolecularproducts.com/





Other Cancers


GL-ONC1 Genelux peritoneal carcinomatosis Phase I/II

(oncolytic virus immunomodulator) San Diego, CA (see also head/neck, lung) www.genelux.com

HPV-16 E6 TCR Kite Pharma HPV-associated cancers (vaginal, cervical, anal, Phase I/II

(T-cell receptor antigen antagonist) Santa Monica, CA penile, or oropharyngeal cancers) www.kitepharma.com


Bethesda, MD

IMMU-132 Immunomedics advanced epithelial cancer Phase I/II

(sacituzumab govitecan) Morris Plains, NJ (see also breast) www.immunomedics.com

INO-3106 Inovio Pharmaceuticals HPV-6-associated aerodigestive cancers Phase I/II

(cancer immunotherapy) Plymouth Meeting, PA www.inovio.com

INO-3112 Inovio Pharmaceuticals cervical cancer caused by HPV types 16 and 18 Phase I/II

(cancer immunotherapy) Plymouth Meeting, PA www.inovio.com

JCAR023 Juno Therapeutics neuroblastoma (pediatric) Phase I


KTN3379 Kolltan Pharmaceuticals BRAF mutant, radioiodine-refractory thyroid cancer Phase I

(ErbB3 kinase inhibitor) New Haven, CT (see also solid tumors) www.kolltan.com

Lenvima® Eisai endometrial cancer Phase II

lenvatinib Woodcliff Lake, NJ (see also kidney, liver, lung, skin, solid tumors) www.eisai.com

LY2940680 Eli Lilly advanced cancer Phase II

(hedgehog/SMO inhibitor) Indianapolis, IN www.lilly.com

milciclib Nerviano Medical Sciences malignant thymoma Phase II

(CDK inhibitor) Nerviano, Italy www.nervianoms.com







http://www.kolltan.com/



http://www.nervianoms.com/

Other Cancers


mirvetuximab soravtansine ImmunoGen FOLR1-overexpressing endometrial cancer Phase I

(folate receptor 1 inhibitor) Waltham, MA (see also ovarian) www.immunogen.com

neuroblastoma vaccine MabVax Therapeutics neuroblastoma Phase I

Orphan Drug San Diego, CA www.mabvax.com

Nexavar® Bayer HealthCare Pharmaceuticals differentiated thyroid cancer Phase III

sorafenib Whippany, NJ (see also kidney) www.healthcare.bayer.com

Opdivo® Bristol-Myers Squibb esophageal cancer Phase II


hematological, kidney, liver, lung, lymphoma, skin,

solid tumors, stomach)

pediatric cancer Phase I

www.bms.com

pasireotide long acting release Novartis Pharmaceuticals neuroendocrine tumors, pituitary cancer Phase II

(SOM230) East Hanover, NJ (see also prostate, skin) www.novartis.com

PDS0101 PDS Biotechnology cervical cancer prevention (HPV-16) Phase I

(cancer immunotherapy) North Brunswick, NJ www.pdsbiotech.com

PLX3397 Plexxikon tenosynovial giant cell tumor Phase III

(CSF-1R inhibitor) Berkeley, CA (see also brain, breast, ovarian, skin) www.plexxikon.com

Orphan Drug

PU-H71 Samus Therapeutics advanced malignancies Phase I

(HSP90 heat-shock protein inhibitor) New York, NY

Memorial Sloan-Kettering Cancer Center

New York, NY



http://www.bms.com/

http://www.bms.com/


http://www.pdsbiotech.com/


Other Cancers


refametinib Bayer HealthCare Pharmaceuticals advanced or metastatic cancer Phase II

(MEK inhibitor) Whippany, NJ www.healthcare.bayer.com

Reolysin® Oncolytics Biotech fallopian tube cancer, peritoneal cancer Phase II


Orphan Drug myeloma, ovarian, pancreatic)

RRx-001 EpicentRx neuroendocrine tumors Phase II

(free radical stimulant) Mountain View, CA (see also colorectal, liver, lung, lymphoma) www.radiorx.com

rucaparib Clovis Oncology fallopian tube cancer, peritoneal cancer Phase III

(PARP inhibitor) Boulder, CO (see also breast, ovarian, pancreatic) www.clovisoncology.com

SC-002 Stemcentrx neuroendocrine tumors Phase I

(immunoconjugate) South San Francisco, CA (see also lung) www.stemcentrx.com

selinexor (oral) Karyopharm Therapeutics gynecologic malignancies Phase II


leukemia, lymphoma, myeloma, prostate, sarcoma)

selumetinib AstraZeneca differentiated thyroid cancer, Phase III

(MEK inhibitor) Wilmington, DE uveal melanoma www.astrazeneca.com

Orphan Drug

TAK-228 Takeda Oncology endometrial cancer Phase II

(mTORC1/2 inhibitor) Cambridge, MA (see also breast, kidney) www.takedaoncology.com

telotristat etiprate Lexicon Pharmaceuticals malignant carcinoid syndrome (Fast Track) Phase III

(TPH1 inhibitor) The Woodlands, TX www.lexicon-genetics.com

Orphan Drug








http://www.lexicon-genetics.com/

Other Cancers


TKM-PLK1 Arbutus Biopharma adrenocortical carcinoma Phase I

(PLK1 inhibitor) Burnaby, Canada (see other stomach) www.arbutusbio.com

TRC105 TRACON Pharmaceuticals choriocarcinoma Phase II


lung, sarcoma)

Triapine® Nanotherapeutics non-localized cervical cancer Phase II

ribonuclease inhibitor Alachua, FL www.nanotherapeutics.com


Bethesda, MD

Unituxin™ United Therapeutics neuroblastoma (adults up to age 30 years) Phase III

dinutuximab Silver Spring, MD www.unither.com

Orphan Drug

VB-111 VBL Therapeutics thyroid cancer Phase II

(targeted anti-angiogenic agent) Tel Aviv, Israel (see also brain, ovarian) www.vblrx.com

WNT974 Novartis Pharmaceuticals malignancies dependent on Wnt ligands Phase I

(WNT signaling pathway inhibitor) East Hanover, NJ www.novartis.com

Zelboraf® Genentech/Roche BRAF mutation-positive papillary thyroid cancer Phase II

vemurafenib South San Francisco, CA (see also colorectal, skin) www.roche.com

Daiichi Sankyo

Parsippany, NJ

zoptarelin doxorubicin Aeterna Zentaris endometrial cancer (2nd-line) Phase III

(type II DNA topoisomerase Quebec, Canada (see also prostate) www.aezsinc.com

inhibitor)

http://www.arbutusbio.com/


http://www.nanotherapeutics.com/

http://www.unither.com/




http://www.aezsinc.com/

Unspecified


ABBV-075 AbbVie Phase I

(bromodomain inhibitor) North Chicago, IL www.abbvie.com

AGS67E Agensys Phase I


Astellas Pharma www.astellas.com

Tokyo, Japan

BAY1082439 Bayer HealthCare Pharmaceuticals Phase I

(allosteric Akt 1/2 inhibitor) Whippany, NJ www.healthcare.bayer.com


(Pan-FGFR inhibitor) Whippany, NJ www.healthcare.bayer.com


(FGFR2 antibody drug conjugate) Whippany, NJ www.healthcare.bayer.com


(PSMA BiTE antibody) Whippany, NJ www.healthcare.bayer.com

CHML Glory Pharmaceuticals in clinical trials

(cytotropic heterogeneous molecular lipids) Vienna, VA www.anticancerdrug.com

CSF-1R mAb Eli Lilly Phase I

(LY3022855) Indianapolis, IN www.lilly.com

fenretinide intravenous CerRx Phase I

Lubbock, TX www.cerrx.com

G1T28 G1 Therapeutics Phase I

(CDK 4/6 inhibitor) Research Triangle Park, NC www.g1therapeutics.com








http://www.anticancerdrug.com/


http://www.cerrx.com/

http://www.g1therapeutics.com/

Unspecified


HBI-8000 Huya Bioscience Phase I

(HDAC inhibitor) San Diego, CA www.huyabio.com

IGF-methotrexate conjugate IGF Oncology Phase I

Birchwood, MN www.igfoncology.com

IP-112 InnoPharma application submitted

Piscataway, NJ www.innopharmainc.com

LY2874455 Eli Lilly Phase II

(FGF receptor inhibitor) Indianapolis, IN www.lilly.com

LY3009120 Eli Lilly Phase I

(Pan-Raf inhibitor) Indianapolis, IN www.lilly.com


(NOTCH inhibitor) Indianapolis, IN www.lilly.com


(MET/EGFR bispecific antibody) Indianapolis, IN www.lilly.com

merestinib Eli Lilly Phase II

(c-Met inhibitor) Indianapolis, IN www.lilly.com

notch inhibitor Bristol-Myers Squibb Phase I


OMN54 Omnitura Therapeutics Phase I

(signal transduction pathway Redwood Shores, CA www.omnitura.com

inhibitor)

http://www.huyabio.com/

http://www.igfoncology.com/

http://www.innopharmainc.com/






http://www.bms.com/

http://www.omnitura.com/

Unspecified


OPB-51602 Otsuka Pharmaceutical Phase I

(molecular targeting drug) Rockville, MD www.otsuka.com

REGN1400 Regeneron Pharmaceuticals Phase I

(ERBB-3 receptor modulator) Tarrytown, NY www.regeneron.com

REGN2810 Regeneron Pharmaceuticals Phase I

(PD-1 protein inhibitor) Tarrytown, NY www.regeneron.com

SNX-5422 Esanex Phase I

(Hsp90 inhibitor) Indianapolis, In

TRF-DOX Faulk Pharmaceuticals Phase I completed

(doxorubicin transferrin conjugate) Raleigh, NC www.faulkpharma.com

Panther Biotechnology www.pantherbiotechnology.com

Chicago, IL

VEGFR-3 mAb Eli Lilly Phase I

Indianapolis, IN www.lilly.com

VOLT03 Levolta Pharmaceuticals Phase I

(thromboxane synthase inhibitor) Bethlehem, PA www.levoltapharma.com

Definitions

Application Submitted—An application for marketing has been submitted by the company to the U.S. Food and Drug Administration (FDA).

Fast Track—Upon request by a sponsor, the FDA can grant this designation to facilitate the development and expedite the review of a drug or biologic to treat a serious condition and fill an

unmet medical need. When considering a biopharmaceutical company’s request for Fast Track designation for an investigational drug or biologic, the FDA evaluates whether it will affect

factors such as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one, and whether a condition

can be adequately addressed by available therapy. With Fast Track designation, early and frequent communication between the FDA and the biopharmaceutical company is encouraged

throughout the entire drug development and review process to help to quickly resolve and questions or issues that arise, potentially leading to an earlier approval and access by patients.

Orphan Designation—Upon request by a sponsor, the FDA can grant special status (“orphan status”) to a drug or biologic to treat a rare disease or disease or condition. In order to

receive an orphan designation, a qualifying drug or biologic must be intended for the treatment, diagnosis, or prevention of a rare disease or condition that affects fewer than 200,000

people in the United States, or that affects more than 200,000 persons but is not expected to recover the costs of its development and marketing.

http://www.otsuka.com/



http://www.faulkpharma.com/

http://www.pantherbiotechnology.com/


http://www.levoltapharma.com/

Phase I—Researchers test the investigational drug or biologic in a small group of people, usually between 20 and 100 healthy adult volunteers, to evaluate its initial safety and

tolerability profile, determine a safe dosage range, and identify potential side effects.

Phase II—The investigational drug or biologic is given to volunteer patients, usually between 100 and 500, to determine whether it is effective, identify an optimal dose, and to further

evaluate its short-term safety.

Phase III—The investigational drug or biologic is given to a larger, more diverse patient population, often involving between 1,000 and 5,000 patients ( but sometimes many more),

to generate statistically significant evidence to confirm its safety and effectiveness. Phase III studies are the longest studies and usually take place in multiple sites around the world.

The content of this report has been obtained through public, government and industry sources, and the Adis “R&D Insight” database based on the latest information. Report current as of

August 21, 2015. The medicines in this listing include medicines being developed by U.S.-based companies conducting trials in the United States and abroad, PhRMA-member companies conducting

trials in the United States and abroad, and foreign companies conducting clinical trials in the United States. The information may not be comprehensive. For more specific information about a

particular product, contact the individual company directly or go to www.clinicaltrials.gov. The entire series of Medicines in Development is available on PhRMA's website at www.phrma.org.

Documents

2015 Medicines in Development for Cancer Drug List - …phrma-docs.phrma.org/sites/default/files/pdf/2015_cancer_drug_list.pdf · 2015 Medicines in Development for Cancer ... ACP-196